primaquine has been researched along with Plasmodium vivax Malaria in 470 studies
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to early- or delayed treatment." | 9.69 | Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment. ( Batty, KT; Davis, TME; Kasian, B; Laman, M; Lorry, L; Manning, L; Moore, BR; Pomat, W; Robinson, LJ; Salman, S; Tesine, P; Woon, SA; Yadi, G; Yambo, P, 2023) |
| "Tafenoquine, co-administered with chloroquine, is approved for the radical cure (prevention of relapse) of Plasmodium vivax malaria." | 9.69 | Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. ( Baird, JK; Berni, A; Budiman, W; Cedar, E; Chand, K; Crenna-Darusallam, C; Duparc, S; Ekawati, LL; Elyazar, I; Fernando, D; Fletcher, K; Goyal, N; Green, JA; Instiaty, I; Jones, S; Kleim, JP; Lardo, S; Martin, A; Noviyanti, R; Prasetya, CB; Rolfe, K; Santy, YW; Satyagraha, AW; Sharma, H; Soebandrio, A; Subekti, D; Sutanto, I; Tan, LK; Taylor, M, 2023) |
| "The World Health Organization recommends that primaquine should be given once weekly for 8-weeks to patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase (G6PD) deficiency, but data on its antirelapse efficacy and safety are limited." | 9.69 | Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency. ( Assefa, A; Baird, JK; Bancone, G; Chand, K; Chau, NH; Day, NP; Degaga, TS; Dhorda, M; Dondorp, A; Ekawati, LL; Hailu, A; Hasanzai, MA; Ley, B; Meagher, N; Naddim, MN; Pasaribu, AP; Price, RN; Rahim, AG; Satyagraha, A; Simpson, JA; Sutanto, I; Taylor, WRJ; Thanh, NV; Thriemer, K; Tuyet-Trinh, NT; von Seidlein, L; Waithira, N; White, NJ; Woyessa, A, 2023) |
| "Primaquine is the only widely available drug for radical cure of Plasmodium vivax malaria." | 9.41 | Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with Plasmodium vivax Malaria. ( Aung, AA; Blessborn, D; Chu, CS; Hanpithakpong, W; Imwong, M; Kraft, K; Ling, C; Nosten, FH; Phyo, AP; Proux, S; Soe, NL; Tarning, J; Thinraow, S; Watson, JA; White, NJ; Wilaisrisak, P; Win, HH; Yotyingaphiram, W, 2021) |
| "Ophthalmic safety observations are reported from a clinical trial comparing tafenoquine (TQ) efficacy and safety versus sequential chloroquine (CQ)/primaquine (PQ) for acute Plasmodium vivax malaria." | 9.30 | Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. ( Euswas, A; Fukuda, MM; Ittiverakul, M; Krudsood, S; Miller, RS; Ohrt, C; Warrasak, S, 2019) |
| "Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P." | 9.30 | Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. ( Angus, B; Aruachan, S; Bancone, G; Breton, JJ; Brito, MAM; Casapía, M; Chu, CS; Chuquiyauri, R; Clover, DD; Costa, MRF; Craig, G; Duparc, S; Green, JA; Hardaker, E; Hien, TT; Jones, SW; Kendall, L; Koh, GCKW; Lacerda, MVG; Llanos-Cuentas, A; Mohamed, K; Monteiro, WM; Namaik-Larp, C; Nguyen, CH; Nosten, FH; Papwijitsil, R; Rousell, VM; Val, F; Vélez, ID; Villegas, MF; Wilches, VM, 2019) |
| "Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain." | 9.30 | Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. ( Bancone, G; Carrara, VI; Chu, CS; Imwong, M; Jeeyapant, A; Lee, SJ; Nosten, F; Paw, MK; Phyo, AP; Poe, NP; Proux, S; Raksapraidee, R; Sriprawat, K; Tarning, J; Thinraow, S; Turner, C; Watson, J; White, NJ; Wiladphaingern, J; Wilairisak, P; Win, HH; Yotyingaphiram, W, 2019) |
| "Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor." | 9.30 | Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. ( Assawariyathipat, T; Assefa, A; Auburn, S; Baird, JK; Chand, K; Chau, NH; Cheah, PY; Day, NP; Degaga, TS; Devine, A; Dhorda, M; Dondorp, A; Dong, LT; Ekawati, LL; Fahmi, F; Hailu, A; Hasanzai, MA; Hien, TT; Khu, H; Ley, B; Lubell, Y; Marfurt, J; Mohammad, H; Moore, KA; Naddim, MN; Pasaribu, AP; Pasaribu, S; Price, RN; Promnarate, C; Rahim, AG; Simpson, JA; Sirithiranont, P; Solomon, H; Sudoyo, H; Sutanto, I; Taylor, WRJ; Thanh, NV; Thriemer, K; Tuyet-Trinh, NT; von Seidlein, L; Waithira, N; White, NJ; Woyessa, A; Yamin, FY; Yuentrakul, P, 2019) |
| " Artesunate cleared parasitemia significantly faster than chloroquine." | 9.27 | Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( Aung, AA; Bancone, G; Carrara, VI; Cheah, PY; Chu, CS; Chue, AL; Imwong, M; Lwin, KM; Moore, KA; Nosten, F; Phyo, AP; Proux, S; Raksapraidee, R; San, T; Sriprawat, K; Tarning, J; Watson, J; White, NJ; Wiladphaingern, J; Win, HH; Winterberg, M, 2018) |
| "Radical cure of Plasmodium vivax malaria with 8-aminoquinolines (primaquine or tafenoquine) is complicated by haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency." | 9.24 | Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens. ( Bancone, G; Charunwatthana, P; Chowwiwat, N; Chu, CS; Keereecharoen, L; Moore, KA; Nosten, F; Phyo, AP; Po, C; Proux, S; Raksapraidee, R; Thitipanawan, N; White, NJ; Wilairisak, P; Win, HH, 2017) |
| "Primaquine (PQ) is recommended to prevent relapses in patients with Plasmodium vivax malaria infection." | 9.14 | Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment. ( Alvarez, G; Carmona-Fonseca, J; Maestre, A, 2009) |
| "Thai adult males (N = 85) with acute Plasmodium vivax malaria and normal glucose-6-phosphate dehydrogenase screening were randomized to receive 30 mg or 60 mg primaquine daily for 7 days (N = 43 and 42, respectively)." | 9.14 | A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. ( Chotivanich, K; Day, NP; Imwong, M; Pukrittayakamee, S; Singhasivanon, P; White, NJ, 2010) |
| "Tafenoquine is being developed for radical cure and post-exposure prophylaxis of Plasmodium vivax malaria." | 9.13 | The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. ( Edstein, MD; Elmes, NJ; Kitchener, SJ; Kocisko, DA; Nasveld, PE, 2008) |
| " In a previous dose-ranging study in Thailand, 3 tafenoquine regimens with total doses ranging from 500 mg to 3000 mg prevented relapse of Plasmodium vivax malaria in most patients when administered 2 days after receipt of a blood schizonticidal dose of chloroquine." | 9.11 | Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. ( Brewer, TG; Heppner, DG; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Siriyanonda, D; Tang, DB; Walsh, DS; Wilairatana, P, 2004) |
| "For over 4 decades the antimalarial program in India has been prescribing a 5-day primaquine regimen as an antirelapse therapy to treat Plasmodium vivax malaria." | 9.10 | Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India. ( Ghosh, SK; Yadav, RS, 2002) |
| "To improve upon the efficacy of primaquine prophylaxis for malaria (94%, Plasmodium falciparum malaria; 85%, Plasmodium vivax malaria), we administered chloroquine (300 mg weekly) in combination with primaquine (30 mg daily) to nonimmune Colombian soldiers during 16 weeks of patrol in a region of endemicity and for a further 1 week in base camp." | 9.09 | Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers. ( Berman, J; Herrera, R; Padilla, J; Rodriquez, M; Sanchez, J; Soto, J; Toledo, J, 1999) |
| ", Basel Switzerland) (pyrimethamine and sulfadoxine), primaquine in a high dose, and artesunate for treating acute Plasmodium vivax malaria, we conducted a comparative clinical trial of these 3 drugs in an open-label study." | 9.09 | Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. ( Bussaratid, V; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Singhasivanon, P; Srivilirit, S; Treeprasertsuk, S; Wilairatana, P, 1999) |
| "25 mg of base/kg of body weight/day over 14 days) and chloroquine (25 mg of base/kg over 3 days) were compared in 85 adult Thai men with acute Plasmodium vivax malaria." | 9.07 | Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. ( Chantra, A; Clemens, R; Pukrittayakamee, S; Vanijanonta, S; White, NJ, 1994) |
| "primaquine (PQ) is the only drug available in the market to prevent Plasmodium vivax malaria recurrence, but several aspects are still unknown." | 8.88 | [Plasmodium vivax malaria recurrence according to the use of primaquine: analysis of longitudinal descriptive studies]. ( Carmona-Fonseca, J, 2012) |
| "Primaquine is essential for the radical cure of Plasmodium vivax malaria, but it poses a potential danger of severe hemolysis in G6PD-deficient (G6PDd) patients." | 8.31 | Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency. ( Cui, L; Kim, K; Lakshmi, S; Liu, H; Malla, P; Menezes, L; Wang, C; Yang, Z; Zeng, W, 2023) |
| "Primaquine prevents relapses of Plasmodium vivax malaria but can cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency." | 8.31 | Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function. ( Anstey, NM; Douglas, NM; Ley, B; Piera, KA; Price, RN; Rumaseb, A, 2023) |
| "Primaquine (PQ) kills Plasmodium vivax hypnozoites but can cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency." | 8.31 | Severe Hemolysis during Primaquine Radical Cure of Plasmodium vivax Malaria: Two Systematic Reviews and Individual Patient Data Descriptive Analyses. ( Brito-Sousa, JD; Chu, C; Commons, RJ; Douglas, NM; Groves, ES; Lacerda, MVG; Monteiro, WM; Price, RN; Thriemer, K; Yilma, D, 2023) |
| "Plasmodium vivax malaria elimination requires radical cure with chloroquine/primaquine." | 8.12 | Active Pharmacovigilance for Primaquine Radical Cure of Plasmodium vivax Malaria in Odisha, India. ( Ahmed, N; Anvikar, AR; Duparc, S; Grewal Daumerie, P; Pradhan, MM; Pradhan, S; Sahu, P; Sharma, S; Valecha, N; Yadav, CP, 2022) |
| "Primaquine and tafenoquine are the only licensed drugs that effectively kill the hypnozoite stage and are used to prevent Plasmodium vivax malaria relapse." | 8.12 | Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure. ( Boonyuen, U; Chamchoy, K; Krudsood, S; Patrapuvich, R; Sudsumrit, S; Thita, T, 2022) |
| "Primaquine and tafenoquine are the two 8-aminoquinoline (8-AQ) antimalarial drugs approved for malarial radical cure - the elimination of liver stage hypnozoites after infection with Plasmodium vivax." | 8.02 | Liver-targeted polymeric prodrugs of 8-aminoquinolines for malaria radical cure. ( Burke, PA; Chavas, TEJ; Flaherty, SM; Ho, DK; Huber, HE; Jackson, C; LeGuyader, CLM; Li, Q; Lin, H; Maktabi, M; Pottenger, A; Pybus, B; Rochford, R; Roy, D; Srinivasan, S; Stayton, PS; Strauch, P; Vlaskin, V; Wesche, D; Zhang, J, 2021) |
| "We reviewed the clinical efficacy of chloroquine for Plasmodium vivax malaria, the changing trend of parasite clearance time, and fever clearance time during 2000-2016 in South Korea." | 7.96 | Increasing Malaria Parasite Clearance Time after Chloroquine Therapy, South Korea, 2000-2016. ( Cho, SH; Kwak, YG; Lee, KS; Lee, SE; Park, SY; Park, Y; Park, YS; Shin, HI; Song, JE; Yeom, JS, 2020) |
| "Primaquine (PQ) is the only drug used to prevent relapse of malaria due to P." | 7.85 | Synthesis of primaquine glyco-conjugates as potential tissue schizontocidal antimalarial agents. ( Anand, N; Azad, CS; Bhardwaj, J; Dutta, GP; Puri, SK; Saxena, AK; Saxena, M; Siddiqui, AJ, 2017) |
| "Several reports of chloroquine treatment failure and resistance in Plasmodium vivax malaria from Southeast Asian countries have been published." | 7.83 | Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India. ( Ashok, H; Kamath, A; Kamath, V; Kumar, R; Kundapura, P; Mukhopadhyay, C; Saravu, K, 2016) |
| "We evaluated the efficacy of chloroquine and primaquine on uncomplicated Plasmodium vivax malaria in Cruzeiro do Sul, Brazil, in 2014." | 7.83 | Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil. ( Chenet, SM; de Oliveira, AM; de Souza, TM; Farias, S; Marchesini, P; Negreiros, S; Okoth, SA; Povoa, MM; Santelli, AC; Udhayakumar, V; Viana, GM, 2016) |
| "Chloroquine-primaquine (CQ-PQ) continues to be the frontline therapy for radical cure of Plasmodium vivax malaria." | 7.81 | Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar. ( Baird, JK; Cao, Y; Cui, L; Fan, Q; Gupta, B; Lee, MC; Liu, H; Parker, DM; Wang, Y; Xiao, Y; Yan, G; Yang, Z; Yuan, L; Zhou, G, 2015) |
| "Of late there have been accounts of therapeutic failure and chloroquine resistance in Plasmodium vivax malaria especially from Southeast Asian regions." | 7.81 | Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India. ( Acharya, RV; Acharya, V; Belle, J; Hande, MH; Kamath, A; Rishikesh, K; Saravu, K; Shastry, AB; Vidyasagar, S, 2015) |
| "Relapse of Plasmodium vivax malaria following standard primaquine dosing has been reported from many areas, and more recently from sub-Saharan Africa." | 7.70 | Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. ( Kurnik, D; Regev-Yochay, G; Schwartz, E, 2000) |
| "The antimalarial effects of rifampin in 60 adults with Plasmodium vivax malaria were assessed." | 7.69 | Antimalarial effects of rifampin in Plasmodium vivax malaria. ( Charoenlarp, P; Pukrittayakamee, S; Viravan, C; White, NJ; Wilson, RJ; Yeamput, C, 1994) |
| "The presence of chloroquine-resistant Plasmodium vivax malaria in the New World has been suspected but not confirmed." | 7.69 | Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. ( Kain, KC; Keystone, JS; Phillips, EJ, 1996) |
| "Acute Plasmodium vivax malaria is associated with haemolysis, bone marrow suppression, reticulocytopenia, and post-treatment reticulocytosis leading to haemoglobin recovery." | 7.01 | Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria. ( Baird, JK; Christophel, E; Kerleguer, A; Kheng, S; Kim, S; Luzzatto, L; Menard, D; Mukaka, M; Muth, S; Taylor, WRJ; Tor, P, 2021) |
| "Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P." | 6.90 | Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. ( Abdissa, A; Abebe, C; Angus, B; Batista Pereira, D; Beck, HP; Brand, F; Breton, JJ; Brito, MAM; Buathong, N; Casapía, M; Chuquiyauri, R; Clover, DD; Costa, MRF; Diro, E; Duparc, S; Espino, FEJ; Fletcher, K; Getie, S; Green, JA; Hardaker, E; Jones, SW; Kellam, LM; Kleim, JP; Koh, GCKW; Krudsood, S; Lacerda, MVG; Llanos-Cuentas, A; Lon, C; Mia, RZ; Mohamed, K; Mohammed, R; Monteiro, WM; Noedl, H; Rousell, VM; Saunders, DL; Tada, MS; Ugwuegbulam, CO; Val, F; Wubie, KM; Yilma, D; Zeynudin, A, 2019) |
| " Most of the adverse events were mild in all treatment arms." | 6.87 | Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial. ( Alexandre, MAA; Alves de Lima E Silva, JC; Daher, A; Dos Santos, TC; Lacerda, MVG; Lalloo, DG; Maia, I; Marchesini, P; Nascimento, CT; Pereira, D; Ruffato, R; Santelli, AC; Tada, M, 2018) |
| " There were no serious adverse events, with most adverse events classified as mild." | 6.82 | Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment. ( Daher, A; Fonseca, L; Fontes, CJ; Maia, I; Marchesini, P; Pereira, D; Pitta, L; Ruffato, R; Zanini, G, 2016) |
| "vivax malaria were eligible for study." | 6.78 | Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. ( Baird, JK; Basri, H; Ekawati, LL; Elyazar, I; Farrar, J; Meilia, RA; Nurleila, S; Putri, FA; Setiabudy, R; Sudoyo, H; Sutanto, I; Taylor, WR; Tjahjono, B, 2013) |
| " Factors related to the reappearance of vivax malaria included inadequate total primaquine dosage received (< 2." | 6.75 | Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. ( Day, NP; Imwong, M; Kaewkungwal, J; Kobayashi, J; Lawpoolsri, S; Maneeboonyang, W; Puangsa-art, S; Pukrittayakamee, S; Singhasivanon, P; Takeuchi, R; Thanyavanich, N, 2010) |
| " We evaluated the efficacy, safety, and tolerability of alternative primaquine dosing regimens combined with artesunate among 399 Thai patients with acute, symptomatic P." | 6.73 | High-dose primaquine regimens against relapse of Plasmodium vivax malaria. ( Baird, JK; Brittenham, GM; Krudsood, S; Looareesuwan, S; Phophak, N; Tangpukdee, N; Wilairatana, P, 2008) |
| " We evaluated the anti-relapse efficacy of total primaquine doses of 45, 105, and 210 mg administered at a dosage of 15 mg/day in 210 adults with P." | 6.72 | Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. ( Alvarez, G; Blair, S; Carmona-Fonseca, J; Maestre, A; Piñeros, JG; Ríos, A; Tobón, A, 2006) |
| "Tafenoquine (TQ) is a new alternative to PQ with a longer half-life and can be used as a single-dose treatment." | 6.66 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2020) |
| "Randomized controlled trials (RCTs) of adults and children with P vivax malaria using any regimen of either chloroquine or an artemisinin-based combination therapy (ACT) plus primaquine with either higher daily doses for 14 days, shorter regimens with the same total dose, or using weekly dosing regimens; compared with the usual standard regimens recommended by the WHO (0." | 6.61 | Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria. ( Daher, A; Graves, PM; Milligan, R, 2019) |
| "Primaquine has the potential to reduce malaria-related anaemia at day 42 and beyond by preventing recurrent parasitaemia." | 6.61 | The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. ( Abreha, T; Alemu, SG; Añez, A; Anstey, NM; Aseffa, A; Assefa, A; Awab, GR; Baird, JK; Barber, BE; Borghini-Fuhrer, I; Chu, CS; Commons, RJ; D'Alessandro, U; Dahal, P; Daher, A; de Vries, PJ; Douglas, NM; Erhart, A; Gomes, MSM; Grigg, MJ; Guerin, PJ; Hien, TT; Hwang, J; Kager, PA; Ketema, T; Khan, WA; Lacerda, MVG; Leslie, T; Ley, B; Lidia, K; Monteiro, WM; Nosten, F; Pereira, DB; Phan, GT; Phyo, AP; Price, RN; Rowland, M; Saravu, K; Sibley, CH; Simpson, JA; Siqueira, AM; Stepniewska, K; Taylor, WRJ; Thriemer, K; Thwaites, G; Tran, BQ; Vieira, JLF; Wangchuk, S; Watson, J; White, NJ; William, T; Woodrow, CJ, 2019) |
| "vivax relapse is a major global public health concern." | 6.53 | Primaquine treatment and relapse in Plasmodium vivax malaria. ( Rishikesh, K; Saravu, K, 2016) |
| "Tafenoquine is a new alternative with a longer half-life." | 6.52 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, SD; Rajapakse, S; Rodrigo, C, 2015) |
| "Primaquine was licenced for anti-relapse therapy in 1952 and became available despite threatening patients having an inborn deficiency of glucose-6-phosphate dehydrogenase (G6PD) with acute haemolytic anaemia." | 6.52 | Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria. ( Baird, K, 2015) |
| "Randomized controlled trials (RCTs) and quasi-RCTs comparing various primaquine dosing regimens with the standard primaquine regimen (15 mg/day for 14 days), or with no primaquine, in people with vivax malaria treated for blood stage infection with chloroquine." | 6.49 | Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. ( Galappaththy, GN; Kirubakaran, R; Tharyan, P, 2013) |
| " Different primaquine dosing regimens are in use." | 6.44 | Primaquine for preventing relapses in people with Plasmodium vivax malaria. ( Galappaththy, GN; Omari, AA; Tharyan, P, 2007) |
| "Plasmodium vivax malaria is considered a major threat to malaria eradication." | 5.91 | Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders. ( Aung, PL; Cui, L; Kyaw, MP; Lawpoolsri, S; Linn, NYY; Nguitragool, W; Ring, Z; Sattabongkot, J; Win, KM, 2023) |
| "Malaria is a major cause of death in low-income countries." | 5.72 | Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine. ( Mohan, M; Nain, M; Sharma, A, 2022) |
| "The primaquine dose was increased with 30 mg for 14 days at the third and fourth episodes." | 5.72 | Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function. ( Baek, JH; Choi, H; Choi, S; Han, JH; Kim, MJ; Kim, YC; Kwak, YG; Oh, HS; Park, SY; Shin, HI; Shin, SY; Song, JE; Yeom, JS, 2022) |
| "We aimed to investigate malaria recurrences among participants receiving daily and weekly PQ treatments in a real-life setting of two municipalities in the Amazon between 2019 and 2020." | 5.72 | Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study. ( Balieiro, PCDS; Brito-Sousa, JD; Cordeiro, JSM; Lacerda, M; Melo, GC; Mendes, M; Monteiro, W; Phanor, J; Sampaio, VS; Silva-Neto, AV; Vitor-Silva, S, 2022) |
| "Primaquine was effective in preventing P." | 5.72 | Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area. ( Björklund, D; Carlander, C; Färnert, A; Hellgren, U; Hervius Askling, H; Sondén, K; Stenström, C; Wångdahl, A; Wyss, K; Zhang, J, 2022) |
| "5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to early- or delayed treatment." | 5.69 | Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment. ( Batty, KT; Davis, TME; Kasian, B; Laman, M; Lorry, L; Manning, L; Moore, BR; Pomat, W; Robinson, LJ; Salman, S; Tesine, P; Woon, SA; Yadi, G; Yambo, P, 2023) |
| "Tafenoquine, co-administered with chloroquine, is approved for the radical cure (prevention of relapse) of Plasmodium vivax malaria." | 5.69 | Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. ( Baird, JK; Berni, A; Budiman, W; Cedar, E; Chand, K; Crenna-Darusallam, C; Duparc, S; Ekawati, LL; Elyazar, I; Fernando, D; Fletcher, K; Goyal, N; Green, JA; Instiaty, I; Jones, S; Kleim, JP; Lardo, S; Martin, A; Noviyanti, R; Prasetya, CB; Rolfe, K; Santy, YW; Satyagraha, AW; Sharma, H; Soebandrio, A; Subekti, D; Sutanto, I; Tan, LK; Taylor, M, 2023) |
| "The World Health Organization recommends that primaquine should be given once weekly for 8-weeks to patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase (G6PD) deficiency, but data on its antirelapse efficacy and safety are limited." | 5.69 | Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency. ( Assefa, A; Baird, JK; Bancone, G; Chand, K; Chau, NH; Day, NP; Degaga, TS; Dhorda, M; Dondorp, A; Ekawati, LL; Hailu, A; Hasanzai, MA; Ley, B; Meagher, N; Naddim, MN; Pasaribu, AP; Price, RN; Rahim, AG; Satyagraha, A; Simpson, JA; Sutanto, I; Taylor, WRJ; Thanh, NV; Thriemer, K; Tuyet-Trinh, NT; von Seidlein, L; Waithira, N; White, NJ; Woyessa, A, 2023) |
| "Chloroquine was measured in plasma samples by high-performance liquid chromatography with fluorescence detection." | 5.56 | Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ( Mello, AGCN; Sena, LWP; Vieira, JLF; Vieira, MVDF, 2020) |
| " Patients with uncomplicated falciparum malaria, G6PD activity of ≥70% of the adjusted male median (AMM) and haemoglobin levels ≥8g/dl are recruited into the study and randomized to either receive standard schizonticidal treatment plus 7-day high dose primaquine (total dose 7mg/kg) or standard care in a 1:1 ratio." | 5.51 | Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas-a randomized controlled trial (PRIMA). ( Abate, DT; Alam, MS; Anose, RT; Baird, K; Christian, M; Degaga, TS; Hailu, A; Hossain, MS; Karahalios, A; Kibria, MG; Kidane, FG; Lee, G; Ley, B; Mnjala, H; Price, RN; Rajasekhar, M; Rumaseb, A; Simpson, JA; Sutanto, I; Tego, TT; Thriemer, K; Weston, S; Woyessa, A, 2022) |
| "vivax malaria was higher in children 1 to <5 years of age (49." | 5.46 | Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. ( Anstey, NM; Douglas, NM; Kenangalem, E; Malloy, MJ; Patriani, D; Poespoprodjo, JR; Price, RN; Simpson, JA; Soenarto, Y; Sugiarto, P, 2017) |
| "Primaquine is the only widely available drug for radical cure of Plasmodium vivax malaria." | 5.41 | Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with Plasmodium vivax Malaria. ( Aung, AA; Blessborn, D; Chu, CS; Hanpithakpong, W; Imwong, M; Kraft, K; Ling, C; Nosten, FH; Phyo, AP; Proux, S; Soe, NL; Tarning, J; Thinraow, S; Watson, JA; White, NJ; Wilaisrisak, P; Win, HH; Yotyingaphiram, W, 2021) |
| " We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine." | 5.40 | Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report. ( Dragsted, UB; Kristensen, KL, 2014) |
| "Primaquine dosing was classified as no dose, low dose (<420 mg), high dose (≥420 mg), or unknown." | 5.38 | Relapse of imported Plasmodium vivax malaria is related to primaquine dose: a retrospective study. ( Looke, D; McCarthy, JS; McDougall, D; Townell, N, 2012) |
| "Ophthalmic safety observations are reported from a clinical trial comparing tafenoquine (TQ) efficacy and safety versus sequential chloroquine (CQ)/primaquine (PQ) for acute Plasmodium vivax malaria." | 5.30 | Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. ( Euswas, A; Fukuda, MM; Ittiverakul, M; Krudsood, S; Miller, RS; Ohrt, C; Warrasak, S, 2019) |
| "Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P." | 5.30 | Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. ( Angus, B; Aruachan, S; Bancone, G; Breton, JJ; Brito, MAM; Casapía, M; Chu, CS; Chuquiyauri, R; Clover, DD; Costa, MRF; Craig, G; Duparc, S; Green, JA; Hardaker, E; Hien, TT; Jones, SW; Kendall, L; Koh, GCKW; Lacerda, MVG; Llanos-Cuentas, A; Mohamed, K; Monteiro, WM; Namaik-Larp, C; Nguyen, CH; Nosten, FH; Papwijitsil, R; Rousell, VM; Val, F; Vélez, ID; Villegas, MF; Wilches, VM, 2019) |
| "Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain." | 5.30 | Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. ( Bancone, G; Carrara, VI; Chu, CS; Imwong, M; Jeeyapant, A; Lee, SJ; Nosten, F; Paw, MK; Phyo, AP; Poe, NP; Proux, S; Raksapraidee, R; Sriprawat, K; Tarning, J; Thinraow, S; Turner, C; Watson, J; White, NJ; Wiladphaingern, J; Wilairisak, P; Win, HH; Yotyingaphiram, W, 2019) |
| "Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor." | 5.30 | Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. ( Assawariyathipat, T; Assefa, A; Auburn, S; Baird, JK; Chand, K; Chau, NH; Cheah, PY; Day, NP; Degaga, TS; Devine, A; Dhorda, M; Dondorp, A; Dong, LT; Ekawati, LL; Fahmi, F; Hailu, A; Hasanzai, MA; Hien, TT; Khu, H; Ley, B; Lubell, Y; Marfurt, J; Mohammad, H; Moore, KA; Naddim, MN; Pasaribu, AP; Pasaribu, S; Price, RN; Promnarate, C; Rahim, AG; Simpson, JA; Sirithiranont, P; Solomon, H; Sudoyo, H; Sutanto, I; Taylor, WRJ; Thanh, NV; Thriemer, K; Tuyet-Trinh, NT; von Seidlein, L; Waithira, N; White, NJ; Woyessa, A; Yamin, FY; Yuentrakul, P, 2019) |
| "The relapses were due to a combination of decreased primaquine sensitivity and incorrect prescription of primaquine." | 5.30 | [Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment]. ( Dolmans, WM; Mulder, L; Telgt, DS, 1997) |
| " Artesunate cleared parasitemia significantly faster than chloroquine." | 5.27 | Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( Aung, AA; Bancone, G; Carrara, VI; Cheah, PY; Chu, CS; Chue, AL; Imwong, M; Lwin, KM; Moore, KA; Nosten, F; Phyo, AP; Proux, S; Raksapraidee, R; San, T; Sriprawat, K; Tarning, J; Watson, J; White, NJ; Wiladphaingern, J; Win, HH; Winterberg, M, 2018) |
| "Radical cure of Plasmodium vivax malaria requires treatment with a blood schizonticide and a hypnozoitocide (primaquine) to eradicate the dormant liver stages." | 5.27 | A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India. ( Bava, A; Bhat, K; Brahmarouphu, G; Channabasavaiah, JP; Guddattu, V; Kulavalli, S; Saadi, AV; Saravu, K; Satyamoorthy, K; Srinivas, NK; Tellapragada, C; Umakanth, S; Xavier, W, 2018) |
| "Radical cure of Plasmodium vivax malaria with 8-aminoquinolines (primaquine or tafenoquine) is complicated by haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency." | 5.24 | Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens. ( Bancone, G; Charunwatthana, P; Chowwiwat, N; Chu, CS; Keereecharoen, L; Moore, KA; Nosten, F; Phyo, AP; Po, C; Proux, S; Raksapraidee, R; Thitipanawan, N; White, NJ; Wilairisak, P; Win, HH, 2017) |
| "Chloroquine combined with primaquine has been the standard radical curative regimen for Plasmodium vivax and Plasmodium ovale malaria for over half a century." | 5.19 | Pharmacokinetic interactions between primaquine and chloroquine. ( Ashley, EA; Charunwatthana, P; Day, NP; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Lawpoolsri, S; Lee, SJ; Pukrittayakamee, S; Tarning, J; White, NJ, 2014) |
| "Primaquine (PQ) is recommended to prevent relapses in patients with Plasmodium vivax malaria infection." | 5.14 | Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment. ( Alvarez, G; Carmona-Fonseca, J; Maestre, A, 2009) |
| "Thai adult males (N = 85) with acute Plasmodium vivax malaria and normal glucose-6-phosphate dehydrogenase screening were randomized to receive 30 mg or 60 mg primaquine daily for 7 days (N = 43 and 42, respectively)." | 5.14 | A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. ( Chotivanich, K; Day, NP; Imwong, M; Pukrittayakamee, S; Singhasivanon, P; White, NJ, 2010) |
| "Tafenoquine is being developed for radical cure and post-exposure prophylaxis of Plasmodium vivax malaria." | 5.13 | The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. ( Edstein, MD; Elmes, NJ; Kitchener, SJ; Kocisko, DA; Nasveld, PE, 2008) |
| "We conducted a study to compare the safety and tolerability of anti-relapse drugs elubaquine and primaquine against Plasmodium vivax malaria." | 5.12 | Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand. ( Brittenham, GM; Chalermrut, K; Krudsood, S; Looareesuwan, S; Luplertlop, N; Muangnoicharoen, S; Srivilairit, S; Tangpukdee, N; Thanachartwet, V; Wilairatana, P, 2006) |
| " In a previous dose-ranging study in Thailand, 3 tafenoquine regimens with total doses ranging from 500 mg to 3000 mg prevented relapse of Plasmodium vivax malaria in most patients when administered 2 days after receipt of a blood schizonticidal dose of chloroquine." | 5.11 | Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. ( Brewer, TG; Heppner, DG; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Siriyanonda, D; Tang, DB; Walsh, DS; Wilairatana, P, 2004) |
| "For over 4 decades the antimalarial program in India has been prescribing a 5-day primaquine regimen as an antirelapse therapy to treat Plasmodium vivax malaria." | 5.10 | Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India. ( Ghosh, SK; Yadav, RS, 2002) |
| "We studied prospectively 801 Thai patients admitted to the Bangkok Hospital for Tropical Diseases with acute, symptomatic Plasmodium vivax malaria to determine the optimum duration of treatment with oral artesunate and the safety, tolerability, and effectiveness of a high dose of primaquine in prevention of relapse." | 5.10 | Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. ( Brittenham, GM; Chalearmrult, K; Gourdeuk, VR; Krudsood, S; Looareesuwan, S; Maneekan, P; Mint, HY; Silachamroon, U; Treeprasertsuk, S; White, NJ; Wilairatana, P, 2003) |
| "To improve upon the efficacy of primaquine prophylaxis for malaria (94%, Plasmodium falciparum malaria; 85%, Plasmodium vivax malaria), we administered chloroquine (300 mg weekly) in combination with primaquine (30 mg daily) to nonimmune Colombian soldiers during 16 weeks of patrol in a region of endemicity and for a further 1 week in base camp." | 5.09 | Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers. ( Berman, J; Herrera, R; Padilla, J; Rodriquez, M; Sanchez, J; Soto, J; Toledo, J, 1999) |
| "Chloroquine has been the standard treatment for Plasmodium vivax malaria for more than 40 years in most regions of the world." | 5.09 | Chloroquine sensitivity of Plasmodium vivax in Thailand. ( Bussaratid, V; Chalermrut, K; Chokjindachai, W; Krudsood, S; Looareesuwan, S; Singhasivanon, P; Treeprasertsuk, S; Viriyavejakul, P; Walsh D, S; White, J; Wilairatana, P, 1999) |
| ", Basel Switzerland) (pyrimethamine and sulfadoxine), primaquine in a high dose, and artesunate for treating acute Plasmodium vivax malaria, we conducted a comparative clinical trial of these 3 drugs in an open-label study." | 5.09 | Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. ( Bussaratid, V; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Singhasivanon, P; Srivilirit, S; Treeprasertsuk, S; Wilairatana, P, 1999) |
| "In an investigation of relapse patterns, 5541 cases of Plasmodium vivax malaria, from four major industrial complexes, each received at least one, 5-day course of primaquine (at 15 mg/day)." | 5.09 | Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India. ( Dua, VK; Sharma, VP, 2001) |
| "25 mg of base/kg of body weight/day over 14 days) and chloroquine (25 mg of base/kg over 3 days) were compared in 85 adult Thai men with acute Plasmodium vivax malaria." | 5.07 | Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. ( Chantra, A; Clemens, R; Pukrittayakamee, S; Vanijanonta, S; White, NJ, 1994) |
| "To reduce the risk of drug-induced haemolysis, all patients should be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) prior to prescribing primaquine (PQ)-based radical cure for the treatment of vivax malaria." | 5.01 | Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis. ( Bancone, G; Douglas, NM; Espino, F; Henriques, G; Karahalios, A; Ley, B; Menard, D; Oo, NN; Parikh, S; Pfeffer, DA; Price, RN; Rahmat, H; von Fricken, ME; von Seidlein, L; Winasti Satyagraha, A, 2019) |
| "Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria despite increasing reports of treatment failure." | 4.98 | The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. ( Abreha, T; Alemu, SG; Añez, A; Anstey, NM; Awab, GR; Baird, JK; Barber, BE; Borghini-Fuhrer, I; Chu, CS; Commons, RJ; D'Alessandro, U; Dahal, P; Daher, A; de Vries, PJ; Erhart, A; Gomes, MSM; Gonzalez-Ceron, L; Grigg, MJ; Guerin, PJ; Heidari, A; Humphreys, GS; Hwang, J; Kager, PA; Ketema, T; Khan, WA; Lacerda, MVG; Leslie, T; Ley, B; Lidia, K; Monteiro, WM; Nosten, F; Pereira, DB; Phan, GT; Phyo, AP; Price, RN; Rowland, M; Saravu, K; Sibley, CH; Simpson, JA; Siqueira, AM; Stepniewska, K; Sutanto, I; Taylor, WRJ; Thriemer, K; Thwaites, G; Tran, BQ; Tran, HT; Valecha, N; Vieira, JLF; Wangchuk, S; White, NJ; William, T; Woodrow, CJ; Zuluaga-Idarraga, L, 2018) |
| " Relapse prevention (radical cure) with primaquine is required for optimal management, control and ultimately elimination of Plasmodium vivax malaria." | 4.93 | Management of relapsing Plasmodium vivax malaria. ( Chu, CS; White, NJ, 2016) |
| "primaquine (PQ) is the only drug available in the market to prevent Plasmodium vivax malaria recurrence, but several aspects are still unknown." | 4.88 | [Plasmodium vivax malaria recurrence according to the use of primaquine: analysis of longitudinal descriptive studies]. ( Carmona-Fonseca, J, 2012) |
| "Primaquine is essential for the radical cure of Plasmodium vivax malaria, but it poses a potential danger of severe hemolysis in G6PD-deficient (G6PDd) patients." | 4.31 | Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency. ( Cui, L; Kim, K; Lakshmi, S; Liu, H; Malla, P; Menezes, L; Wang, C; Yang, Z; Zeng, W, 2023) |
| "Primaquine prevents relapses of Plasmodium vivax malaria but can cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency." | 4.31 | Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function. ( Anstey, NM; Douglas, NM; Ley, B; Piera, KA; Price, RN; Rumaseb, A, 2023) |
| "8-Aminoquinoline antimalarial drugs (primaquine, tafenoquine) are required for complete cure of Plasmodium vivax malaria, but they are contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency." | 4.31 | Performance of a Commercial Multiplex Allele-Specific Polymerase Chain Reaction Kit to Genotype African-Type Glucose-6-Phosphate Dehydrogenase Deficiency. ( Basco, L; Briolant, S; Djigo, OKM; Gomez, N; Ould Ahmedou Salem, MS; Ould Mohamed Salem Boukhary, A, 2023) |
| "Ethiopia rolled out primaquine nationwide in 2018 for radical cure along with chloroquine for the treatment of uncomplicated Plasmodium vivax malaria in its bid for malaria elimination by 2030." | 4.31 | Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response. ( Abadura, GS; Bayissa, GA; Behaksra, SW; Bulto, MG; Gadisa, E; Mekonnen, DA; Tadesse, FG; Taffese, HS; Tessema, TS, 2023) |
| "Primaquine (PQ) kills Plasmodium vivax hypnozoites but can cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency." | 4.31 | Severe Hemolysis during Primaquine Radical Cure of Plasmodium vivax Malaria: Two Systematic Reviews and Individual Patient Data Descriptive Analyses. ( Brito-Sousa, JD; Chu, C; Commons, RJ; Douglas, NM; Groves, ES; Lacerda, MVG; Monteiro, WM; Price, RN; Thriemer, K; Yilma, D, 2023) |
| "Plasmodium vivax malaria elimination requires radical cure with chloroquine/primaquine." | 4.12 | Active Pharmacovigilance for Primaquine Radical Cure of Plasmodium vivax Malaria in Odisha, India. ( Ahmed, N; Anvikar, AR; Duparc, S; Grewal Daumerie, P; Pradhan, MM; Pradhan, S; Sahu, P; Sharma, S; Valecha, N; Yadav, CP, 2022) |
| " Therefore, malaria patient treatment using primaquine should be monitored closely for any adverse effects." | 4.12 | Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre, Eastern Ethiopia. ( Adamu, A; Feleke, SM; Gebremichael, SG; Gidey, B; Hailu, A; Kebede, T; Kepple, D; Lo, E; Nega, D; Negash, MT; Shenkutie, TT; Tasew, G; Witherspoon, L, 2022) |
| "v infection by Village Malaria Workers (VMWs) were referred to local health centres for point-of-care G6PD testing and initiation of radical cure treatment with 14-day or 8-week primaquine regimens depending on G6PD status." | 4.12 | G6PD testing and radical cure for Plasmodium vivax in Cambodia: A mixed methods implementation study. ( Ir, P; Kak, N; Kheang, ST; Lek, D; Ngeth, E; Ngor, P; Phon, S; Ridley, R; Sovannaroth, S; Yeung, S, 2022) |
| "Primaquine and tafenoquine are the only licensed drugs that effectively kill the hypnozoite stage and are used to prevent Plasmodium vivax malaria relapse." | 4.12 | Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure. ( Boonyuen, U; Chamchoy, K; Krudsood, S; Patrapuvich, R; Sudsumrit, S; Thita, T, 2022) |
| "To investigate the impact of Plasmodium vivax malaria and chloroquine-primaquine chemotherapy on CYP2D6 and CYP2C19 activity in patients from the Brazilian Amazon." | 4.02 | Impact of Plasmodium vivax malaria and antimalarial treatment on cytochrome P450 activity in Brazilian patients. ( Almeida, AC; Brasil, LW; da Costa, AG; de Lacerda, MVG; de Melo, GC; Elias, ABR; Figueiredo, EFG; Lanchote, VL; Marques, MP; Monteiro, WM; Rodrigues-Soares, F; Suarez-Kurtz, G, 2021) |
| "Primaquine and tafenoquine are the two 8-aminoquinoline (8-AQ) antimalarial drugs approved for malarial radical cure - the elimination of liver stage hypnozoites after infection with Plasmodium vivax." | 4.02 | Liver-targeted polymeric prodrugs of 8-aminoquinolines for malaria radical cure. ( Burke, PA; Chavas, TEJ; Flaherty, SM; Ho, DK; Huber, HE; Jackson, C; LeGuyader, CLM; Li, Q; Lin, H; Maktabi, M; Pottenger, A; Pybus, B; Rochford, R; Roy, D; Srinivasan, S; Stayton, PS; Strauch, P; Vlaskin, V; Wesche, D; Zhang, J, 2021) |
| "Primaquine is an approved radical cure treatment for Plasmodium vivax malaria but treatment can result in life-threatening hemolysis if given to a glucose-6-phosphate dehydrogenase deficient (G6PDd) patient." | 3.96 | Evaluation of the CareStart™ glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in the field settings and assessment of perceived risk from primaquine at the community level in Cambodia. ( Boonchan, T; Buathong, N; Chann, S; Dao, V; Feldman, M; Fukuda, MM; Gosi, P; Hom, S; Huy, R; Ittiverakul, M; Kong, N; Kuntawunginn, W; Lek, D; Lon, C; Ly, S; Nou, S; Oung, P; Pheap, V; Sea, D; Smith, P; Sok, C; Sok, S; Spring, M; Sriwichai, S; Thay, K; Uthaimongkol, N; Wojnarski, B; Wojnarski, M, 2020) |
| "We reviewed the clinical efficacy of chloroquine for Plasmodium vivax malaria, the changing trend of parasite clearance time, and fever clearance time during 2000-2016 in South Korea." | 3.96 | Increasing Malaria Parasite Clearance Time after Chloroquine Therapy, South Korea, 2000-2016. ( Cho, SH; Kwak, YG; Lee, KS; Lee, SE; Park, SY; Park, Y; Park, YS; Shin, HI; Song, JE; Yeom, JS, 2020) |
| " Treatment of Plasmodium vivax malaria with primaquine poses a potential risk of mild to severe acute haemolytic anaemia in G6PD deficient people." | 3.91 | Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia. ( Koepfli, C; Lee, MC; Lo, E; Pestana, K; Raya, B; Yan, G; Yewhalaw, D; Zhong, D, 2019) |
| "Primaquine is the only drug providing radical cure of Plasmodium vivax malaria." | 3.88 | Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures. ( Bancone, G; Carrara, VI; Chu, CS; Gilder, ME; Hanpithakphong, W; Hilda, N; Hoglund, RM; McGready, R; Nosten, F; Singhasivanon, P; Tarning, J; White, NJ; Win, HH, 2018) |
| "Primaquine (PQ) is the only drug used to prevent relapse of malaria due to P." | 3.85 | Synthesis of primaquine glyco-conjugates as potential tissue schizontocidal antimalarial agents. ( Anand, N; Azad, CS; Bhardwaj, J; Dutta, GP; Puri, SK; Saxena, AK; Saxena, M; Siddiqui, AJ, 2017) |
| "Several reports of chloroquine treatment failure and resistance in Plasmodium vivax malaria from Southeast Asian countries have been published." | 3.83 | Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India. ( Ashok, H; Kamath, A; Kamath, V; Kumar, R; Kundapura, P; Mukhopadhyay, C; Saravu, K, 2016) |
| "We evaluated the efficacy of chloroquine and primaquine on uncomplicated Plasmodium vivax malaria in Cruzeiro do Sul, Brazil, in 2014." | 3.83 | Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil. ( Chenet, SM; de Oliveira, AM; de Souza, TM; Farias, S; Marchesini, P; Negreiros, S; Okoth, SA; Povoa, MM; Santelli, AC; Udhayakumar, V; Viana, GM, 2016) |
| "Chloroquine-primaquine (CQ-PQ) continues to be the frontline therapy for radical cure of Plasmodium vivax malaria." | 3.81 | Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar. ( Baird, JK; Cao, Y; Cui, L; Fan, Q; Gupta, B; Lee, MC; Liu, H; Parker, DM; Wang, Y; Xiao, Y; Yan, G; Yang, Z; Yuan, L; Zhou, G, 2015) |
| "Safe treatment of Plasmodium vivax requires diagnosis of both the infection and status of erythrocytic glucose-6-phosphate dehydrogenase (G6PD) activity because hypnozoitocidal therapy against relapse requires primaquine, which causes a mild to severe acute hemolytic anemia in G6PD deficient patients." | 3.81 | G6PD deficiency at Sumba in Eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing Vivax malaria. ( Baird, JK; Baramuli, V; Coutrier, FN; Elvira, R; Elyazar, I; Harahap, AR; Noviyanti, R; Ridenour, C; Sadhewa, A; Satyagraha, AW, 2015) |
| "Of late there have been accounts of therapeutic failure and chloroquine resistance in Plasmodium vivax malaria especially from Southeast Asian regions." | 3.81 | Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India. ( Acharya, RV; Acharya, V; Belle, J; Hande, MH; Kamath, A; Rishikesh, K; Saravu, K; Shastry, AB; Vidyasagar, S, 2015) |
| "Administering primaquine (PQ) to treat malaria patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency can pose a serious risk of drug-induced hemolysis (DIH)." | 3.80 | Performance of the CareStart glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in Gressier, Haiti. ( Beau de Rochars, MV; Eaton, WT; Masse, R; Okech, BA; von Fricken, ME; Weppelmann, TA, 2014) |
| " This feature could be used as a screening tool for G6PD-deficient persons who are unable to use primaquine for the radical cure of Plasmodium vivax malaria." | 3.80 | High frequency of diabetes and impaired fasting glucose in patients with glucose-6-phosphate dehydrogenase deficiency in the Western brazilian Amazon. ( Alecrim, MG; Brito, MA; Costa, MR; Lacerda, MV; Monteiro, WM; Sampaio, VS; Santana, MS, 2014) |
| " Radical cure with primaquine was prescribed after the first bout of malaria for 6 patients." | 3.80 | Compliance to recommendations for the management of curative treatment of Plasmodium vivax/ovale infections. ( Bellanger, AP; Chirouze, C; Faucher, JF; Hoen, B; Hustache-Mathieu, L; Shaniya, N, 2014) |
| "Primaquine (PQ) remains the sole available drug to prevent relapse of Plasmodium vivax malaria more than 60 years after licensure." | 3.80 | Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta). ( Gettyacamin, M; Imerbsin, R; Khemawoot, P; Lanteri, C; Nanayakkara, NP; Ohrt, C; Sampath, A; Saunders, D; Siripokasupkul, R; Teja-Isavadharm, P; Tekwani, BL; Vanachayangkul, P; Walker, L, 2014) |
| "Primaquine is the only drug available for preventing relapse following a primary attack by Plasmodium vivax malaria." | 3.80 | The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. ( Baird, JK; Crenna-Darusallam, C; Ingram, RJ; Noviyanti, R; Soebianto, S, 2014) |
| "Patients with Plasmodium vivax malaria are treated with primaquine to prevent relapse infections." | 3.79 | Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria. ( Alenazi, T; Bright, AT; Houston, S; Paganotti, GM; Shokoples, S; Tarning, J; White, NJ; Winzeler, EA; Yanow, SK, 2013) |
| " After sporozoite inoculation and blood-stage cure of initial parasitemia with chloroquine, rhesus macaques were treated on subsequent relapses with chloroquine in conjunction with test regimens of approved drugs." | 3.78 | Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances. ( Bennett, K; Deye, GA; Fracisco, S; Gettayacamin, M; Hansukjariya, P; Im-erbsin, R; Macareo, L; Magill, AJ; Ohrt, C; Rothstein, Y; Sattabongkot, J, 2012) |
| "In Honduras, chloroquine and primaquine are recommended and still appear to be effective for treatment of Plasmodium falciparum and Plasmodium vivax malaria." | 3.77 | Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America. ( Alger, J; Banegas, E; Bjorkman, A; Enamorado, IG; Ferreira, PE; Fontecha, G; Jovel, IT; Mejía, RE; Piedade, R; Ursing, J; Veiga, MI, 2011) |
| " knowlesi infection had uncomplicated malaria that responded to chloroquine and primaquine treatment." | 3.75 | Clinical and laboratory features of human Plasmodium knowlesi infection. ( Cox-Singh, J; Daneshvar, C; Davis, TM; Divis, PC; Rafa'ee, MZ; Singh, B; Zakaria, SK, 2009) |
| "The standard adult treatment regimen for Plasmodium vivax malaria is chloroquine (1500 mg over 3 d) plus primaquine (15 or 30 mg daily for 14 d), but patient compliance tends to be poor with the lengthy course." | 3.74 | Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine. ( Chavchich, M; Cuong, BT; Dai, B; Dao, NV; Duy, DN; Edstein, MD; Ngoa, ND; Rieckmann, KH; Thanh, NX; The, ND; Thuy, le TT, 2007) |
| "Primaquine is now the only drug available to eradicate Plasmodium vivax malaria." | 3.73 | [How much primaquine is needed to eradicate Plasmodium vivax hypnozoites?]. ( Alonso, D; Corachán, M; Gascón, J; Muñoz, J; Valls, ME; Velasco, M, 2006) |
| "The influence of combinations containing the blood schizontocides chloroquine (CQ) or mefloquine (MEF), together with the 8-aminoquinolines (8AQ) primaquine (PQ) or the new, long-acting compound, tafenoquine (TAF), on the rate of selection of resistance to the individual compounds was examined using the asexual, intra-erythrocytic stages in rodent malaria models." | 3.72 | The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines. ( Peters, W; Robinson, BL; Stewart, LB, 2003) |
| "Relapse of Plasmodium vivax malaria following standard primaquine dosing has been reported from many areas, and more recently from sub-Saharan Africa." | 3.70 | Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. ( Kurnik, D; Regev-Yochay, G; Schwartz, E, 2000) |
| "Seventy-nine adults with Plasmodium vivax malaria, from the Porto Velho area of Rond nia (western Amazon region, Brazil), gave informed consent to participate in a blind, clinical study of two regimens of treatment with chloroquine (CQ) and primaquine." | 3.70 | In-vivo sensitivity of Plasmodium vivax isolates from Rond nia (western Amazon region, Brazil) to regimens including chloroquine and primaquine. ( Kimura, E; Menezes, MJ; Pereira da Silva, LH; Tada, MS; Villalobos-Salcedo, JM, 2000) |
| "The antimalarial effects of rifampin in 60 adults with Plasmodium vivax malaria were assessed." | 3.69 | Antimalarial effects of rifampin in Plasmodium vivax malaria. ( Charoenlarp, P; Pukrittayakamee, S; Viravan, C; White, NJ; Wilson, RJ; Yeamput, C, 1994) |
| "The presence of chloroquine-resistant Plasmodium vivax malaria in the New World has been suspected but not confirmed." | 3.69 | Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. ( Kain, KC; Keystone, JS; Phillips, EJ, 1996) |
| "8 patients with paludism diagnosis due to Plasmodium vivax and deficiency of glucose-6-phosphate dehydrogenase that should receive antipaludism radical treatment with primaquine were studied." | 3.69 | [Hemolysis and primaquine treatment. Preliminary report]. ( Díaz Pérez, L; Luzardo Suárez, C; Menéndez Capote, R, 1997) |
| "Primaquine radical cure has the potential to reduce P vivax recurrences in patients presenting with P falciparum as well as P vivax malaria but is undermined by poor adherence to the currently recommended 14-day regimen." | 3.11 | Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial. ( Burdam, FH; Candrawati, F; Indrawanti, R; Kenangalem, E; Ley, B; Meagher, N; Poespoprodjo, JR; Price, DJ; Price, RN; Simpson, JA; Thriemer, K; Trianty, L, 2022) |
| " Herein, the results of three bioequivalence studies are presented, providing individual pharmacokinetic data on chloroquine and primaquine of more than a hundred healthy volunteers and using up-to-date analytical methods." | 3.11 | Pharmacokinetics of chloroquine and primaquine in healthy volunteers. ( da Fonseca, LB; da Silva, DMD; da Silva, LSFV; Daher, A; Esteves, AL; Mendonça, JS; Pereira, HM; Pinto, DP; Soares Medeiros, JJ, 2022) |
| "Acute Plasmodium vivax malaria is associated with haemolysis, bone marrow suppression, reticulocytopenia, and post-treatment reticulocytosis leading to haemoglobin recovery." | 3.01 | Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria. ( Baird, JK; Christophel, E; Kerleguer, A; Kheng, S; Kim, S; Luzzatto, L; Menard, D; Mukaka, M; Muth, S; Taylor, WRJ; Tor, P, 2021) |
| "vivax recurrence between days 7 and 90 was investigated by Cox regression analysis." | 3.01 | Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. ( Abreha, T; Adam, I; Awab, GR; Baird, JK; Brasil, LW; Chu, CS; Commons, RJ; Cui, L; Daher, A; Dini, S; do Socorro M Gomes, M; Gonzalez-Ceron, L; Guerin, PJ; Hwang, J; Karunajeewa, H; Lacerda, MVG; Ladeia-Andrade, S; Leslie, T; Ley, B; Lidia, K; Llanos-Cuentas, A; Longley, RJ; Mehdipour, P; Monteiro, WM; Pereira, DB; Price, RN; Rajasekhar, M; Rijal, KR; Saravu, K; Simpson, JA; Sutanto, I; Taylor, WRJ; Thanh, PV; Thriemer, K; Vieira, JLF; White, NJ; Zaloumis, S; Zuluaga-Idarraga, LM, 2023) |
| "The median time to recurrence of P." | 2.94 | The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR. ( Adhikari, B; Cobelens, F; Day, NPJ; Dhorda, M; Dondorp, AM; Henriques, G; Imwong, M; Mayxay, M; Mukaka, M; Newton, PN; Peerawaranun, P; Peto, TJ; Phommasone, K; Pongvongsa, T; Promnarate, C; Sirithiranont, P; van Leth, F; von Seidlein, L; White, NJ, 2020) |
| "We show that individual vivax malaria recurrences can be characterised probabilistically by combined modelling of time-to-event and genetic data within a framework incorporating identity-by-descent." | 2.90 | Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. ( Buckee, CO; Chu, CS; Day, NPJ; Duanguppama, J; Imwong, M; Neafsey, DE; Nosten, F; Puaprasert, K; Taylor, AR; Watson, JA; White, NJ, 2019) |
| "Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P." | 2.90 | Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. ( Abdissa, A; Abebe, C; Angus, B; Batista Pereira, D; Beck, HP; Brand, F; Breton, JJ; Brito, MAM; Buathong, N; Casapía, M; Chuquiyauri, R; Clover, DD; Costa, MRF; Diro, E; Duparc, S; Espino, FEJ; Fletcher, K; Getie, S; Green, JA; Hardaker, E; Jones, SW; Kellam, LM; Kleim, JP; Koh, GCKW; Krudsood, S; Lacerda, MVG; Llanos-Cuentas, A; Lon, C; Mia, RZ; Mohamed, K; Mohammed, R; Monteiro, WM; Noedl, H; Rousell, VM; Saunders, DL; Tada, MS; Ugwuegbulam, CO; Val, F; Wubie, KM; Yilma, D; Zeynudin, A, 2019) |
| " Most of the adverse events were mild in all treatment arms." | 2.87 | Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial. ( Alexandre, MAA; Alves de Lima E Silva, JC; Daher, A; Dos Santos, TC; Lacerda, MVG; Lalloo, DG; Maia, I; Marchesini, P; Nascimento, CT; Pereira, D; Ruffato, R; Santelli, AC; Tada, M, 2018) |
| "vivax malaria were treated with AS/SP." | 2.87 | Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan. ( Abdelbagi, H; Basheir, HM; Boshara, SA; Chen, I; Elobied, ME; Elsafi, HMH; Gosling, R; Gumaa, SA; Hamid, MMA; Hamid, T; Ley, B; Mahgoub, NS; Marfurt, J; Price, RN; Thriemer, K, 2018) |
| "Characterization of the pharmacokinetic properties of the enantiomers of primaquine and carboxyprimaquine following administration of racemic primaquine given alone and in combination with commonly used antimalarial drugs." | 2.87 | Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. ( Blessborn, D; Chairat, K; Day, NPJ; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Pukrittayakamee, S; Tarning, J; White, NJ, 2018) |
| "Chloroquine serves as a drug of choice, with primaquine as a radical cure." | 2.82 | Global scenario of Plasmodium vivax occurrence and resistance pattern. ( Kaur, D; Sehgal, R; Sinha, S, 2022) |
| " No clear dose-response pattern was evident for heterologous recurrences of P." | 2.82 | Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping. ( Beck, HP; Carter, N; Duparc, S; Green, JA; Koh, G; Krudsood, S; Lacerda, MV; Llanos-Cuentas, A; Osorio, L; Rubio, JP; Rueangweerayut, R; Wampfler, R, 2016) |
| " There were no serious adverse events, with most adverse events classified as mild." | 2.82 | Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment. ( Daher, A; Fonseca, L; Fontes, CJ; Maia, I; Marchesini, P; Pereira, D; Pitta, L; Ruffato, R; Zanini, G, 2016) |
| "Pyronaridine-artesunate is a newly introduced artemisinin-based combination treatment which may be deployed together with primaquine." | 2.80 | Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. ( Ashley, EA; Blessborn, D; Chairat, K; Day, NP; Hanboonkunupakarn, B; Jittamala, P; Lee, SJ; Nosten, F; Panapipat, S; Pukrittayakamee, S; Tarning, J; Thana, P; White, NJ, 2015) |
| "Some parasite recurrences were detected by PCR and/or serological testing." | 2.80 | Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico. ( Betanzos, AF; Galindo-Virgen, S; Gonzalez-Ceron, L; Palomeque, OL; Rodriguez, MH; Rosales, AF; Sandoval, MA; Santillan, F, 2015) |
| "Plasmodium vivax malaria is a major cause of morbidity and recognised as an important contributor to mortality in some endemic areas." | 2.80 | Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. ( , 2015) |
| " We assessed primaquine (PQ) as hypnozoitocide when administered with dihydroartemisinin-piperaquine (Eurartesim®, DHA-PP) or artesunate-pyronaridine (Pyramax®, AS-PYR) to affirm its good tolerability and efficacy." | 2.80 | Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. ( Baird, JK; Basri, H; Chand, K; Djoko, D; Duparc, S; Ekasari, T; Ekawati, LL; Elyazar, I; Nelwan, EJ; Noviyanti, R; Setiabudy, R; Subekti, D; Sudoyo, H; Sutanto, I; Taylor, WR; Tjahjono, B, 2015) |
| "A high prevalence of chloroquine-resistant Plasmodium vivax in Indonesia has shifted first-line treatment to artemisinin-based combination therapies, combined with primaquine (PQ) for radical cure." | 2.78 | A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia. ( Chavez, I; Chokejindachai, W; Dondorp, AM; Imwong, M; Pasaribu, AP; Pasaribu, S; Sirivichayakul, C; Tanomsing, N; Tjitra, E; White, NJ, 2013) |
| "Radical cure of vivax malaria is one of challenges for malaria elimination." | 2.78 | Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China. ( Li, CF; Liu, H; Nie, RH; Wang, JZ; Xu, JW; Yang, HL, 2013) |
| "vivax malaria were eligible for study." | 2.78 | Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. ( Baird, JK; Basri, H; Ekawati, LL; Elyazar, I; Farrar, J; Meilia, RA; Nurleila, S; Putri, FA; Setiabudy, R; Sudoyo, H; Sutanto, I; Taylor, WR; Tjahjono, B, 2013) |
| " Chloroquine, either alone or in combination with primaquine, is still effective against P." | 2.78 | In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes. ( Bera, DK; Biswas, A; Das, S; Ganguly, S; Guha, SK; Kundu, PK; Maji, AK; Ray, K; Saha, B; Saha, P, 2013) |
| "This suggested that 32 of the 47 recurrences were probable relapses of which 22 (69%) were genetically homologous." | 2.77 | Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata. ( Addy, M; Day, NP; Dondorp, AM; Imwong, M; Kim, JR; Maji, AK; Nandy, A; Pukrittayakamee, S; White, NJ, 2012) |
| "Primaquine treatment also reduced the risk of quantitative real-time polymerase chain reaction- and light microscopy-positive P." | 2.77 | Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. ( Alonso, PL; Bassat, Q; Betuela, I; de Lazzari, E; Del Portillo, HA; Kiniboro, B; Mueller, I; Rosanas-Urgell, A; Samol, L; Siba, P; Stanisic, DI, 2012) |
| "A safe and reproducible Plasmodium vivax infectious challenge method is required to evaluate the efficacy of malaria vaccine candidates." | 2.76 | Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. ( Arévalo-Herrera, M; Echavarría, JF; Epstein, JE; Herrera, S; Jordán-Villegas, A; Palacios, R; Ramírez, O; Richie, TL; Rocha, L; Solarte, Y; Vélez, JD, 2011) |
| " The most common adverse events were nausea, abdominal pain, headache and insomnia, many of which were mild in severity (30%; 60/203) and transient; 19% of subjects (39/203) experienced moderate (with some interference with daily duties requiring no or minimal medical therapy) adverse events." | 2.76 | Evaluation of the safety and tolerability of a short higher-dose primaquine regimen for presumptive anti-relapse therapy in healthy subjects. ( Baker, J; Ebringer, A; Edstein, MD; Heathcote, G; Shanks, GD; Waller, M, 2011) |
| " Factors related to the reappearance of vivax malaria included inadequate total primaquine dosage received (< 2." | 2.75 | Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. ( Day, NP; Imwong, M; Kaewkungwal, J; Kobayashi, J; Lawpoolsri, S; Maneeboonyang, W; Puangsa-art, S; Pukrittayakamee, S; Singhasivanon, P; Takeuchi, R; Thanyavanich, N, 2010) |
| "A practical radical treatment for vivax malaria is essential for control and elimination of the disease." | 2.73 | A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan. ( Erasmus, P; Kolaczinski, J; Leslie, T; Mayan, I; Mohammed, N; Rowland, M; Whitty, CJ, 2008) |
| " We evaluated the efficacy, safety, and tolerability of alternative primaquine dosing regimens combined with artesunate among 399 Thai patients with acute, symptomatic P." | 2.73 | High-dose primaquine regimens against relapse of Plasmodium vivax malaria. ( Baird, JK; Brittenham, GM; Krudsood, S; Looareesuwan, S; Phophak, N; Tangpukdee, N; Wilairatana, P, 2008) |
| "FDA for the treatment of P." | 2.72 | Tafenoquine for ( Gautam, CS; Sharma, J; Singh, H; Singh, J, 2021) |
| " We evaluated the anti-relapse efficacy of total primaquine doses of 45, 105, and 210 mg administered at a dosage of 15 mg/day in 210 adults with P." | 2.72 | Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. ( Alvarez, G; Blair, S; Carmona-Fonseca, J; Maestre, A; Piñeros, JG; Ríos, A; Tobón, A, 2006) |
| "Vivax malaria was endemic on the Korean peninsula for many centuries until the late 1970's when the Republic of Korea (ROK) was declared "malaria free"." | 2.71 | Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army. ( Ahn, SY; Cha, JE; Choi, DH; Kim, YA; Lee, JH; Oh, S; Oh, YH; Park, JW; Ryu, SH; Song, KJ; Yang, HY; Yeom, JS, 2005) |
| "Primaquine was better tolerated than chloroquine." | 2.68 | Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. ( Baird, JK; Bangs, MJ; Basri, H; Fryauff, DJ; Leksana, B; Masbar, S; Richie, TL; Subianto, B; Wiady, I, 1995) |
| "Halofantrine-primaquine was significantly more effective than chloroquine-primaquine against falciparum malaria (P < 0." | 2.68 | Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia. ( Baird, JK; Bangs, MJ; Basri, H; Fryauff, DJ; Harjosuwarno, S; Hoffman, SL; Richie, TL; Subianto, B; Tjitra, E; Wiady, I, 1997) |
| " We do not know whether there is a difference in adverse events resulting in discontinuation of treatment with the high-standard dosage (RR 4." | 2.66 | Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax. ( Bergman, H; Daher, A; Graves, PM; Milligan, R; Villanueva, G, 2020) |
| "Tafenoquine (TQ) is a new alternative to PQ with a longer half-life and can be used as a single-dose treatment." | 2.66 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2020) |
| "vivax recurrence between days 7 and 42 after starting treatment were investigated by Cox regression analyses according to an a priori analysis plan." | 2.61 | The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. ( Abreha, T; Adam, I; Anstey, NM; Assefa, A; Awab, GR; Baird, JK; Barber, BE; Chu, CS; Commons, RJ; Dahal, P; Daher, A; Davis, TME; Dondorp, AM; Grigg, MJ; Guerin, PJ; Hien, TT; Humphreys, GS; Hwang, J; Karunajeewa, H; Laman, M; Lidia, K; Moore, BR; Mueller, I; Nosten, F; Pasaribu, AP; Pereira, DB; Phyo, AP; Poespoprodjo, JR; Price, RN; Sibley, CH; Simpson, JA; Stepniewska, K; Sutanto, I; Thriemer, K; Thwaites, G; White, NJ; William, T; Woodrow, CJ, 2019) |
| "Randomized controlled trials (RCTs) of adults and children with P vivax malaria using any regimen of either chloroquine or an artemisinin-based combination therapy (ACT) plus primaquine with either higher daily doses for 14 days, shorter regimens with the same total dose, or using weekly dosing regimens; compared with the usual standard regimens recommended by the WHO (0." | 2.61 | Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria. ( Daher, A; Graves, PM; Milligan, R, 2019) |
| "Primaquine has the potential to reduce malaria-related anaemia at day 42 and beyond by preventing recurrent parasitaemia." | 2.61 | The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. ( Abreha, T; Alemu, SG; Añez, A; Anstey, NM; Aseffa, A; Assefa, A; Awab, GR; Baird, JK; Barber, BE; Borghini-Fuhrer, I; Chu, CS; Commons, RJ; D'Alessandro, U; Dahal, P; Daher, A; de Vries, PJ; Douglas, NM; Erhart, A; Gomes, MSM; Grigg, MJ; Guerin, PJ; Hien, TT; Hwang, J; Kager, PA; Ketema, T; Khan, WA; Lacerda, MVG; Leslie, T; Ley, B; Lidia, K; Monteiro, WM; Nosten, F; Pereira, DB; Phan, GT; Phyo, AP; Price, RN; Rowland, M; Saravu, K; Sibley, CH; Simpson, JA; Siqueira, AM; Stepniewska, K; Taylor, WRJ; Thriemer, K; Thwaites, G; Tran, BQ; Vieira, JLF; Wangchuk, S; Watson, J; White, NJ; William, T; Woodrow, CJ, 2019) |
| " Another priority is exploring alternative 8-aminoquinoline dosing regimens that are practical and improve safety in G6PD deficient individuals." | 2.58 | Primaquine-induced haemolysis in females heterozygous for G6PD deficiency. ( Bancone, G; Chu, CS; Luzzatto, L; Nosten, F; White, NJ, 2018) |
| "Tafenoquine was recently approved for Plasmodium vivax radical cure (KRINTAFEL™) and malaria prevention (ARAKODA™)." | 2.58 | Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines. ( Berman, J; Brown, T; Dow, G; Toovey, S, 2018) |
| "vivax relapse is a major global public health concern." | 2.53 | Primaquine treatment and relapse in Plasmodium vivax malaria. ( Rishikesh, K; Saravu, K, 2016) |
| "Primaquine resistance is a complex issue, as the mechanism of resistance is not clear." | 2.53 | Therapeutic failure of primaquine and need for new medicines in radical cure of Plasmodium vivax. ( Cooper, JC; Sundararaj, KG; Tazerouni, H; Thomas, D, 2016) |
| "Tafenoquine is a new alternative with a longer half-life." | 2.52 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, SD; Rajapakse, S; Rodrigo, C, 2015) |
| "Primaquine was licenced for anti-relapse therapy in 1952 and became available despite threatening patients having an inborn deficiency of glucose-6-phosphate dehydrogenase (G6PD) with acute haemolytic anaemia." | 2.52 | Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria. ( Baird, K, 2015) |
| "Testing for G6PD deficiency is not widely available, and so whilst it is widely recommended, primaquine is often not prescribed." | 2.50 | Mass primaquine treatment to eliminate vivax malaria: lessons from the past. ( Ashley, EA; Baranova, AM; Kondrashin, A; Recht, J; Sergiev, VP; White, NJ, 2014) |
| "Randomized controlled trials (RCTs) and quasi-RCTs comparing various primaquine dosing regimens with the standard primaquine regimen (15 mg/day for 14 days), or with no primaquine, in people with vivax malaria treated for blood stage infection with chloroquine." | 2.49 | Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. ( Galappaththy, GN; Kirubakaran, R; Tharyan, P, 2013) |
| "G6PD deficiency is a highly variable disorder, in terms of spatial heterogeneity in prevalence and molecular variants, as well as its interactions with P." | 2.49 | G6PD deficiency: global distribution, genetic variants and primaquine therapy. ( Baird, JK; Battle, KE; Hay, SI; Howes, RE; Satyagraha, AW, 2013) |
| "Primaquine regimens were categorized according to the total dose administered: very low (≤2." | 2.48 | Primaquine radical cure of Plasmodium vivax: a critical review of the literature. ( Baird, JK; Douglas, NM; John, GK; Nosten, F; Price, RN; von Seidlein, L; White, NJ, 2012) |
| "Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952." | 2.47 | Primaquine in vivax malaria: an update and review on management issues. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2011) |
| "In the meantime, AL treatment of vivax malaria may be a pragmatic choice for areas with chloroquine-resistant P." | 2.47 | The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. ( Bassat, Q, 2011) |
| " Different primaquine dosing regimens are in use." | 2.44 | Primaquine for preventing relapses in people with Plasmodium vivax malaria. ( Galappaththy, GN; Omari, AA; Tharyan, P, 2007) |
| "Primaquine treatment, the only therapeutic option against relapse, might also be failing." | 2.44 | Neglect of Plasmodium vivax malaria. ( Baird, JK, 2007) |
| "Rarely, cerebral malaria is a presenting complication or occurs during the course of P." | 2.43 | Cerebral malaria owing to Plasmodium vivax: case report. ( Atambay, M; Daldal, N; Gungor, S; Ozen, M, 2006) |
| " For optimal efficacy, treatment regimens must be adjusted with regard to dosage of primaquine and association with halofantrine, mefloquine or other new antimalarial agents." | 2.41 | [Epidemiological and therapeutic aspects of plasmodial infection from Plasmodium vivax]. ( Granier, H; Klotz, F; Martin, J; Nicolas, X, 2000) |
| "G6PD deficiency was found among 13." | 1.91 | Factors hindering coverage of targeted mass treatment with primaquine in a malarious township of northern Myanmar in 2019-2020. ( Aung, PL; Cui, L; Kyaw, MP; Okanurak, K; Oo, TL; Parker, DM; Sattabongkot, J; Soe, MT; Soe, TN; Win, KM, 2023) |
| "Malaria was considered to be cured with 'blue drugs' (referring to dihydroartemisinin-piperaquine)." | 1.91 | Adherence to 14-day radical cure for Plasmodium vivax malaria in Papua, Indonesia: a mixed-methods study. ( Burdam, FH; Devine, A; Gryseels, C; Kenangalem, E; Landuwulang, CUR; Ley, B; Peeters Grietens, K; Poespoprodjo, JR; Price, RN; Rahmalia, A; Ronse, M; Thriemer, K, 2023) |
| "Malaria is caused by parasite of the genus Plasmodium and is still one of the most important infectious diseases in the world." | 1.91 | Transmission-blocking activity of antimalarials for Plasmodium vivax malaria in Anopheles darlingi. ( Aguiar, ACC; Andrade, AO; Araújo, JE; Araújo, MS; Bastos, AS; G Teles, CB; Gazzinelli, RT; Lima, AA; Martinez, LN; Medeiros, JF; Pereira, DB; Pontual, JDC; Santos, NAC; Silva, AMV; Vinetz, JM, 2023) |
| "Malaria is endemic and represents an important public health issue in Brazil." | 1.91 | A fatal respiratory complication of malaria caused by Plasmodium vivax. ( Brasil, P; Bressan, CS; Calvet, GA; Daniel-Ribeiro, CT; de Bruycker-Nogueira, F; de Fátima Ferreira-da-Cruz, M; de Pina-Costa, A; Detepo, PJT; Ferreira, MT; Filippis, AMB; López, AR; Lupi, O; Mamani, RF; Martins, EB; Pacheco-Silva, AB; Silva, MFB; Siqueira, A, 2023) |
| "Plasmodium vivax malaria is considered a major threat to malaria eradication." | 1.91 | Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders. ( Aung, PL; Cui, L; Kyaw, MP; Lawpoolsri, S; Linn, NYY; Nguitragool, W; Ring, Z; Sattabongkot, J; Win, KM, 2023) |
| "Screening for G6PD deficiency can inform disease management including malaria." | 1.91 | Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis. ( Adissu, W; Alam, MS; Bancone, G; Bansil, P; Brito, M; Bryan, A; Chu, CS; Das, S; Domingo, GJ; Garbin, E; Gerth-Guyette, E; Hann, A; Kublin, J; Lacerda, MVG; Layton, M; Ley, B; Macedo, M; Monteiro, W; Mukherjee, SK; Murphy, SC; Myburg, J; Nosten, F; Pal, S; Pereira, D; Price, RN; Sharma, A; Talukdar, A; Yilma, D; Zobrist, S, 2023) |
| "Malaria is a major cause of death in low-income countries." | 1.72 | Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine. ( Mohan, M; Nain, M; Sharma, A, 2022) |
| "According to our findings, testing G6PD deficiency and monitoring the potential PQ toxicity in patients who receive PQ are highly recommended." | 1.72 | Prevalence of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency among Malaria Patients in Southern Thailand: 8 Years Retrospective Study. ( Buncherd, H; Khammanee, T; Sawangjaroen, N; Thanapongpichat, S; Tun, AW, 2022) |
| "The primaquine dose was increased with 30 mg for 14 days at the third and fourth episodes." | 1.72 | Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function. ( Baek, JH; Choi, H; Choi, S; Han, JH; Kim, MJ; Kim, YC; Kwak, YG; Oh, HS; Park, SY; Shin, HI; Shin, SY; Song, JE; Yeom, JS, 2022) |
| "We aimed to investigate malaria recurrences among participants receiving daily and weekly PQ treatments in a real-life setting of two municipalities in the Amazon between 2019 and 2020." | 1.72 | Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study. ( Balieiro, PCDS; Brito-Sousa, JD; Cordeiro, JSM; Lacerda, M; Melo, GC; Mendes, M; Monteiro, W; Phanor, J; Sampaio, VS; Silva-Neto, AV; Vitor-Silva, S, 2022) |
| "Therefore, G6PD deficiency testing should precede hypnozoite elimination with 8-aminoquinoline." | 1.72 | An Evaluation of a New Quantitative Point-of Care Diagnostic to Measure Glucose-6-phosphate Dehydrogenase Activity. ( Ahn, SK; Bahk, YY; Jeon, HJ; Lee, SK; Na, BK; Shin, HJ, 2022) |
| "Malaria recurrence was defined as more than one episode of vivax malaria in the same or consecutive years." | 1.72 | Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients. ( Baek, JH; Cho, SH; Choi, H; Choi, S; Kim, M; Kim, MJ; Kim, YC; Kwak, YG; Kwon, JR; Lee, SE; Oh, HS; Park, S; Park, SY; Shin, HI; Shin, SY; Song, JE; Yeom, JS, 2022) |
| "Primaquine was effective in preventing P." | 1.72 | Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area. ( Björklund, D; Carlander, C; Färnert, A; Hellgren, U; Hervius Askling, H; Sondén, K; Stenström, C; Wångdahl, A; Wyss, K; Zhang, J, 2022) |
| "Primaquine doses were calculated using allometric scaling to derive a weight-based primaquine regimen over a weight range from 5 to 100 kg." | 1.62 | Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria. ( Buchy, P; Debackere, M; Dondorp, AM; Dysoley, L; Fairhurst, RM; H Nosten, F; Hien, TT; Hoglund, RM; Kheang, ST; Kheng, S; Landier, J; Mayxay, M; Menard, D; Mukaka, M; Muth, S; Neeraj, K; Nguyen, TN; Peerawaranun, P; Peto, TJ; Phommasone, K; Rithea, L; Roca-Feltrer, A; Say, C; Smithuis, F; Song, N; Tarantola, A; Tarning, J; Taylor, WR; Tripura, R; von Seidlein, L; White, NJ, 2021) |
| "The prevalence of G6PD deficiency was previously reported negligible in Korea." | 1.62 | A Profile of Glucose-6-Phosphate Dehydrogenase Variants and Deficiency of Multicultural Families in Korea. ( Ahn, SK; Bahk, YY; Im, JH; Jang, W; Kan, H; Kim, M; Kim, TS; Kwon, J; Lee, J; Park, S; Yeom, JS, 2021) |
| " Most HCPs were unaware of G6PD deficiency and primaquine-related adverse effects." | 1.62 | Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study). ( Arcanjo, AR; Baia-da-Silva, DC; Bancone, G; Barbosa, LRA; Bassat, Q; Batista, TSB; Brito, MAM; Brito-Sousa, JD; Domingo, GJ; Figueiredo, EFG; Lacerda, MVG; Marques, LLG; Melo, GC; Melo, MM; Mendes, MO; Monteiro, WM; Murta, F; Nakagawa, TH; Recht, J; Rodovalho, S; Sampaio, VS; Santos, APC; Santos, TC; Silva, EL; Silva-Neto, AV; Siqueira, AM; Souza, BKA; Vitor-Silva, S, 2021) |
| "Relapses in vivax malaria have posed great challenges for malaria control, and they also account for a great proportion of reported cases." | 1.62 | Evaluation of the effect of supervised anti-malarial treatment on recurrences of Plasmodium vivax malaria. ( Brito-Sousa, JD; Dinelly, KMO; Lacerda, MVG; Melo, GC; Monteiro, WM; Omena, AG; Peterka, C; Rodovalho, S; Sampaio, VS; Silva, MGO; Siqueira, AM; Vitor-Silva, S, 2021) |
| " Higher primaquine dosage was safe and effectively prevented relapses in two patients and should be further investigated as an option in Latin America." | 1.62 | Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases. ( Brasil, P; da Rosa Santos, OHL; da Silva, ADT; Daniel-Ribeiro, CT; de Deus Henriques, KM; de Pina-Costa, A; Dos Santos, EM; Moreira, J; Pedro, RS; Silvino, ACR; Siqueira, AM; Sousa, TN; Umana, GL, 2021) |
| " vivax relapses after a correct treatment and, especially, it should be considered in any study of dosage and duration of primaquine treatment." | 1.56 | Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function. ( Bernal Fernández, MJ; Domingo García, D; Gutierrez Liarte, Á; Lanza Suárez, M; Lombardia González, C; Martin Ramírez, A; Rubio, JM; Soler Maniega, T, 2020) |
| "We compare recurrence rates observed after primary P." | 1.56 | Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil. ( Corder, RM; Davenport, MP; de Lima, ACP; Docken, SS; Ferreira, MU; Khoury, DS, 2020) |
| "Chloroquine was measured in plasma samples by high-performance liquid chromatography with fluorescence detection." | 1.56 | Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ( Mello, AGCN; Sena, LWP; Vieira, JLF; Vieira, MVDF, 2020) |
| "We report a case of splenic infarction with acute kidney injury in a case of P." | 1.51 | Multiple Splenic Infarcts Complicating Plasmodium vivax Malaria. ( Kaur, M; Saha, A; Tripathi, N, 2019) |
| "Quantitative diagnostic tests for G6PD deficiency are complex and require sophisticated laboratories." | 1.51 | Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities. ( Advani, N; Cohen, J; Domingo, GJ; Kalnoky, M; Kelley, M; Parker, M; Rowley, E; Satyagraha, AW; Sibley, CH, 2019) |
| "There was no difference in time to recurrence or recurrence frequency between patients treated with 14-day or 7-9 day primaquine regimens (HR = 1." | 1.51 | Evaluation of Plasmodium vivax malaria recurrence in Brazil. ( Daher, A; Fontes, CJ; Lalloo, DG; Marchesini, P; Silva, JCAL; Stevens, A; Ter Kuile, FO, 2019) |
| "In the north, other G6PD deficiency variants might be more prevalent." | 1.51 | Prevalence of G6PD Viangchan variant in malaria endemic areas in Lao PDR: an implication for malaria elimination by 2030. ( Araki, H; Brey, PT; Hongvanthong, B; Iwagami, M; Jimba, M; Kano, S; Keomalaphet, S; Khattignavong, P; Lorpachan, L; Ong, KIC; Pongvongsa, T; Prasayasith, P; Soundala, P; Xangsayalath, P, 2019) |
| "vivax malaria were randomized to receive chloroquine (CQ; 25 mg base/kg given over 3 days) alone or together with primaquine (PQ; 0." | 1.51 | Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal. ( Adhikari, B; Banjara, MR; Chotivanich, K; Das Thakur, G; Day, NPJ; Ghimire, P; Hanboonkunupakarn, B; Imwong, M; Pukrittayakamee, S; Rijal, KR; White, NJ, 2019) |
| "Time to first vivax recurrence was estimated by Kaplan-Meier survival analysis, and risk factors for first and recurrent infections were identified by Cox regression models." | 1.51 | Plasmodium vivax morbidity after radical cure: A cohort study in Central Vietnam. ( A Cleves, M; Aguirre, AR; D'Alessandro, U; Erhart, A; Hens, N; Le, HX; Nguyen, HV; Nguyen, TT; Nguyen, VV; Nguyen, XX; Pham, TV; Rosanas-Urgell, A; Speybroeck, N; Tran, DT, 2019) |
| "vivax malaria episode until the recurrence did not differ between patients with AS of ≤ 1 versus ≥ 1." | 1.48 | CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. ( Almeida, ACG; Brasil, LW; Kühn, A; Lacerda, MVG; Monteiro, WM; Ramasawmy, R; Rodrigues-Soares, F; Santoro, AB; Suarez-Kurtz, G, 2018) |
| "Independent of G6PD deficiency, the current pregnancy and lactation restrictions will exclude ~13% of females from radical cure treatment." | 1.48 | Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. ( Bancone, G; Chu, CS; Jittamala, P; Taylor, WRJ; Watson, J; White, NJ, 2018) |
| " This systematically increased dosage needs to be evaluated according to epidemiological context." | 1.48 | Primaquine 30 mg/day versus 15 mg/day during 14 days for the prevention of Plasmodium vivax relapses in adults in French Guiana: a historical comparison. ( Abboud, P; Blaise, N; Blanchet, D; Demar, M; Djossou, F; Epelboin, L; Melzani, A; Mosnier, E; Nacher, M; Valdes, A; Vesin, G; Walter, G, 2018) |
| "vivax malaria is rising." | 1.46 | An outbreak of locally acquired Plasmodium vivax malaria among migrant workers in Oman. ( Al Mukhaini, SK; Al-Abri, S; Ali, OAM; Bienvenu, AL; Bonnot, G; Petersen, E; Picot, S; Simon, B; Sow, F, 2017) |
| "vivax malaria was higher in children 1 to <5 years of age (49." | 1.46 | Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. ( Anstey, NM; Douglas, NM; Kenangalem, E; Malloy, MJ; Patriani, D; Poespoprodjo, JR; Price, RN; Simpson, JA; Soenarto, Y; Sugiarto, P, 2017) |
| "The developed model to predict recurrence was found to be of good accuracy and could be a useful tool in targeting patients at a higher risk for recurrence for closer monitoring during follow-up, after treatment with primaquine." | 1.46 | A clinical tool to predict Plasmodium vivax recurrence in Malaysia. ( Islahudin, F; Kumolosasi, E; Makmor-Bakry, M; Mat Ariffin, N, 2017) |
| "Takayasu arteritis, also known as "pulseless disease," causes proximal occlusion of the lumen of large arteries of the neck and arm, leading to impalpable pulses and "pseudohypotension." | 1.46 | A Curious Case of "Septic Shock". ( Jain, S; Kumari, S; Lakshman, A; Sharma, N; Singh, C; Singhal, M; Varma, S, 2017) |
| "1." | 1.43 | UK malaria treatment guidelines 2016. ( Beeching, NJ; Bell, DJ; Chiodini, PL; Lalloo, DG; Shingadia, D; Whitty, CJM, 2016) |
| "The prevalence of G6PD deficiency in the Bamar, Karen and in the whole sample set was 6." | 1.43 | Validation of G6PD Point-of-Care Tests among Healthy Volunteers in Yangon, Myanmar. ( Bancone, G; Bansil, P; Chowwiwat, N; Domingo, GJ; Htun, MM; Htut, Y; Maw, LZ; Nosten, F; Oo, NN; Thant, KZ, 2016) |
| "Plasmodium vivax malaria is characterized by periodic relapses of symptomatic blood stage parasite infections likely initiated by activation of dormant liver stage parasites-hypnozoites." | 1.42 | Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. ( Adams, JH; Baldwin, M; Camargo, N; Fishbaugher, M; Kangwanrangsan, N; Kappe, SH; Kaushansky, A; Lakshmanan, V; Lindner, SE; Mikolajczak, SA; Prachumsri, J; Rezakhani, N; Roobsoong, W; Sattabongkot, J; Singh, N; Vaughan, AM; Yimamnuaychok, N, 2015) |
| "The primaquine doses were adjusted for the patients' weight." | 1.42 | Efficacy in the treatment of malaria by Plasmodium vivax in Oiapoque, Brazil, on the border with French Guiana: the importance of control over external factors. ( Couto, ÁA; Couto, VS; Gomes, Mdo S; Júnior, AA; Legrand, E; Machado, RL; Menezes, RA; Musset, L; Nacher, M; Sousa, AP; Stefani, A; Vieira, JL, 2015) |
| "Two Plasmodium vivax recurrences in a Peruvian sailor with weight above the 60 kg (cap for primaquine dosage) highlight the importance of adequate radical cure weight dosage for patient treatment and control efforts, particularly within the military." | 1.42 | Repeated Plasmodium vivax malaria relapses in a Peruvian sailor. ( Cavalcanti, S; Gonzalez, S; Lescano, AG; McFarland, AP; Mercado, A; Sanchez, JF; Ventocilla, JA, 2015) |
| " We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine." | 1.40 | Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report. ( Dragsted, UB; Kristensen, KL, 2014) |
| "Since conventional 14-day primaquine (PMQ) radical cure of vivax malaria is associated with poor compliance, and as total dose, not therapy duration, determines efficacy, a preliminary pharmacokinetic study of two doses (0." | 1.40 | Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria. ( Batty, KT; Benjamin, J; Betuela, I; Davis, TM; Moore, BR; Mueller, I; Page-Sharp, M; Robinson, LJ; Salman, S; Siba, P; Waita, E, 2014) |
| "By comparison individuals with G6PD deficiency showed a highly skewed haplotype distribution, with 95% showing the CT haplotype, a finding consistent with relatively recent appearance and positive selection of the Mediterranean variant in Afghanistan." | 1.40 | A population survey of the glucose-6-phosphate dehydrogenase (G6PD) 563C>T (Mediterranean) mutation in Afghanistan. ( Awab, GR; Day, NP; Dondorp, AM; Imwong, M; Jamornthanyawat, N; Pukrittayakamee, S; Tanomsing, N; White, NJ; Woodrow, CJ; Yamin, F, 2014) |
| "vivax malaria is a substantial risk." | 1.40 | Imported malaria is stable from Africa but declining from Asia. ( David, K; Møller, CH, 2014) |
| "No G6PD deficiency was observed using phenotypic- or genetic-based tests in individuals residing in vivax malaria endemic regions in the ROK." | 1.40 | First evaluation of glucose-6-phosphate dehydrogenase (G6PD) deficiency in vivax malaria endemic regions in the Republic of Korea. ( Cho, SH; Goo, YK; Ji, SY; Kim, JY; Lee, WJ; Moon, JH; Shin, HI, 2014) |
| "The current available treatment for P." | 1.40 | Evaluation of antimalarial activity and toxicity of a new primaquine prodrug. ( Aguiar, AC; Campos, ML; Chin, CM; da Fonseca, LM; Davanço, MG; de Andrade, CR; Dos Santos, JL; Dos Santos, LA; Krettli, AU; Padilha, EC; Peccinini, RG, 2014) |
| "Primaquine dosing was classified as no dose, low dose (<420 mg), high dose (≥420 mg), or unknown." | 1.38 | Relapse of imported Plasmodium vivax malaria is related to primaquine dose: a retrospective study. ( Looke, D; McCarthy, JS; McDougall, D; Townell, N, 2012) |
| " The overall median time to relapse, obtained by the Kaplan-Meier method, was 108 days, and the survival analysis demonstrated an association between non-weight-adjusted primaquine dosing and the occurrence of relapse (p < 0." | 1.38 | Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil. ( Brasil, P; Campos, DP; Costa, AP; Daniel-Ribeiro, CT; Guaraldo, L; Pedro, RS, 2012) |
| "Prednisolone was then tapered and stopped." | 1.37 | Auto-immune haemolytic anaemia concurrent with Plasmodium vivax infection: a case report. ( Anurathapan, U; Chanthavanich, P; Sirachainan, N; Sitcharungsi, R, 2011) |
| "Patients who were being treated for P." | 1.37 | Adherence to Plasmodium vivax malaria treatment in the Brazilian Amazon Region. ( Fontes, CJ; Ishikawa, EA; Pereira, EA, 2011) |
| "In Plasmodium vivax infection, however, retinal hemorrhage is very rare; only five cases have been reported in the literature." | 1.36 | Retinal hemorrhage in Plasmodium vivax malaria. ( Chin, HS; Chung, MH; Lee, JH; Moon, YS, 2010) |
| "Malarial hepatitis is also unusual in P." | 1.36 | [A case of malarial hepatitis by Plasmodium vivax]. ( Park, JM; Sung, YH, 2010) |
| " All recurring cases were completely cured using the same dosage and regimen used for the first or second treatments." | 1.35 | Recurrence rate of vivax malaria in the Republic of Korea. ( Kim, C; Kim, YK; Ko, DH; Moon, KT; Park, I; Shin, DC, 2009) |
| "Here we describe high rates of P." | 1.35 | Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia. ( da Silva, NS; da Silva-Nunes, M; Ferreira, MU; Orjuela-Sánchez, P, 2009) |
| "Splenic infarction is a rare complication in malaria cases, and is caused primarily by Plasmodium falciparum." | 1.34 | A case of symptomatic splenic infarction in vivax malaria. ( Chung, MH; Kim, A; Kim, ES; Lee, JS; Park, YK, 2007) |
| "Pulmonary edema is a recognized complication of Plasmodium falciparum malaria but is uncommon with Plasmodium vivax infection." | 1.34 | Pulmonary edema due to Plasmodium vivax malaria in an American missionary. ( Allen, BL; Illamperuma, C, 2007) |
| "The patient was given chloroquine by his captain in a dosage regimen appropriate for quinine (2 tablets 3 times daily for 7 d)." | 1.32 | Toxicity related to chloroquine treatment of resistant vivax malaria. ( Barrett, PH; Davis, TM; Ilett, KF; Syed, DA, 2003) |
| "Cases of vivax malaria have rapidly increased annually among counties bordering the DMZ, and have spread to approximately 40 km south of the DMZ." | 1.32 | Vivax malaria: a continuing health threat to the Republic of Korea. ( Chai, JY; Choe, KW; Kim, TS; Klein, TA; Lee, HC; Moon, SH; Oh, MD; Pacha, LA; Park, JW; Ryu, SH; Yeom, JS, 2003) |
| "Primaquine is an old drug recently demonstrated to offer effective prophylaxis." | 1.32 | Primaquine for prevention of malaria in travelers. ( Baird, JK; Fryauff, DJ; Hoffman, SL, 2003) |
| "Primaquine was used as a negative control and a dihydroacridine-dione (WR-250547) was used as a positive control." | 1.32 | Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand. ( Coleman, RE; Eikarat, N; Kittayapong, P; Ponsa, N; Sattabongkot, J, 2003) |
| " The elimination half-life was 3." | 1.32 | Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria. ( Chung, WC; Kang, MW; Kim, MY; Kim, SI; Kim, YR; Kim, YS; Kuh, HJ, 2004) |
| "vivax malaria were compared with 20, apparently healthy controls." | 1.31 | Immunological alterations associated with Plasmodium vivax malaria in South Korea. ( Han, K; Kang, CS; Kim, BK; Kim, M; Kim, Y; Lee, EJ; Lee, HK; Lee, J; Lee, S; Lim, J; Oh, EJ; Oh, J, 2001) |
| " Three of these soldiers had received a higher dosage of primaquine (30 mg base daily for 14 days) after their second attack." | 1.30 | Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia. ( DeFraites, RF; Kain, KC; Magill, AJ; Smoak, BL; Wellde, BT, 1997) |
| "The relapses were due to a combination of decreased primaquine sensitivity and incorrect prescription of primaquine." | 1.30 | [Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment]. ( Dolmans, WM; Mulder, L; Telgt, DS, 1997) |
| "falciparum." | 1.30 | Profound thrombocytopenia in Plasmodium vivax malaria. ( Bhoi, S; Kakar, A; Kakar, S; Prakash, V, 1999) |
| "20 patients hemizygous for mild G6PD deficiency (GdB- variant), 2 patients hemizygous for severe deficiency (Gd-Myanmar variant) completed the trial." | 1.29 | The use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (G6PD) deficiency in Myanmar. ( , 1994) |
| "To assess the causal prophylactic activity (activity against the pre-erythrocytic liver stage) of a daily regimen of doxycycline combined with low dose primaquine against malaria in Australian Defence Force personnel deployed to Papua New Guinea (PNG)." | 1.29 | Effectiveness of doxycycline combined with primaquine for malaria prophylaxis. ( Barnett, A; Edstein, MD; Rieckmann, KH; Shanks, GD, 1995) |
| "Primaquine may also cause serious toxic side effects, including methaemoglobin formation and haemolytic anaemia, especially in individuals with erythrocyte glucose-6-phosphate dehydrogenase (G-6-PD) deficiency." | 1.29 | [Recurrence problems with preventive primaquine treatment in patients with malaria]. ( Bygbjerg, IC; Rønn, AM, 1993) |
| "Vivax malaria is the most frequent among imported malaria in Japan, comprising about 60% of the total cases." | 1.29 | [A study of relapsed cases of vivax malaria after the standard primaquine therapy]. ( Kimura, M; Ohtomo, H; Takizawa, Y; Tomizawa, I, 1996) |
| "Primaquine has been found adequate to prevent relapse in more than 90% vivax cases, while efficacy of chloroquine-pyrimethamine and chloroquine alone was almost comparable." | 1.29 | Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat. ( Bhatt, RM; Sharma, SK; Sharma, VP; Srivastava, HC, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (4.04) | 18.7374 |
| 1990's | 63 (13.40) | 18.2507 |
| 2000's | 81 (17.23) | 29.6817 |
| 2010's | 209 (44.47) | 24.3611 |
| 2020's | 98 (20.85) | 2.80 |
| Authors | Studies |
|---|---|
| Taylor, WRJ | 10 |
| Kim, S | 3 |
| Kheng, S | 5 |
| Muth, S | 4 |
| Tor, P | 3 |
| Christophel, E | 3 |
| Mukaka, M | 5 |
| Kerleguer, A | 3 |
| Luzzatto, L | 2 |
| Baird, JK | 39 |
| Menard, D | 7 |
| Taylor, WR | 6 |
| Hoglund, RM | 2 |
| Peerawaranun, P | 3 |
| Nguyen, TN | 2 |
| Hien, TT | 6 |
| Tarantola, A | 1 |
| von Seidlein, L | 11 |
| Tripura, R | 3 |
| Peto, TJ | 4 |
| Dondorp, AM | 8 |
| Landier, J | 2 |
| H Nosten, F | 1 |
| Smithuis, F | 2 |
| Phommasone, K | 3 |
| Mayxay, M | 3 |
| Kheang, ST | 2 |
| Say, C | 1 |
| Neeraj, K | 1 |
| Rithea, L | 1 |
| Dysoley, L | 7 |
| Roca-Feltrer, A | 2 |
| Debackere, M | 1 |
| Fairhurst, RM | 1 |
| Song, N | 1 |
| Buchy, P | 1 |
| White, NJ | 39 |
| Tarning, J | 10 |
| Aung, PL | 3 |
| Soe, MT | 2 |
| Soe, TN | 2 |
| Oo, TL | 2 |
| Aung, PP | 2 |
| Khin, A | 1 |
| Thi, A | 1 |
| Phuanukoonnon, S | 3 |
| Okanurak, K | 3 |
| Cui, L | 9 |
| Kyaw, MP | 3 |
| Parker, DM | 6 |
| Poespoprodjo, JR | 8 |
| Burdam, FH | 3 |
| Candrawati, F | 1 |
| Ley, B | 20 |
| Meagher, N | 3 |
| Kenangalem, E | 6 |
| Indrawanti, R | 1 |
| Trianty, L | 1 |
| Thriemer, K | 21 |
| Price, DJ | 2 |
| Simpson, JA | 15 |
| Price, RN | 34 |
| Grobusch, MP | 2 |
| Schlagenhauf, P | 2 |
| Bahk, YY | 2 |
| Ahn, SK | 2 |
| Lee, J | 3 |
| Im, JH | 1 |
| Yeom, JS | 9 |
| Park, S | 2 |
| Kwon, J | 1 |
| Kan, H | 1 |
| Kim, M | 3 |
| Jang, W | 1 |
| Kim, TS | 2 |
| Kaagaard, MD | 1 |
| Matos, LO | 1 |
| Holm, AE | 1 |
| Gomes, LC | 1 |
| Wegener, A | 1 |
| Lima, KO | 1 |
| Vieira, IVM | 1 |
| de Souza, RM | 1 |
| Marinho, CRF | 2 |
| Hviid, L | 1 |
| Vestergaard, LS | 1 |
| Dominguez, H | 1 |
| Biering-Sørensen, T | 1 |
| Silvestre, OM | 1 |
| Brainin, P | 1 |
| Vanachayangkul, P | 3 |
| Sea, D | 3 |
| Wojnarski, M | 3 |
| Sok, S | 3 |
| Kodchakorn, C | 1 |
| Ta-Aksorn, W | 1 |
| Hom, S | 2 |
| Ittiverakul, M | 4 |
| Kuntawunginn, W | 3 |
| Arsanok, M | 2 |
| Buathong, N | 3 |
| Heng, TK | 1 |
| Nareth, K | 1 |
| Nou, S | 3 |
| Chandara, S | 1 |
| Ly, S | 2 |
| Oung, P | 2 |
| Vesely, B | 1 |
| Bennett, J | 1 |
| Reichard, G | 2 |
| Pybus, B | 2 |
| Lanteri, C | 2 |
| Saunders, D | 2 |
| Fukuda, M | 1 |
| Smith, P | 2 |
| Rekol, H | 2 |
| Waters, NC | 2 |
| Spring, M | 2 |
| Daher, A | 11 |
| Pinto, DP | 1 |
| da Fonseca, LB | 1 |
| Pereira, HM | 1 |
| da Silva, DMD | 1 |
| da Silva, LSFV | 1 |
| Esteves, AL | 1 |
| Soares Medeiros, JJ | 1 |
| Mendonça, JS | 1 |
| Nain, M | 2 |
| Mohan, M | 2 |
| Sharma, A | 3 |
| Anvikar, AR | 1 |
| Sahu, P | 1 |
| Pradhan, MM | 1 |
| Sharma, S | 1 |
| Ahmed, N | 1 |
| Yadav, CP | 1 |
| Pradhan, S | 1 |
| Duparc, S | 10 |
| Grewal Daumerie, P | 1 |
| Valecha, N | 4 |
| Khammanee, T | 1 |
| Sawangjaroen, N | 1 |
| Buncherd, H | 1 |
| Tun, AW | 1 |
| Thanapongpichat, S | 1 |
| Choi, S | 2 |
| Choi, H | 2 |
| Park, SY | 3 |
| Kwak, YG | 3 |
| Song, JE | 3 |
| Shin, SY | 2 |
| Baek, JH | 2 |
| Shin, HI | 4 |
| Oh, HS | 2 |
| Kim, YC | 2 |
| Han, JH | 1 |
| Kim, MJ | 2 |
| Brito-Sousa, JD | 6 |
| Peixoto, HM | 5 |
| Devine, A | 8 |
| Silva-Neto, AV | 3 |
| Balieiro, PCS | 1 |
| Sampaio, VS | 7 |
| Vitor-Silva, S | 4 |
| Mendes, MO | 2 |
| Souza, BKA | 2 |
| Lacerda, MVG | 13 |
| Monteiro, WM | 20 |
| Chamma-Siqueira, NN | 2 |
| Negreiros, SC | 1 |
| Ballard, SB | 1 |
| Farias, S | 2 |
| Silva, SP | 1 |
| Chenet, SM | 3 |
| Santos, EJM | 1 |
| Pereira de Sena, LW | 1 |
| Póvoa da Costa, F | 1 |
| Cardoso-Mello, AGN | 1 |
| Marchesini, PB | 1 |
| Peterka, CRL | 1 |
| Viana, GMR | 2 |
| Macedo de Oliveira, A | 2 |
| Greenwood, B | 1 |
| Drakeley, C | 2 |
| Llanos-Cuentas, A | 9 |
| Manrrique, P | 1 |
| Rosas-Aguirre, A | 1 |
| Herrera, S | 2 |
| Hsiang, MS | 1 |
| Gandrala, D | 2 |
| Gupta, N | 2 |
| Lavu, A | 2 |
| Nallapati, VT | 2 |
| Guddattu, V | 3 |
| Saravu, K | 10 |
| Aung, YN | 1 |
| Tun, STT | 1 |
| Vanisaveth, V | 1 |
| Chindavongsa, K | 1 |
| Kanya, L | 1 |
| Phanor, J | 1 |
| Balieiro, PCDS | 1 |
| Cordeiro, JSM | 1 |
| Mendes, M | 1 |
| Melo, GC | 6 |
| Lacerda, M | 2 |
| Monteiro, W | 2 |
| Watson, JA | 5 |
| Nekkab, N | 1 |
| White, M | 1 |
| Alam, MS | 6 |
| Satyagraha, AW | 8 |
| Phru, CS | 2 |
| Tadesse, D | 1 |
| Shibiru, T | 1 |
| Hailu, A | 6 |
| Kibria, MG | 3 |
| Hossain, MS | 3 |
| Rahmat, H | 2 |
| Khan, WA | 6 |
| Degaga, TS | 4 |
| Christian, M | 2 |
| Tego, TT | 2 |
| Abate, DT | 2 |
| Weston, S | 2 |
| Karahalios, A | 3 |
| Rajasekhar, M | 3 |
| Rumaseb, A | 4 |
| Mnjala, H | 2 |
| Lee, G | 2 |
| Anose, RT | 2 |
| Kidane, FG | 1 |
| Woyessa, A | 6 |
| Baird, K | 3 |
| Sutanto, I | 12 |
| Sharma, J | 1 |
| Gautam, CS | 1 |
| Singh, H | 1 |
| Singh, J | 1 |
| Flaherty, S | 1 |
| Strauch, P | 2 |
| Maktabi, M | 2 |
| Pybus, BS | 2 |
| Walker, LA | 1 |
| Rochford, R | 2 |
| Suh, J | 1 |
| Kim, JH | 1 |
| Kim, JD | 1 |
| Kim, C | 4 |
| Choi, JY | 2 |
| Nguyen Pouplin, J | 1 |
| Liu, H | 3 |
| Zeng, W | 2 |
| Malla, P | 1 |
| Wang, C | 1 |
| Lakshmi, S | 1 |
| Kim, K | 1 |
| Menezes, L | 1 |
| Yang, Z | 3 |
| Jeon, HJ | 1 |
| Na, BK | 1 |
| Lee, SK | 1 |
| Shin, HJ | 1 |
| Shenkutie, TT | 1 |
| Nega, D | 1 |
| Kepple, D | 1 |
| Witherspoon, L | 1 |
| Lo, E | 2 |
| Negash, MT | 1 |
| Adamu, A | 1 |
| Gebremichael, SG | 1 |
| Gidey, B | 1 |
| Tasew, G | 1 |
| Feleke, SM | 1 |
| Kebede, T | 1 |
| Kaur, D | 1 |
| Sinha, S | 1 |
| Sehgal, R | 1 |
| Markus, MB | 2 |
| Adhikari, B | 4 |
| Callery, JJ | 1 |
| Heng, C | 1 |
| Vanda, T | 1 |
| Simvieng, O | 1 |
| Cassidy-Seyoum, S | 1 |
| Cho, SH | 3 |
| Lee, SE | 3 |
| Kwon, JR | 1 |
| Ridley, R | 1 |
| Ngeth, E | 1 |
| Ir, P | 1 |
| Ngor, P | 1 |
| Sovannaroth, S | 1 |
| Lek, D | 4 |
| Phon, S | 1 |
| Kak, N | 1 |
| Yeung, S | 2 |
| Boum, Y | 3 |
| Moukoko, CEE | 3 |
| Parikh, S | 4 |
| Chamchoy, K | 2 |
| Sudsumrit, S | 2 |
| Thita, T | 2 |
| Krudsood, S | 19 |
| Patrapuvich, R | 2 |
| Boonyuen, U | 2 |
| Douglas, NM | 10 |
| Piera, KA | 2 |
| Anstey, NM | 9 |
| Morais, CMG | 1 |
| Brito, RMM | 1 |
| Weselucha-Birczyńska, A | 1 |
| Pereira, VSS | 1 |
| Pereira-Silva, JW | 1 |
| Menezes, A | 1 |
| Pessoa, FAC | 1 |
| Kucharska, M | 1 |
| Birczyńska-Zych, M | 1 |
| Ríos-Velásquez, CM | 1 |
| de Andrade-Neto, VF | 1 |
| Djigo, OKM | 1 |
| Gomez, N | 1 |
| Ould Ahmedou Salem, MS | 1 |
| Basco, L | 1 |
| Ould Mohamed Salem Boukhary, A | 1 |
| Briolant, S | 2 |
| Saita, S | 1 |
| Roobsoong, W | 3 |
| Khammaneechan, P | 1 |
| Sukchan, P | 1 |
| Lawpoolsri, S | 5 |
| Sattabongkot, J | 9 |
| Gill, J | 1 |
| Calit, J | 2 |
| Araújo, JE | 2 |
| Deng, B | 1 |
| Miura, K | 1 |
| Gaitán, XA | 2 |
| Araújo, MDS | 1 |
| Medeiros, JF | 2 |
| Long, CA | 1 |
| Simeonov, A | 1 |
| Eastman, RT | 1 |
| Bargieri, DY | 2 |
| Woon, SA | 1 |
| Moore, BR | 4 |
| Laman, M | 3 |
| Tesine, P | 1 |
| Lorry, L | 2 |
| Kasian, B | 2 |
| Yambo, P | 1 |
| Yadi, G | 2 |
| Pomat, W | 1 |
| Batty, KT | 3 |
| Salman, S | 3 |
| Robinson, LJ | 5 |
| Davis, TME | 3 |
| Manning, L | 2 |
| Win, KM | 2 |
| Mekonnen, DA | 1 |
| Abadura, GS | 1 |
| Behaksra, SW | 1 |
| Taffese, HS | 1 |
| Bayissa, GA | 1 |
| Bulto, MG | 1 |
| Tessema, TS | 1 |
| Tadesse, FG | 1 |
| Gadisa, E | 1 |
| Aung, TH | 1 |
| Suansomjit, C | 1 |
| Tun, ZM | 1 |
| Hlaing, TM | 1 |
| Kaewkungwal, J | 2 |
| Rahmalia, A | 2 |
| Landuwulang, CUR | 1 |
| Ronse, M | 1 |
| Peeters Grietens, K | 2 |
| Gryseels, C | 2 |
| Soebandrio, A | 1 |
| Ekawati, LL | 6 |
| Chand, K | 5 |
| Noviyanti, R | 6 |
| Subekti, D | 4 |
| Santy, YW | 1 |
| Crenna-Darusallam, C | 3 |
| Instiaty, I | 1 |
| Budiman, W | 1 |
| Prasetya, CB | 1 |
| Lardo, S | 1 |
| Elyazar, I | 6 |
| Cedar, E | 1 |
| Rolfe, K | 1 |
| Fernando, D | 4 |
| Berni, A | 1 |
| Jones, S | 1 |
| Kleim, JP | 3 |
| Fletcher, K | 2 |
| Sharma, H | 1 |
| Martin, A | 1 |
| Taylor, M | 2 |
| Goyal, N | 1 |
| Green, JA | 7 |
| Tan, LK | 1 |
| Tobe, R | 1 |
| Benjamin, J | 2 |
| Page-Sharp, M | 3 |
| Betuela, I | 6 |
| Mueller, I | 7 |
| Andrade, AO | 1 |
| Santos, NAC | 1 |
| Bastos, AS | 1 |
| Pontual, JDC | 1 |
| Silva, AMV | 1 |
| Martinez, LN | 1 |
| Lima, AA | 1 |
| Aguiar, ACC | 1 |
| G Teles, CB | 1 |
| Pereira, DB | 5 |
| Vinetz, JM | 1 |
| Gazzinelli, RT | 1 |
| Araújo, MS | 1 |
| Anjani, QK | 1 |
| Volpe-Zanutto, F | 1 |
| Hamid, KA | 1 |
| Sabri, AHB | 1 |
| Moreno-Castellano, N | 1 |
| Donnelly, RF | 1 |
| Yilma, D | 3 |
| Groves, ES | 1 |
| Chu, C | 1 |
| Commons, RJ | 6 |
| Bancone, G | 18 |
| Satyagraha, A | 2 |
| Assefa, A | 4 |
| Chau, NH | 2 |
| Dhorda, M | 4 |
| Hasanzai, MA | 2 |
| Naddim, MN | 2 |
| Pasaribu, AP | 5 |
| Rahim, AG | 2 |
| Thanh, NV | 2 |
| Tuyet-Trinh, NT | 2 |
| Waithira, N | 2 |
| Dondorp, A | 2 |
| Day, NP | 10 |
| López, AR | 1 |
| Martins, EB | 1 |
| de Pina-Costa, A | 2 |
| Pacheco-Silva, AB | 1 |
| Ferreira, MT | 1 |
| Mamani, RF | 1 |
| Detepo, PJT | 1 |
| Lupi, O | 1 |
| Bressan, CS | 1 |
| Calvet, GA | 1 |
| Silva, MFB | 1 |
| de Fátima Ferreira-da-Cruz, M | 1 |
| de Bruycker-Nogueira, F | 1 |
| Filippis, AMB | 1 |
| Daniel-Ribeiro, CT | 4 |
| Siqueira, A | 1 |
| Brasil, P | 3 |
| Ring, Z | 1 |
| Linn, NYY | 1 |
| Nguitragool, W | 2 |
| Mehdipour, P | 1 |
| Dini, S | 2 |
| Zaloumis, S | 1 |
| Abreha, T | 5 |
| Adam, I | 2 |
| Awab, GR | 5 |
| Brasil, LW | 3 |
| Chu, CS | 20 |
| do Socorro M Gomes, M | 1 |
| Gonzalez-Ceron, L | 4 |
| Hwang, J | 9 |
| Karunajeewa, H | 4 |
| Ladeia-Andrade, S | 3 |
| Leslie, T | 5 |
| Lidia, K | 4 |
| Longley, RJ | 2 |
| Rijal, KR | 2 |
| Thanh, PV | 2 |
| Vieira, JLF | 6 |
| Zuluaga-Idarraga, LM | 2 |
| Guerin, PJ | 4 |
| Adissu, W | 1 |
| Brito, M | 2 |
| Garbin, E | 1 |
| Macedo, M | 1 |
| Mukherjee, SK | 1 |
| Myburg, J | 1 |
| Bansil, P | 4 |
| Pal, S | 2 |
| Zobrist, S | 1 |
| Bryan, A | 1 |
| Das, S | 3 |
| Domingo, GJ | 7 |
| Hann, A | 1 |
| Kublin, J | 1 |
| Layton, M | 1 |
| Murphy, SC | 1 |
| Nosten, F | 20 |
| Pereira, D | 3 |
| Talukdar, A | 2 |
| Gerth-Guyette, E | 2 |
| Sadhewa, A | 3 |
| Panggalo, LV | 2 |
| Kiros, FG | 1 |
| He, X | 1 |
| Pan, M | 1 |
| Zou, C | 1 |
| Pi, L | 1 |
| Qin, Y | 1 |
| Zhao, L | 1 |
| Qin, P | 1 |
| Lu, Y | 1 |
| Huang, Y | 1 |
| Kostić, M | 1 |
| Milosavljević, MN | 1 |
| Stefanović, S | 1 |
| Ranković, G | 1 |
| Janković, SM | 1 |
| Bjorge, S | 2 |
| Topps, N | 1 |
| Kosal, K | 2 |
| Sothea, K | 2 |
| Souy, P | 2 |
| Char, CM | 2 |
| Vanna, C | 2 |
| Ly, P | 2 |
| Khieu, V | 2 |
| Pantaleo, A | 1 |
| Barber, BE | 3 |
| Dahal, P | 3 |
| Grigg, MJ | 3 |
| Humphreys, GS | 2 |
| Phyo, AP | 7 |
| Sibley, CH | 5 |
| Stepniewska, K | 3 |
| Thwaites, G | 3 |
| William, T | 3 |
| Woodrow, CJ | 4 |
| Zhong, D | 1 |
| Raya, B | 1 |
| Pestana, K | 1 |
| Koepfli, C | 1 |
| Lee, MC | 2 |
| Yewhalaw, D | 1 |
| Yan, G | 2 |
| Tripathi, N | 1 |
| Saha, A | 1 |
| Kaur, M | 1 |
| Carrara, VI | 4 |
| Proux, S | 6 |
| Charunwatthana, P | 4 |
| McGready, R | 4 |
| Taylor, AR | 2 |
| Puaprasert, K | 1 |
| Duanguppama, J | 1 |
| Day, NPJ | 5 |
| Neafsey, DE | 1 |
| Buckee, CO | 1 |
| Imwong, M | 15 |
| Winasti Satyagraha, A | 1 |
| von Fricken, ME | 2 |
| Pfeffer, DA | 1 |
| Espino, F | 1 |
| Henriques, G | 2 |
| Oo, NN | 2 |
| van Leth, F | 2 |
| Pongvongsa, T | 3 |
| Promnarate, C | 3 |
| Sirithiranont, P | 2 |
| Cobelens, F | 2 |
| Newton, PN | 2 |
| Brummaier, T | 1 |
| Gilder, ME | 2 |
| Gornsawun, G | 2 |
| Pimanpanarak, M | 1 |
| Chotivanich, K | 4 |
| Wojnarski, B | 1 |
| Lon, C | 3 |
| Sriwichai, S | 2 |
| Chann, S | 2 |
| Boonchan, T | 1 |
| Sok, C | 1 |
| Kong, N | 1 |
| Pheap, V | 1 |
| Thay, K | 1 |
| Dao, V | 1 |
| Feldman, M | 1 |
| Gosi, P | 2 |
| Uthaimongkol, N | 1 |
| Huy, R | 3 |
| Fukuda, MM | 2 |
| Lwin, KM | 2 |
| Kajeechiwa, L | 1 |
| Thwin, MM | 1 |
| Wiladphaingern, J | 3 |
| Nosten, S | 1 |
| Nguon, C | 1 |
| Davoeung, C | 1 |
| Hanboonkunupakarn, B | 6 |
| Jittmala, P | 1 |
| Cheah, PY | 4 |
| Pukrittayakamee, S | 12 |
| Thwaites, GE | 1 |
| Nosten, FH | 4 |
| Silvino, ACR | 3 |
| Kano, FS | 1 |
| Costa, MA | 1 |
| Fontes, CJF | 1 |
| Soares, IS | 2 |
| de Brito, CFA | 1 |
| Carvalho, LH | 2 |
| Sousa, TN | 3 |
| Howes, RE | 6 |
| Moore, KA | 4 |
| Dittrich, S | 1 |
| Teklehaimanot, A | 2 |
| Teklehaimanot, H | 1 |
| Girmay, A | 1 |
| Spring, MD | 1 |
| Kheang Heng, T | 1 |
| Lin, JT | 1 |
| Manning, JE | 1 |
| Jongsakul, K | 1 |
| Pichyangkul, S | 1 |
| Satharath, P | 1 |
| Smith, PL | 1 |
| Saunders, DL | 2 |
| Mat Salleh, NH | 1 |
| Rahman, MFA | 1 |
| Samsusah, S | 1 |
| De Silva, JR | 1 |
| Ng, DC | 1 |
| Ghozali, AH | 1 |
| Tan, JH | 1 |
| Lai, MY | 1 |
| Amir, A | 1 |
| Liew, JWK | 1 |
| Lau, YL | 1 |
| James, R | 1 |
| Martin Ramírez, A | 1 |
| Lombardia González, C | 1 |
| Soler Maniega, T | 1 |
| Gutierrez Liarte, Á | 1 |
| Domingo García, D | 1 |
| Lanza Suárez, M | 1 |
| Bernal Fernández, MJ | 1 |
| Rubio, JM | 1 |
| Park, YS | 1 |
| Park, Y | 1 |
| Lee, KS | 1 |
| Vieira, MVDF | 3 |
| Matos Lopes, TR | 1 |
| Mello, AGNC | 2 |
| de Sena, LWP | 1 |
| Corder, RM | 3 |
| de Lima, ACP | 1 |
| Khoury, DS | 1 |
| Docken, SS | 1 |
| Davenport, MP | 2 |
| Ferreira, MU | 4 |
| Milligan, R | 2 |
| Villanueva, G | 1 |
| Bergman, H | 1 |
| Graves, PM | 2 |
| Rodrigo, C | 3 |
| Rajapakse, S | 3 |
| Marasinghe, MM | 1 |
| Karunasena, VM | 1 |
| Seneratne, AS | 1 |
| Herath, HDB | 1 |
| Wickremasinghe, R | 1 |
| Mendis, KN | 1 |
| Ranaweera, D | 1 |
| Almeida, AC | 2 |
| Elias, ABR | 1 |
| Marques, MP | 1 |
| de Melo, GC | 1 |
| da Costa, AG | 1 |
| Figueiredo, EFG | 2 |
| Rodrigues-Soares, F | 2 |
| de Lacerda, MVG | 1 |
| Lanchote, VL | 1 |
| Suarez-Kurtz, G | 2 |
| Mello, AGCN | 1 |
| Sena, LWP | 2 |
| Sugiarto, P | 3 |
| Nobrega de Sousa, T | 1 |
| Rangel, GW | 1 |
| Johansen, IC | 1 |
| Gil, JP | 1 |
| Srinivasan, S | 1 |
| Roy, D | 1 |
| Chavas, TEJ | 1 |
| Vlaskin, V | 1 |
| Ho, DK | 1 |
| Pottenger, A | 1 |
| LeGuyader, CLM | 1 |
| Jackson, C | 1 |
| Flaherty, SM | 1 |
| Lin, H | 1 |
| Zhang, J | 2 |
| Li, Q | 1 |
| Huber, HE | 1 |
| Burke, PA | 1 |
| Wesche, D | 2 |
| Stayton, PS | 1 |
| Popovici, J | 2 |
| Tebben, K | 1 |
| Witkowski, B | 1 |
| Serre, D | 1 |
| Fernandez-Miñope, C | 1 |
| Delgado-Ratto, C | 2 |
| Contreras-Mancilla, J | 1 |
| Ferrucci, HR | 1 |
| Gamboa, D | 3 |
| Van Geertruyden, JP | 2 |
| Murta, F | 1 |
| Brito, MAM | 3 |
| Batista, TSB | 1 |
| Santos, APC | 1 |
| Marques, LLG | 1 |
| Barbosa, LRA | 1 |
| Melo, MM | 1 |
| Baia-da-Silva, DC | 1 |
| Santos, TC | 2 |
| Silva, EL | 1 |
| Rodovalho, S | 2 |
| Nakagawa, TH | 1 |
| Arcanjo, AR | 2 |
| Siqueira, AM | 9 |
| Recht, J | 3 |
| Bassat, Q | 8 |
| Battle, KE | 5 |
| Gething, PW | 1 |
| Lubell, Y | 4 |
| Spiegelenberg, JP | 1 |
| Bastiaens, GJH | 1 |
| Hassing, RJ | 1 |
| Dinelly, KMO | 1 |
| Silva, MGO | 1 |
| Peterka, C | 1 |
| Omena, AG | 1 |
| Tang, ASO | 1 |
| Soo, XY | 1 |
| Yeo, ST | 1 |
| Mansor, NA | 1 |
| Chew, LP | 1 |
| Chua, HH | 1 |
| Wångdahl, A | 1 |
| Sondén, K | 1 |
| Wyss, K | 2 |
| Stenström, C | 1 |
| Björklund, D | 1 |
| Hervius Askling, H | 1 |
| Carlander, C | 1 |
| Hellgren, U | 1 |
| Färnert, A | 1 |
| Soebianto, S | 3 |
| Mahpud, N | 1 |
| Harahap, AR | 2 |
| Dos Santos, EM | 1 |
| Pedro, RS | 2 |
| Moreira, J | 1 |
| Umana, GL | 1 |
| da Silva, ADT | 1 |
| da Rosa Santos, OHL | 1 |
| de Deus Henriques, KM | 1 |
| Win, HH | 5 |
| Yotyingaphiram, W | 2 |
| Thinraow, S | 2 |
| Soe, NL | 1 |
| Aung, AA | 2 |
| Wilaisrisak, P | 2 |
| Kraft, K | 1 |
| Hanpithakpong, W | 3 |
| Blessborn, D | 3 |
| Ling, C | 1 |
| Pradines, B | 1 |
| Basco, LK | 1 |
| Gunawardena, S | 1 |
| Daniels, RF | 1 |
| Yahathugoda, TC | 1 |
| Weerasooriya, MV | 1 |
| Durfee, K | 1 |
| Volkman, SK | 1 |
| Wirth, DF | 1 |
| Karunaweera, ND | 2 |
| Vieira, JL | 4 |
| Ferreira, MES | 1 |
| Ferreira, MVD | 1 |
| Gomes, MM | 1 |
| Tadesse, Y | 1 |
| Girma, S | 1 |
| Melaku, Z | 2 |
| Assef, A | 1 |
| Kassa, M | 2 |
| Chatfield, MD | 1 |
| Landman, KZ | 1 |
| Lucchi, NW | 1 |
| Udhayakumar, V | 4 |
| Zhou, Z | 1 |
| Shi, YP | 1 |
| Kachur, SP | 2 |
| Jima, D | 2 |
| Kebede, A | 1 |
| Solomon, H | 2 |
| Mekasha, A | 1 |
| Alemayehu, BH | 2 |
| Malone, JL | 2 |
| Dissanayake, G | 1 |
| Teka, H | 1 |
| Auburn, S | 2 |
| Parmiter, M | 1 |
| Maneerattanasak, S | 1 |
| Chimma, P | 1 |
| Tongshoob, J | 1 |
| Mahakunkijcharoen, Y | 1 |
| Sukasem, C | 2 |
| Snounou, G | 3 |
| Khusmith, S | 1 |
| Dombrowski, JG | 1 |
| Souza, RM | 1 |
| Curry, J | 1 |
| Hinton, L | 1 |
| Silva, NRM | 1 |
| Grignard, L | 1 |
| Gonçalves, LA | 1 |
| Gomes, AR | 1 |
| Epiphanio, S | 1 |
| Huggett, J | 1 |
| Clark, TG | 1 |
| Campino, S | 1 |
| Gebreyohannes, EA | 1 |
| Bhagavathula, AS | 1 |
| Seid, MA | 1 |
| Tegegn, HG | 1 |
| Simon, B | 1 |
| Sow, F | 1 |
| Al Mukhaini, SK | 1 |
| Al-Abri, S | 1 |
| Ali, OAM | 1 |
| Bonnot, G | 2 |
| Bienvenu, AL | 2 |
| Petersen, E | 1 |
| Picot, S | 2 |
| Wampfler, R | 2 |
| Hofmann, NE | 1 |
| Karl, S | 1 |
| Kinboro, B | 1 |
| Silkey, M | 1 |
| Felger, I | 1 |
| Jaswal, J | 1 |
| Poirot, E | 2 |
| Qi, G | 2 |
| Kheong, CC | 2 |
| Shamsudin, UK | 1 |
| Chen, I | 2 |
| Gosling, R | 3 |
| Patriani, D | 1 |
| Malloy, MJ | 1 |
| Soenarto, Y | 1 |
| Kitchakarn, S | 1 |
| Thol, S | 1 |
| Hok, C | 1 |
| Saejeng, A | 1 |
| Chinanonwait, N | 1 |
| Thimasarn, K | 2 |
| Wongsrichanalai, C | 2 |
| Hassett, MR | 1 |
| Riegel, BE | 1 |
| Callaghan, PS | 1 |
| Roepe, PD | 1 |
| Sortica, VA | 1 |
| Lindenau, JD | 1 |
| Cunha, MG | 1 |
| O Ohnishi, MD | 1 |
| R Ventura, AM | 1 |
| Ribeiro-Dos-Santos, ÂK | 1 |
| Santos, SE | 1 |
| Guimarães, LS | 1 |
| Hutz, MH | 1 |
| Eperon, G | 1 |
| Durieux-Paillard, S | 1 |
| Mauris, A | 1 |
| Chappuis, F | 1 |
| Gysin, N | 1 |
| Mat Ariffin, N | 1 |
| Islahudin, F | 1 |
| Kumolosasi, E | 1 |
| Makmor-Bakry, M | 1 |
| Alexandre, MAA | 1 |
| Nascimento, CT | 1 |
| Alves de Lima E Silva, JC | 1 |
| Tada, M | 1 |
| Ruffato, R | 2 |
| Maia, I | 2 |
| Dos Santos, TC | 1 |
| Marchesini, P | 4 |
| Santelli, AC | 2 |
| Lalloo, DG | 4 |
| Santoro, AB | 1 |
| Almeida, ACG | 1 |
| Kühn, A | 1 |
| Ramasawmy, R | 1 |
| Steinkamp, N | 1 |
| Hamid, MMA | 1 |
| Elobied, ME | 1 |
| Mahgoub, NS | 1 |
| Boshara, SA | 1 |
| Elsafi, HMH | 1 |
| Gumaa, SA | 1 |
| Hamid, T | 1 |
| Abdelbagi, H | 1 |
| Basheir, HM | 1 |
| Marfurt, J | 3 |
| Hanpithakphong, W | 1 |
| Hilda, N | 1 |
| Singhasivanon, P | 7 |
| Watson, J | 5 |
| Jittamala, P | 4 |
| Porn, P | 1 |
| Lover, AA | 1 |
| Sümer, Ş | 1 |
| Aktuğ Demir, N | 1 |
| Ural, O | 1 |
| Çimen, G | 1 |
| Yalçınkaya, E | 1 |
| San, T | 1 |
| Raksapraidee, R | 3 |
| Sriprawat, K | 2 |
| Winterberg, M | 1 |
| Chue, AL | 1 |
| Valdes, A | 1 |
| Epelboin, L | 1 |
| Mosnier, E | 1 |
| Walter, G | 1 |
| Vesin, G | 1 |
| Abboud, P | 1 |
| Melzani, A | 1 |
| Blanchet, D | 1 |
| Blaise, N | 1 |
| Nacher, M | 4 |
| Demar, M | 2 |
| Djossou, F | 2 |
| Bobogare, A | 1 |
| Gudo, CS | 1 |
| Ashley, E | 2 |
| Jambert, E | 1 |
| Laihad, F | 1 |
| van den Boogaard, C | 1 |
| Ghimire, P | 2 |
| Hawley, B | 1 |
| Mudin, RNB | 1 |
| Sumiwi, ME | 1 |
| Ahmed, R | 1 |
| Aktaruzzaman, MM | 1 |
| Awasthi, KR | 1 |
| Bardaji, A | 1 |
| Bell, D | 1 |
| Boaz, L | 1 |
| Chandramohan, D | 1 |
| Cheng, Q | 2 |
| Chindawongsa, K | 1 |
| Culpepper, J | 1 |
| Deray, R | 1 |
| Desai, M | 1 |
| Domingo, G | 1 |
| Duoquan, W | 1 |
| Floranita, R | 1 |
| Hugo, C | 1 |
| Jagoe, G | 1 |
| Sariwati, E | 1 |
| Jhora, ST | 1 |
| Jinwei, W | 1 |
| Lal, BK | 1 |
| Landuwulang, C | 1 |
| Le Perru, E | 1 |
| Makita, LS | 1 |
| McCarthy, J | 1 |
| Mekuria, A | 1 |
| Mishra, N | 1 |
| Naket, E | 1 |
| Nambanya, S | 1 |
| Nausien, J | 1 |
| Duc, TN | 1 |
| Thi, TN | 1 |
| Pfeffer, D | 1 |
| Rogerson, S | 1 |
| Samad, I | 1 |
| Shanks, D | 1 |
| Sharma, SN | 1 |
| Sungkar, A | 1 |
| Syafruddin, D | 1 |
| Ter Kuile, F | 1 |
| Thapa, S | 1 |
| Theodora, M | 1 |
| Huy, TT | 1 |
| Waramin, E | 1 |
| Waramori, G | 1 |
| Xa, NX | 2 |
| Hermawan, L | 1 |
| Nowak, S | 1 |
| Jaya, I | 1 |
| Supargiyono, S | 1 |
| Grietens, KP | 2 |
| Alemu, SG | 2 |
| Añez, A | 2 |
| Borghini-Fuhrer, I | 2 |
| D'Alessandro, U | 6 |
| de Vries, PJ | 2 |
| Erhart, A | 6 |
| Gomes, MSM | 2 |
| Heidari, A | 2 |
| Kager, PA | 4 |
| Ketema, T | 2 |
| Phan, GT | 2 |
| Rowland, M | 4 |
| Tran, BQ | 2 |
| Tran, HT | 1 |
| Wangchuk, S | 2 |
| Zuluaga-Idarraga, L | 3 |
| Chairat, K | 2 |
| Tellapragada, C | 1 |
| Kulavalli, S | 1 |
| Xavier, W | 1 |
| Umakanth, S | 1 |
| Brahmarouphu, G | 1 |
| Srinivas, NK | 1 |
| Channabasavaiah, JP | 1 |
| Bava, A | 1 |
| Saadi, AV | 1 |
| Satyamoorthy, K | 1 |
| Bhat, K | 1 |
| Advani, N | 1 |
| Rowley, E | 1 |
| Kalnoky, M | 2 |
| Cohen, J | 1 |
| Parker, M | 1 |
| Kelley, M | 1 |
| Redditt, V | 1 |
| Bogoch, I | 1 |
| Rashid, M | 1 |
| Warrasak, S | 1 |
| Euswas, A | 1 |
| Miller, RS | 1 |
| Ohrt, C | 3 |
| Paixão, TPD | 1 |
| Pinto, ACG | 1 |
| Grisólia, DPA | 1 |
| Silva, MT | 1 |
| Kondrashin, AV | 1 |
| Boranova, AM | 1 |
| Morozovz, LF | 1 |
| Tokmalaev, AK | 1 |
| Stepanova, EV | 1 |
| Morozov, EN | 1 |
| Saipov, FS | 1 |
| Berman, J | 4 |
| Brown, T | 1 |
| Dow, G | 1 |
| Toovey, S | 1 |
| Avalos, S | 2 |
| Mejia, RE | 2 |
| Banegas, E | 2 |
| Salinas, C | 1 |
| Gutierrez, L | 1 |
| Fajardo, M | 1 |
| Galo, S | 1 |
| Pinto, A | 1 |
| Mejia, A | 1 |
| Fontecha, G | 3 |
| Mansanguan, C | 1 |
| Phumratanaprapin, W | 3 |
| Louisa, M | 2 |
| Ekawati, L | 1 |
| Gayatri, A | 1 |
| Djoko, D | 2 |
| Hasto, BD | 1 |
| Meriyenes, D | 1 |
| Nelwan, EJ | 2 |
| Sudoyo, H | 4 |
| Setiabudy, R | 3 |
| Mohammed, R | 1 |
| Batista Pereira, D | 1 |
| Espino, FEJ | 1 |
| Mia, RZ | 1 |
| Chuquiyauri, R | 2 |
| Val, F | 3 |
| Casapía, M | 2 |
| Costa, MRF | 2 |
| Noedl, H | 1 |
| Diro, E | 1 |
| Getie, S | 1 |
| Wubie, KM | 1 |
| Abdissa, A | 1 |
| Zeynudin, A | 1 |
| Abebe, C | 1 |
| Tada, MS | 2 |
| Brand, F | 1 |
| Beck, HP | 2 |
| Angus, B | 2 |
| Kellam, LM | 1 |
| Rousell, VM | 2 |
| Jones, SW | 2 |
| Hardaker, E | 2 |
| Mohamed, K | 2 |
| Clover, DD | 2 |
| Breton, JJ | 2 |
| Ugwuegbulam, CO | 1 |
| Koh, GCKW | 3 |
| Vélez, ID | 1 |
| Namaik-Larp, C | 1 |
| Villegas, MF | 1 |
| Nguyen, CH | 1 |
| Aruachan, S | 1 |
| Papwijitsil, R | 1 |
| Craig, G | 1 |
| Kendall, L | 1 |
| Wilches, VM | 1 |
| Silva, JCAL | 1 |
| Stevens, A | 1 |
| Fontes, CJ | 6 |
| Ter Kuile, FO | 1 |
| Alecrim, GC | 1 |
| Menezes, MJ | 2 |
| de Sousa, TN | 1 |
| de Carvalho, JF | 1 |
| Salla, LC | 1 |
| Nery, OA | 1 |
| de Melo, GNP | 1 |
| Rodrigues, PT | 1 |
| Rodríguez-Morales, AJ | 1 |
| Yoshii, A | 1 |
| Sekihara, M | 1 |
| Furusawa, T | 1 |
| Hombhanje, F | 1 |
| Tsukahara, T | 1 |
| Corpolongo, A | 1 |
| Pisapia, R | 1 |
| Oliva, A | 1 |
| Giancola, ML | 1 |
| Mencarini, P | 1 |
| Bevilacqua, N | 1 |
| Ghirga, P | 1 |
| Mariano, A | 1 |
| Vulcano, A | 1 |
| Paglia, MG | 1 |
| Nicastri, E | 1 |
| Ong, KIC | 1 |
| Iwagami, M | 1 |
| Araki, H | 1 |
| Khattignavong, P | 1 |
| Soundala, P | 1 |
| Keomalaphet, S | 1 |
| Prasayasith, P | 1 |
| Lorpachan, L | 1 |
| Xangsayalath, P | 1 |
| Hongvanthong, B | 1 |
| Brey, PT | 1 |
| Kano, S | 4 |
| Jimba, M | 1 |
| Banjara, MR | 1 |
| Das Thakur, G | 1 |
| Setyadi, A | 1 |
| Arguni, E | 1 |
| Hasanuddin, A | 1 |
| Lampah, DA | 1 |
| Turner, C | 1 |
| Poe, NP | 1 |
| Wilairisak, P | 2 |
| Paw, MK | 1 |
| Lee, SJ | 4 |
| Jeeyapant, A | 1 |
| Chen, N | 1 |
| Dowd, S | 1 |
| Gatton, ML | 1 |
| Auliff, A | 1 |
| Edstein, MD | 7 |
| Quinn, JC | 1 |
| McCarthy, S | 1 |
| Pham, TV | 1 |
| Nguyen, HV | 1 |
| Aguirre, AR | 1 |
| Nguyen, VV | 1 |
| A Cleves, M | 1 |
| Nguyen, XX | 1 |
| Nguyen, TT | 1 |
| Tran, DT | 1 |
| Le, HX | 1 |
| Hens, N | 1 |
| Rosanas-Urgell, A | 4 |
| Speybroeck, N | 2 |
| Rosenthal, PJ | 2 |
| Yuentrakul, P | 1 |
| Assawariyathipat, T | 1 |
| Dong, LT | 1 |
| Fahmi, F | 1 |
| Khu, H | 1 |
| Mohammad, H | 1 |
| Pasaribu, S | 2 |
| Yamin, FY | 1 |
| Aseffa, A | 1 |
| Bright, AT | 1 |
| Alenazi, T | 1 |
| Shokoples, S | 1 |
| Paganotti, GM | 1 |
| Houston, S | 1 |
| Winzeler, EA | 1 |
| Yanow, SK | 1 |
| Zhu, G | 1 |
| Lu, F | 1 |
| Cao, J | 1 |
| Zhou, H | 1 |
| Liu, Y | 1 |
| Han, ET | 1 |
| Gao, Q | 1 |
| Miahipour, A | 1 |
| Keshavarz, H | 1 |
| Raeisi, A | 1 |
| Rezaeian, M | 1 |
| Rezaei, S | 1 |
| Reithinger, R | 1 |
| Tekleyohannes, SG | 1 |
| Birhanu, SG | 1 |
| Demeke, L | 1 |
| Hoos, D | 1 |
| Nettey, H | 2 |
| Green, M | 1 |
| Poe, A | 1 |
| Akinyi, S | 1 |
| Filler, S | 1 |
| Chokejindachai, W | 1 |
| Sirivichayakul, C | 1 |
| Tanomsing, N | 3 |
| Chavez, I | 1 |
| Tjitra, E | 3 |
| Kristensen, KL | 1 |
| Dragsted, UB | 1 |
| Bennett, JW | 1 |
| Yadava, A | 1 |
| Tosh, D | 1 |
| Sousa, JC | 1 |
| McCarthy, WF | 1 |
| Deye, G | 1 |
| Melendez, V | 1 |
| Ockenhouse, CF | 1 |
| Stefani, A | 2 |
| Basurko, C | 2 |
| Lemonnier, D | 1 |
| Elenga, N | 1 |
| Brousse, P | 1 |
| Ville, M | 1 |
| Carme, B | 2 |
| Gogtay, N | 1 |
| Kannan, S | 1 |
| Thatte, UM | 1 |
| Olliaro, PL | 1 |
| Sinclair, D | 1 |
| Galappaththy, GN | 2 |
| Tharyan, P | 2 |
| Kirubakaran, R | 1 |
| Waita, E | 1 |
| Siba, P | 2 |
| Davis, TM | 4 |
| Yang, HL | 1 |
| Xu, JW | 1 |
| Wang, JZ | 1 |
| Nie, RH | 1 |
| Li, CF | 1 |
| Goswami, RP | 2 |
| Mondal, S | 1 |
| Sinha, D | 1 |
| Mandal, S | 1 |
| Mondal, R | 1 |
| Dev, A | 1 |
| Pal, J | 1 |
| Ghosh, A | 1 |
| Dewi, M | 1 |
| Piel, FB | 1 |
| Messina, JP | 1 |
| Sakuntabhai, A | 1 |
| Williams, TN | 1 |
| Hay, SI | 2 |
| Lacerda, MV | 10 |
| Rueangweerayut, R | 3 |
| Gupta, SK | 1 |
| Kochar, SK | 1 |
| Arthur, P | 1 |
| Chuenchom, N | 1 |
| Möhrle, JJ | 1 |
| Ugwuegbulam, C | 1 |
| Carter, N | 3 |
| Kellam, L | 1 |
| Soto-Calle, VE | 1 |
| Van den Eede, P | 1 |
| Rosas, A | 1 |
| Abatih, EN | 1 |
| Rodriguez Ferrucci, H | 1 |
| Lopes, SC | 2 |
| Albrecht, L | 2 |
| Carvalho, BO | 1 |
| Thomson-Luque, R | 1 |
| Nogueira, PA | 1 |
| Fernandez-Becerra, C | 1 |
| Del Portillo, HA | 3 |
| Russell, BM | 1 |
| Rénia, L | 1 |
| Costa, FT | 2 |
| Tanwar, GS | 1 |
| Lahoti, A | 1 |
| Tanwar, P | 1 |
| Agrawal, R | 1 |
| Khatri, PC | 1 |
| Kochar, DK | 1 |
| Kondrashin, A | 1 |
| Baranova, AM | 1 |
| Ashley, EA | 3 |
| Sergiev, VP | 1 |
| Franca, GP | 2 |
| Queiroz, AL | 1 |
| Oliveira, MR | 1 |
| Romero, GA | 4 |
| Jamornthanyawat, N | 1 |
| Yamin, F | 1 |
| Yepes-Jiménez, N | 1 |
| López-Córdoba, C | 1 |
| Blair-Trujillo, S | 1 |
| Durand, S | 1 |
| Cabezas, C | 1 |
| Lescano, AG | 2 |
| Galvez, M | 1 |
| Gutierrez, S | 1 |
| Arrospide, N | 1 |
| Alvarez, C | 1 |
| Santolalla, ML | 1 |
| Bacon, DJ | 1 |
| Graf, PC | 1 |
| Weppelmann, TA | 1 |
| Eaton, WT | 1 |
| Masse, R | 1 |
| Beau de Rochars, MV | 1 |
| Okech, BA | 1 |
| Møller, CH | 1 |
| David, K | 1 |
| Hetzel, MW | 1 |
| Bala, N | 1 |
| Pulford, J | 1 |
| Lavu, EK | 1 |
| Goo, YK | 1 |
| Ji, SY | 1 |
| Moon, JH | 1 |
| Lee, WJ | 3 |
| Kim, JY | 3 |
| Santana, MS | 1 |
| Costa, MR | 2 |
| Brito, MA | 4 |
| Alecrim, MG | 1 |
| Pothapregada, S | 1 |
| Kamalakannan, B | 1 |
| Faucher, JF | 1 |
| Bellanger, AP | 1 |
| Shaniya, N | 1 |
| Hustache-Mathieu, L | 1 |
| Hoen, B | 1 |
| Chirouze, C | 1 |
| Hatipoğlu, M | 1 |
| Ulçay, A | 1 |
| Turhan, V | 1 |
| Karagöz, E | 1 |
| Erdem, H | 1 |
| Acar, A | 1 |
| Oncül, O | 1 |
| Görenek, L | 1 |
| Dos-Santos, JC | 1 |
| Angerami, RN | 1 |
| Castiñeiras, CM | 1 |
| Garcia, MT | 1 |
| Levy, CE | 1 |
| Moretti, ML | 1 |
| Kedar, P | 1 |
| Warang, P | 1 |
| Sanyal, S | 1 |
| Devendra, R | 1 |
| Ghosh, K | 1 |
| Colah, R | 1 |
| Davanço, MG | 1 |
| Aguiar, AC | 1 |
| Dos Santos, LA | 1 |
| Padilha, EC | 1 |
| Campos, ML | 1 |
| de Andrade, CR | 1 |
| da Fonseca, LM | 1 |
| Dos Santos, JL | 1 |
| Chin, CM | 1 |
| Krettli, AU | 1 |
| Peccinini, RG | 1 |
| Val, FF | 2 |
| Fuller, D | 1 |
| Maria Regina F, O | 1 |
| Marcus Vinícius G, L | 1 |
| Cassera, MB | 1 |
| Andrade, RT | 1 |
| Tauil, PL | 1 |
| Imerbsin, R | 1 |
| Khemawoot, P | 1 |
| Siripokasupkul, R | 1 |
| Tekwani, BL | 1 |
| Sampath, A | 1 |
| Nanayakkara, NP | 1 |
| Gettyacamin, M | 1 |
| Teja-Isavadharm, P | 1 |
| Walker, L | 1 |
| Redig, AJ | 1 |
| Vaidya, A | 1 |
| Price, C | 1 |
| Katz, JT | 1 |
| Maguire, JH | 1 |
| Thana, P | 1 |
| Panapipat, S | 1 |
| Ingram, RJ | 1 |
| Yuan, L | 1 |
| Wang, Y | 1 |
| Gupta, B | 1 |
| Fan, Q | 1 |
| Cao, Y | 1 |
| Xiao, Y | 1 |
| Zhou, G | 1 |
| Chowwiwat, N | 3 |
| Somsakchaicharoen, R | 1 |
| McGray, S | 1 |
| Baramuli, V | 1 |
| Elvira, R | 1 |
| Ridenour, C | 1 |
| Coutrier, FN | 1 |
| Adekunle, AI | 1 |
| Pinkevych, M | 1 |
| Luxemburger, C | 1 |
| White, LJ | 1 |
| Cromer, D | 1 |
| Mikolajczak, SA | 1 |
| Vaughan, AM | 1 |
| Kangwanrangsan, N | 1 |
| Fishbaugher, M | 1 |
| Yimamnuaychok, N | 1 |
| Rezakhani, N | 1 |
| Lakshmanan, V | 1 |
| Singh, N | 3 |
| Kaushansky, A | 1 |
| Camargo, N | 1 |
| Baldwin, M | 1 |
| Lindner, SE | 1 |
| Adams, JH | 1 |
| Prachumsri, J | 1 |
| Kappe, SH | 1 |
| de Lacerda, MV | 2 |
| de Oliveira, MR | 2 |
| Fernando, SD | 2 |
| Meltzer, E | 1 |
| Morrison, L | 1 |
| Stienlauf, S | 1 |
| Schwartz, E | 3 |
| Rishikesh, K | 2 |
| Kamath, A | 2 |
| Hande, MH | 1 |
| Vidyasagar, S | 1 |
| Acharya, RV | 1 |
| Acharya, V | 2 |
| Belle, J | 1 |
| Shastry, AB | 1 |
| Cheoymang, A | 1 |
| Ruenweerayut, R | 1 |
| Muhamad, P | 2 |
| Rungsihirunrat, K | 2 |
| Na-Bangchang, K | 3 |
| Tops, N | 1 |
| Ringwald, P | 4 |
| Hong, NV | 1 |
| Van, NV | 1 |
| Hung, le X | 1 |
| Duong, TT | 1 |
| Luter, N | 1 |
| Espino, FE | 1 |
| Conan, N | 1 |
| Dion-Berboso, AG | 1 |
| Kumar, R | 3 |
| Gomes, Mdo S | 1 |
| Machado, RL | 2 |
| Musset, L | 1 |
| Legrand, E | 1 |
| Menezes, RA | 1 |
| Júnior, AA | 1 |
| Sousa, AP | 1 |
| Couto, VS | 1 |
| Couto, ÁA | 1 |
| Koh, G | 1 |
| Osorio, L | 1 |
| Rubio, JP | 2 |
| Rodriguez, MH | 3 |
| Sandoval, MA | 1 |
| Santillan, F | 1 |
| Galindo-Virgen, S | 1 |
| Betanzos, AF | 1 |
| Rosales, AF | 1 |
| Palomeque, OL | 1 |
| McFarland, AP | 1 |
| Sanchez, JF | 1 |
| Mercado, A | 1 |
| Ventocilla, JA | 1 |
| Cavalcanti, S | 1 |
| Gonzalez, S | 1 |
| Tjahjono, B | 2 |
| Ekasari, T | 1 |
| Basri, H | 6 |
| Moura-Neto, JP | 1 |
| Tamayo Perez, ME | 1 |
| Aguirre-Acevedo, DC | 1 |
| Shingadia, D | 2 |
| Bell, DJ | 1 |
| Beeching, NJ | 2 |
| Whitty, CJM | 1 |
| Chiodini, PL | 1 |
| St Jean, PL | 1 |
| Xue, Z | 1 |
| Koh, GC | 1 |
| Beaumont, C | 1 |
| Maw, LZ | 1 |
| Htun, MM | 1 |
| Thant, KZ | 1 |
| Htut, Y | 1 |
| Thomas, D | 1 |
| Tazerouni, H | 1 |
| Sundararaj, KG | 1 |
| Cooper, JC | 1 |
| Blair, S | 2 |
| Akinyi Okoth, S | 1 |
| Marcet, PL | 1 |
| Escalante, AA | 1 |
| Alexander, N | 1 |
| Rojas, C | 1 |
| Almeida, ED | 1 |
| Ashok, H | 1 |
| Kundapura, P | 1 |
| Kamath, V | 1 |
| Mukhopadhyay, C | 1 |
| Mesquita, TC | 1 |
| Martin, TG | 1 |
| Alves, ER | 1 |
| Mello, MB | 1 |
| Nery, AF | 1 |
| Gomes, LT | 1 |
| Silvino, AC | 1 |
| Costa, GL | 1 |
| Araújo, FC | 1 |
| Ascher, DB | 1 |
| Pires, DE | 1 |
| Brito, CF | 1 |
| Subramony, H | 1 |
| Tangpukdee, N | 5 |
| Poovorawan, K | 1 |
| Muangnoicharoen, S | 3 |
| Wilairatana, P | 12 |
| Negreiros, S | 1 |
| Viana, GM | 1 |
| Okoth, SA | 1 |
| de Souza, TM | 1 |
| Povoa, MM | 2 |
| de Oliveira, AM | 1 |
| Sripoorote, P | 1 |
| Chobson, P | 1 |
| Saeseu, T | 1 |
| Zanini, G | 1 |
| Fonseca, L | 1 |
| Pitta, L | 1 |
| Siv, S | 1 |
| Vinjamuri, SB | 1 |
| Bouth, DM | 1 |
| Rashid, MA | 1 |
| By, NP | 1 |
| Lakshman, A | 1 |
| Singh, C | 1 |
| Singhal, M | 1 |
| Jain, S | 1 |
| Sharma, N | 1 |
| Kumari, S | 1 |
| Varma, S | 1 |
| Azad, CS | 1 |
| Saxena, M | 1 |
| Siddiqui, AJ | 1 |
| Bhardwaj, J | 1 |
| Puri, SK | 1 |
| Dutta, GP | 1 |
| Anand, N | 1 |
| Saxena, AK | 1 |
| Thitipanawan, N | 1 |
| Po, C | 1 |
| Keereecharoen, L | 1 |
| Elmes, NJ | 2 |
| Nasveld, PE | 2 |
| Kitchener, SJ | 2 |
| Kocisko, DA | 1 |
| Mayan, I | 1 |
| Mohammed, N | 1 |
| Erasmus, P | 1 |
| Kolaczinski, J | 2 |
| Whitty, CJ | 1 |
| Oliveira-Ferreira, J | 1 |
| Moon, KT | 1 |
| Kim, YK | 3 |
| Ko, DH | 2 |
| Park, I | 3 |
| Shin, DC | 1 |
| Carmona-Fonseca, J | 5 |
| Alvarez, G | 3 |
| Maestre, A | 3 |
| Betanzos-Reyes, AF | 1 |
| Hernández-Avila, JE | 1 |
| Méndez-Galván, JF | 1 |
| Danis-Lozano, R | 1 |
| Altamirano-Jiménez, A | 1 |
| Barreto Miranda, I | 1 |
| Löscher, T | 3 |
| Daneshvar, C | 1 |
| Cox-Singh, J | 1 |
| Rafa'ee, MZ | 1 |
| Zakaria, SK | 1 |
| Divis, PC | 1 |
| Singh, B | 1 |
| Lee, SW | 1 |
| Lee, M | 1 |
| Lee, DD | 1 |
| Kim, YJ | 1 |
| Green, MD | 1 |
| Klein, TA | 3 |
| Kim, HC | 2 |
| Kim, H | 1 |
| Yeshiwondim, AK | 1 |
| Tekle, AH | 1 |
| Dengela, DO | 1 |
| Yohannes, AM | 1 |
| Hanf, M | 1 |
| Stéphani, A | 1 |
| Orjuela-Sánchez, P | 1 |
| da Silva, NS | 1 |
| da Silva-Nunes, M | 1 |
| Lee, JH | 2 |
| Chin, HS | 1 |
| Chung, MH | 3 |
| Moon, YS | 1 |
| Soto, V | 1 |
| Ribera, JM | 1 |
| Toomer, E | 1 |
| Tenorio, A | 1 |
| Montalvo, TG | 1 |
| Rodriguez, H | 1 |
| Cuentas, AL | 1 |
| Kyaw, MK | 1 |
| Phe, O | 1 |
| Win, T | 1 |
| Oo, AP | 1 |
| Naing, AL | 1 |
| Nyo, MY | 1 |
| Myint, NZ | 1 |
| Alexandre, MA | 1 |
| Ferreira, CO | 1 |
| Magalhães, BL | 1 |
| Mourão, MP | 1 |
| Alecrim, Md | 2 |
| Santa-Olalla Peralta, P | 1 |
| Vazquez-Torres, MC | 1 |
| Latorre-Fandos, E | 1 |
| Mairal-Claver, P | 1 |
| Cortina-Solano, P | 1 |
| Puy-Azón, A | 1 |
| Adiego Sancho, B | 1 |
| Leitmeyer, K | 1 |
| Lucientes-Curdi, J | 1 |
| Sierra-Moros, MJ | 1 |
| Takeuchi, R | 1 |
| Kobayashi, J | 1 |
| Puangsa-art, S | 2 |
| Thanyavanich, N | 2 |
| Maneeboonyang, W | 2 |
| Sung, YH | 1 |
| Park, JM | 1 |
| Chattopadhyay, R | 1 |
| Velmurugan, S | 1 |
| Chakiath, C | 1 |
| Andrews Donkor, L | 1 |
| Milhous, W | 1 |
| Barnwell, JW | 1 |
| Collins, WE | 5 |
| Hoffman, SL | 5 |
| Burgoine, KL | 1 |
| Sitcharungsi, R | 1 |
| Anurathapan, U | 1 |
| Sirachainan, N | 1 |
| Chanthavanich, P | 1 |
| Solarte, Y | 1 |
| Jordán-Villegas, A | 1 |
| Echavarría, JF | 1 |
| Rocha, L | 1 |
| Palacios, R | 1 |
| Ramírez, O | 1 |
| Vélez, JD | 1 |
| Epstein, JE | 1 |
| Richie, TL | 6 |
| Arévalo-Herrera, M | 1 |
| Yimsamran, S | 1 |
| Wuthisen, P | 1 |
| Prommongkol, S | 1 |
| Chaimongkul, W | 1 |
| Rukmanee, P | 1 |
| Rukmanee, N | 1 |
| Chavez, IF | 1 |
| Buchachart, K | 3 |
| Ruengweerayut, R | 1 |
| Chacharoenkul, W | 1 |
| Kim, HY | 1 |
| Kim, JM | 1 |
| Ebringer, A | 1 |
| Heathcote, G | 1 |
| Baker, J | 1 |
| Waller, M | 1 |
| Shanks, GD | 2 |
| Sonkar, SK | 1 |
| Uniyal, R | 1 |
| Sonkar, GK | 1 |
| Steinhardt, LC | 1 |
| Magill, AJ | 3 |
| Arguin, PM | 2 |
| Pereira, EA | 1 |
| Ishikawa, EA | 1 |
| Jovel, IT | 1 |
| Piedade, R | 1 |
| Alger, J | 1 |
| Ferreira, PE | 1 |
| Veiga, MI | 1 |
| Enamorado, IG | 1 |
| Bjorkman, A | 1 |
| Ursing, J | 1 |
| Kiniboro, B | 2 |
| Stanisic, D | 1 |
| Siba, PM | 1 |
| Alonso, PL | 2 |
| Congpuon, K | 1 |
| Satimai, W | 2 |
| Sujariyakul, A | 1 |
| Intanakom, S | 1 |
| Harnpitakpong, W | 1 |
| Pranuth, Y | 1 |
| Cholpol, S | 1 |
| Bualombai, P | 1 |
| Zaki, SA | 1 |
| Shanbag, P | 1 |
| Chiang, TY | 1 |
| Lin, WC | 1 |
| Kuo, MC | 1 |
| Ji, DD | 1 |
| Fang, CT | 1 |
| Kumar, K | 1 |
| Jun, G | 1 |
| Shin, EH | 1 |
| Chang, KS | 1 |
| Bang, JH | 1 |
| Oh, S | 2 |
| Kang, JY | 1 |
| Park, JW | 3 |
| Deye, GA | 1 |
| Gettayacamin, M | 1 |
| Hansukjariya, P | 1 |
| Im-erbsin, R | 1 |
| Rothstein, Y | 1 |
| Macareo, L | 1 |
| Fracisco, S | 1 |
| Bennett, K | 1 |
| Townell, N | 1 |
| Looke, D | 1 |
| McDougall, D | 1 |
| McCarthy, JS | 1 |
| Kim, JR | 2 |
| Nandy, A | 2 |
| Maji, AK | 2 |
| Addy, M | 1 |
| Guaraldo, L | 1 |
| Campos, DP | 1 |
| Costa, AP | 1 |
| John, GK | 1 |
| Stanisic, DI | 1 |
| Samol, L | 1 |
| de Lazzari, E | 1 |
| Kusriastuti, R | 1 |
| Surya, A | 1 |
| Sun, XD | 1 |
| Wang, J | 1 |
| Wei, C | 1 |
| Eibach, D | 1 |
| Ceron, N | 1 |
| Krishnalall, K | 1 |
| Carter, K | 1 |
| Andriopoulos, P | 1 |
| Economopoulou, A | 1 |
| Spanakos, G | 1 |
| Assimakopoulos, G | 1 |
| Kiang, KM | 1 |
| Bryant, PA | 1 |
| Ladhani, S | 1 |
| Steer, AC | 1 |
| Burgner, D | 1 |
| Baird, KJ | 1 |
| Maguire, JD | 1 |
| Putri, FA | 1 |
| Meilia, RA | 1 |
| Nurleila, S | 1 |
| Farrar, J | 1 |
| Ganguly, S | 1 |
| Saha, P | 1 |
| Guha, SK | 1 |
| Bera, DK | 1 |
| Biswas, A | 1 |
| Kundu, PK | 1 |
| Saha, B | 1 |
| Ray, K | 1 |
| Roy, M | 1 |
| Bouma, MJ | 1 |
| Ionides, EL | 1 |
| Dhiman, RC | 1 |
| Pascual, M | 1 |
| Hung, le Q | 1 |
| Vries, PJ | 1 |
| Giao, PT | 1 |
| Nam, NV | 1 |
| Binh, TQ | 1 |
| Chong, MT | 1 |
| Quoc, NT | 1 |
| Thanh, TN | 1 |
| Hung, LN | 1 |
| Yadav, RS | 2 |
| Ghosh, SK | 1 |
| Ishikawa, H | 1 |
| Ishii, A | 1 |
| Nagai, N | 1 |
| Ohmae, H | 1 |
| Harada, M | 1 |
| Suguri, S | 1 |
| Leafasia, J | 1 |
| Durante Mangoni, E | 1 |
| Severini, C | 1 |
| Menegon, M | 1 |
| Romi, R | 1 |
| Ruggiero, G | 1 |
| Majori, G | 1 |
| Rieckmann, KH | 5 |
| Syed, DA | 1 |
| Ilett, KF | 1 |
| Barrett, PH | 1 |
| Mehrunnisa, A | 1 |
| Saifi, MA | 1 |
| Khan, HM | 1 |
| Wickremasinghe, AR | 2 |
| Fernandopulle, BM | 1 |
| Weeraratne, CL | 1 |
| Weerasuriya, K | 1 |
| Peters, W | 1 |
| Stewart, LB | 1 |
| Robinson, BL | 1 |
| Silachamroon, U | 3 |
| Treeprasertsuk, S | 4 |
| Chalearmrult, K | 1 |
| Mint, HY | 1 |
| Maneekan, P | 1 |
| Gourdeuk, VR | 1 |
| Brittenham, GM | 3 |
| Looareesuwan, S | 11 |
| Valibayov, A | 1 |
| Abdullayev, F | 1 |
| Mammadov, S | 1 |
| Gasimov, E | 1 |
| Sabatinelli, G | 1 |
| Kondrachine, AV | 1 |
| COOPER, WC | 1 |
| MYATT, AV | 1 |
| HERNANDEZ, T | 1 |
| JEFFERY, GM | 4 |
| COATNEY, GR | 5 |
| ALVING, AS | 12 |
| HANKEY, DD | 3 |
| JONES, R | 5 |
| COKER, WG | 3 |
| GARRISON, PL | 3 |
| DONOVAN, WN | 3 |
| JACKSON, LS | 1 |
| DI LORENZO, A | 3 |
| MARX, RL | 3 |
| LEVY, BL | 1 |
| KENNY, EC | 1 |
| GILBERT, M | 1 |
| JOHNSTON, MN | 1 |
| ROBINSON, DH | 2 |
| SIMMONS, IH | 1 |
| HANSEN, JE | 1 |
| CLEVE, EA | 1 |
| PRUITT, FW | 1 |
| ARNOLD, J | 5 |
| HOCKWALD, RS | 2 |
| CLAYMAN, CB | 3 |
| DERN, RJ | 2 |
| BEUTLER, E | 2 |
| FLANAGAN, CL | 1 |
| Lee, HC | 1 |
| Pacha, LA | 1 |
| Ryu, SH | 2 |
| Moon, SH | 1 |
| Chai, JY | 1 |
| Oh, MD | 1 |
| Choe, KW | 1 |
| JOHNSON, CF | 1 |
| TARLOV, AR | 1 |
| BREWER, GJ | 2 |
| KELLERMEYER, RW | 1 |
| CARSON, PE | 1 |
| COURTNEY, KO | 1 |
| HODGKINSON, R | 1 |
| RAMSEY, R | 1 |
| HAGGERTY, M | 1 |
| VIVONA, S | 1 |
| CONRAD, M | 1 |
| GETZ, ME | 1 |
| MILLER, MJ | 1 |
| MARCUS, DM | 1 |
| CAMERON, DG | 1 |
| de Figuereido Filho, AF | 1 |
| Calvosa, VS | 1 |
| Figueredo, MC | 1 |
| Nascimento, JM | 1 |
| Fryauff, DJ | 6 |
| Ponsa, N | 1 |
| Kittayapong, P | 1 |
| Eikarat, N | 1 |
| Coleman, RE | 1 |
| EDGCOMB, JH | 1 |
| YOUNT, EH | 1 |
| EICHELBERGER, L | 1 |
| EYLES, D | 1 |
| YOUNG, MD | 1 |
| JANNEY, HM | 1 |
| JASTREMSKI, B | 1 |
| Rab, MA | 1 |
| Ahmadzai, H | 1 |
| Durrani, N | 1 |
| Fayaz, M | 1 |
| Kim, YR | 1 |
| Kuh, HJ | 1 |
| Kim, MY | 1 |
| Kim, YS | 1 |
| Chung, WC | 1 |
| Kim, SI | 1 |
| Kang, MW | 1 |
| Walsh, DS | 3 |
| Tang, DB | 1 |
| Heppner, DG | 2 |
| Brewer, TG | 1 |
| Siriyanonda, D | 1 |
| Vijaykadga, S | 1 |
| Rojanawatsirivej, C | 1 |
| Congpoung, K | 1 |
| Uaekowitchai, C | 1 |
| Pumborplub, B | 1 |
| Sittimongkol, S | 1 |
| Pinyorattanachote, A | 1 |
| Prigchoo, P | 1 |
| Hamedi, Y | 1 |
| Safa, O | 1 |
| Zare, S | 1 |
| Tan-ariya, P | 1 |
| Kojima, S | 1 |
| Spudick, JM | 1 |
| Garcia, LS | 1 |
| Graham, DM | 1 |
| Haake, DA | 1 |
| Mishra, AK | 1 |
| Shukla, MM | 1 |
| Chand, SK | 1 |
| Bharti, PK | 1 |
| Berger, SA | 1 |
| David, L | 1 |
| Dierling, AM | 1 |
| Cui, Z | 1 |
| Choi, DH | 1 |
| Song, KJ | 1 |
| Oh, YH | 1 |
| Kim, YA | 1 |
| Ahn, SY | 1 |
| Yang, HY | 1 |
| Cha, JE | 1 |
| Dunne, MW | 1 |
| Shukla, M | 1 |
| Bhattacharyya, PC | 1 |
| Patel, K | 1 |
| Mohapatra, MK | 1 |
| Lakhani, J | 1 |
| Devi, CU | 1 |
| Adak, T | 2 |
| Dev, V | 1 |
| Lele, C | 1 |
| Patki, K | 1 |
| Muñoz, J | 1 |
| Velasco, M | 1 |
| Alonso, D | 1 |
| Valls, ME | 2 |
| Corachán, M | 2 |
| Gascón, J | 2 |
| Ozen, M | 1 |
| Gungor, S | 1 |
| Atambay, M | 1 |
| Daldal, N | 1 |
| Bennett, SM | 1 |
| Abdalla, H | 1 |
| Carthew, TL | 1 |
| Rebholz, CE | 1 |
| Michel, AJ | 1 |
| Maselli, DA | 1 |
| Saipphudin, K | 1 |
| Ajdukiewicz, KM | 1 |
| Ong, EL | 1 |
| Chalermrut, K | 4 |
| Srivilairit, S | 3 |
| Thanachartwet, V | 2 |
| Luplertlop, N | 2 |
| Piñeros, JG | 1 |
| Tobón, A | 1 |
| Ríos, A | 1 |
| Omari, AA | 1 |
| Reddy, P | 1 |
| Flaherty, JP | 1 |
| Goller, JL | 1 |
| Jolley, D | 1 |
| Biggs, BA | 1 |
| Guthmann, JP | 1 |
| Carlton, J | 1 |
| Nair, S | 1 |
| Sudimack, D | 1 |
| Anderson, TJ | 1 |
| Dao, NV | 1 |
| Cuong, BT | 1 |
| Ngoa, ND | 1 |
| Thuy, le TT | 1 |
| The, ND | 1 |
| Duy, DN | 1 |
| Dai, B | 1 |
| Thanh, NX | 1 |
| Chavchich, M | 1 |
| Kim, A | 1 |
| Park, YK | 1 |
| Lee, JS | 1 |
| Kim, ES | 1 |
| Bannister, BA | 1 |
| Illamperuma, C | 1 |
| Allen, BL | 1 |
| Lesko, CR | 1 |
| Newman, RD | 1 |
| de Santana Filho, FS | 1 |
| Chehuan, YM | 1 |
| Martinez-Espinosa, FE | 1 |
| Barbosa, Md | 1 |
| Alecrim, WD | 1 |
| Kim, JS | 1 |
| Oh, JS | 1 |
| Chang, EA | 1 |
| Bae, SY | 1 |
| Nam, DH | 1 |
| Lee, CH | 1 |
| Yang, JH | 1 |
| Lee, CK | 1 |
| Lim, CS | 1 |
| Dubberke, ER | 1 |
| Weil, GJ | 1 |
| Phophak, N | 2 |
| Sumawinata, I | 1 |
| Ohrt, CK | 1 |
| Mouzin, E | 1 |
| Church, CJ | 1 |
| Richards, AL | 1 |
| Bangs, MJ | 2 |
| Subianto, B | 4 |
| Wiady, I | 2 |
| Leksana, B | 2 |
| Masbar, S | 2 |
| Petralanda, I | 1 |
| Barnett, A | 1 |
| Jelinek, T | 1 |
| Nothdurft, HD | 2 |
| Von Sonnenburg, F | 1 |
| McElroy, PD | 1 |
| Wignall, FS | 2 |
| Van den Abbeele, K | 1 |
| Van den Enden, E | 1 |
| Van den Ende, J | 1 |
| Lazar, AI | 1 |
| Cabezos, J | 1 |
| Durán, E | 1 |
| Tomás, D | 1 |
| Bada, JL | 1 |
| Rønn, A | 1 |
| Bygbjerg, I | 1 |
| Vanijanonta, S | 1 |
| Chantra, A | 1 |
| Clemens, R | 2 |
| Gomez Arce, JE | 1 |
| Menendez, C | 1 |
| Viravan, C | 1 |
| Charoenlarp, P | 1 |
| Yeamput, C | 1 |
| Wilson, RJ | 1 |
| Rønn, AM | 1 |
| Bygbjerg, IC | 1 |
| Mathews, ST | 3 |
| Selvam, R | 4 |
| Obana, M | 1 |
| Ohta, S | 1 |
| Matsuoka, Y | 1 |
| Irimajiri, S | 1 |
| Suzuki, M | 1 |
| Weinke, T | 1 |
| Kretschmer, H | 1 |
| Fleischer, K | 1 |
| Braendli, B | 1 |
| Markwalder, K | 1 |
| Schlunk, T | 1 |
| Bock, HL | 1 |
| Yeo, AE | 1 |
| Davis, DR | 1 |
| Hutton, DC | 1 |
| Wheatley, PF | 1 |
| Simpson, R | 1 |
| Hanna, J | 1 |
| Dua, VK | 2 |
| Kar, PK | 1 |
| Sarin, R | 1 |
| Sharma, VP | 4 |
| Tilluckdharry, CC | 1 |
| Chadee, DD | 1 |
| Doon, R | 1 |
| Nehall, J | 1 |
| Phillips, EJ | 1 |
| Keystone, JS | 1 |
| Kain, KC | 3 |
| Kron, MA | 1 |
| Signorini, L | 1 |
| Matteelli, A | 1 |
| Castelnuovo, F | 1 |
| Castelli, F | 1 |
| Oladeji, O | 1 |
| Carosi, G | 1 |
| Kimura, M | 1 |
| Tomizawa, I | 1 |
| Takizawa, Y | 1 |
| Ohtomo, H | 1 |
| Patwari, AK | 1 |
| Awalludin, M | 1 |
| Jones, T | 1 |
| Smoak, BL | 1 |
| DeFraites, RF | 1 |
| Wellde, BT | 1 |
| Harjosuwarno, S | 1 |
| Srivastava, HC | 1 |
| Sharma, SK | 1 |
| Bhatt, RM | 1 |
| Nayar, JK | 1 |
| Baker, RH | 1 |
| Knight, JW | 1 |
| Sullivan, JS | 2 |
| Morris, CL | 3 |
| Richardson, BB | 3 |
| Galland, GG | 2 |
| van der Hoek, W | 1 |
| Premasiri, DA | 1 |
| Whitby, M | 1 |
| Zijlmans, CW | 1 |
| Boele van Hensbroek, M | 1 |
| Wetsteyn, JC | 1 |
| Telgt, DS | 1 |
| Mulder, L | 1 |
| Dolmans, WM | 1 |
| Rattanapong, Y | 2 |
| Amradee, S | 1 |
| Siripiphat, S | 1 |
| Chullawichit, S | 1 |
| Thimasan, K | 1 |
| Triampon, A | 1 |
| Sidi, Y | 1 |
| Yi, KJ | 1 |
| Kim, HS | 1 |
| Kim, CS | 1 |
| Pai, SH | 1 |
| Nguyen-Dinh, P | 1 |
| Nesby, S | 1 |
| Menéndez Capote, R | 1 |
| Díaz Pérez, L | 1 |
| Luzardo Suárez, C | 1 |
| Soto, J | 3 |
| Toledo, J | 3 |
| Rodriquez, M | 2 |
| Sanchez, J | 2 |
| Herrera, R | 2 |
| Padilla, J | 2 |
| Qingjun, L | 1 |
| Jihui, D | 1 |
| Laiyi, T | 1 |
| Xiangjun, Z | 1 |
| Jun, L | 1 |
| Hay, A | 1 |
| Shires, S | 1 |
| Navaratnam, V | 1 |
| Lobel, HO | 1 |
| Coyne, PE | 1 |
| Ocampo, A | 1 |
| García-Bujalance, S | 1 |
| Ladrón de Guevara, C | 1 |
| Gasser, RA | 1 |
| Kester, KE | 1 |
| Na, DJ | 1 |
| Han, JD | 1 |
| Cha, DY | 1 |
| Song, IK | 1 |
| Choi, HW | 1 |
| Chung, EA | 1 |
| Park, CW | 1 |
| Choi, JS | 1 |
| da Cunha, MG | 1 |
| Silva, MN | 1 |
| Souza, JM | 1 |
| Rodrigues, MM | 1 |
| Botella de Maglia, J | 1 |
| Espacio Casanovas, A | 1 |
| Bussaratid, V | 2 |
| Chokjindachai, W | 1 |
| Viriyavejakul, P | 1 |
| Walsh D, S | 1 |
| White, J | 1 |
| Kakar, A | 1 |
| Bhoi, S | 1 |
| Prakash, V | 1 |
| Kakar, S | 1 |
| Srivilirit, S | 1 |
| Gogtay, NJ | 3 |
| Desai, S | 1 |
| Kamtekar, KD | 1 |
| Kadam, VS | 1 |
| Dalvi, SS | 2 |
| Kshirsagar, NA | 2 |
| Hernandez, JE | 1 |
| Nettel, JA | 1 |
| Villarreal, C | 1 |
| Wirtz, RA | 1 |
| Rajgor, D | 1 |
| Wakde, M | 1 |
| Regev-Yochay, G | 1 |
| Kurnik, D | 1 |
| Villalobos-Salcedo, JM | 1 |
| Kimura, E | 1 |
| Pereira da Silva, LH | 1 |
| Vaidya, AD | 1 |
| Joshi, J | 1 |
| Vaidya, RA | 1 |
| Godse, C | 1 |
| Bhatt, R | 1 |
| Bhagwat, AN | 1 |
| Lee, HK | 1 |
| Lim, J | 1 |
| Lee, S | 1 |
| Oh, EJ | 1 |
| Oh, J | 1 |
| Kim, Y | 1 |
| Han, K | 1 |
| Lee, EJ | 1 |
| Kang, CS | 1 |
| Kim, BK | 1 |
| Kumar, A | 1 |
| Kshrisagar, NA | 1 |
| Kroeger, A | 1 |
| Nicolas, X | 1 |
| Granier, H | 1 |
| Martin, J | 1 |
| Klotz, F | 1 |
| Gutierrez, P | 1 |
| Luzz, M | 1 |
| Llinas, N | 1 |
| Cedeño, N | 1 |
| Dunne, M | 1 |
| Eamsila, C | 1 |
| Sasiprapha, T | 1 |
| Kitchener, S | 1 |
| Duarte, EC | 1 |
| Pang, LW | 1 |
| Ribeiro, LC | 1 |
| Khatri, TD | 1 |
| Supeeranuntha, L | 1 |
| Brittenham, G | 1 |
| Seidl, I | 1 |
| Congpuong, K | 1 |
| Tasanor, U | 1 |
| Wernsdorfer, WH | 1 |
| Luzzi, GA | 1 |
| Warrell, DA | 1 |
| Barnes, AJ | 1 |
| Dunbar, EM | 1 |
| Collignon, PJ | 1 |
| Skinner, JC | 1 |
| Millet, P | 1 |
| Broderson, JR | 1 |
| Filipski, VK | 1 |
| Wilkins, PP | 1 |
| Campbell, GH | 1 |
| Stanfill, PS | 1 |
| Kumaresan, PR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)[NCT02787070] | Phase 4 | 420 participants (Actual) | Interventional | 2016-09-14 | Completed | ||
| The Malaria Heart Disease Study: A Novel Pathway to Subclinical Heart Disease[NCT04445103] | 597 participants (Actual) | Observational | 2020-06-21 | Terminated (stopped due to Due to the COVID-19 pandemic it was not possible to complete the study inclusion as originally anticipated.) | |||
| Efficacy of Three Regimens of Chloroquine and Primaquine for the Treatment of Plasmodium Vivax Malaria in Cruzeiro do Sul, Acre, Brazil[NCT03610399] | 257 participants (Actual) | Interventional | 2018-04-09 | Completed | |||
| Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas - a Randomized Controlled Trial[NCT03916003] | Phase 4 | 500 participants (Actual) | Interventional | 2019-08-18 | Completed | ||
| Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria?[NCT05788094] | Phase 4 | 388 participants (Anticipated) | Interventional | 2023-06-26 | Recruiting | ||
| A Randomised, Single-blinded Controlled Treatment Trial of Subclinical Vivax Infections With Primaquine in Nong Province, Laos[NCT02802813] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2016-06-14 | Completed | ||
| Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax[NCT01640574] | Phase 3 | 680 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Ethiopia Antimalarial in Vivo Efficacy Study 2012: Evaluating the Efficacy of Artemether-lumefantrine Alone Compared to Artemether-lumefantrine Plus Primaquine and Chloroquine Alone Compared to Chloroquine Plus Primaquine for Plasmodium Vivax Infection[NCT01680406] | Phase 4 | 398 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Host and Parasites Factors Contributing to Risk of Plasmodium Re-infection and Morbidity in Elementary School Children in Maprik, East Sepik Province[NCT02143934] | Phase 4 | 524 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Health Care Provider Use of Plasmodium Vivax Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru[NCT05361486] | 40 participants (Anticipated) | Observational | 2023-08-28 | Recruiting | |||
| Targeting High-risk Populations With Enhanced Reactive Focal Mass Drug Administration: A Study to Assess the Effectiveness and Feasibility for Plasmodium Falciparum and Plasmodium Vivax Malaria in Thailand[NCT05052502] | 49,118 participants (Anticipated) | Interventional | 2020-11-01 | Recruiting | |||
| Targeting High-risk Populations With Enhanced Reactive Case Detection: a Study to Assess the Effectiveness and Feasibility for Reducing Plasmodium Falciparum and P. Vivax Malaria in Southern Lao Peoples Democratic Republic[NCT04416945] | 31,443 participants (Anticipated) | Interventional | 2020-09-20 | Recruiting | |||
| A Study to Assess Current Standard Malaria Treatment Guidelines and Evaluate Recently Developed G6PD Diagnostic Tools in the Republic of the Sudan[NCT02592408] | Phase 4 | 320 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| A Study of the Pharmacokinetics of Primaquine in Lactating Women and Breastfed Infants for the Radical Treatment of Uncomplicated Maternal P. Vivax[NCT01780753] | Phase 1 | 20 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Clinical Study to Assess the Safety and Feasibility of Controlled Blood-stage Plasmodium Vivax Human Malaria Infection Through Experimental Inoculation of Cryopreserved Infected Erythrocytes in Healthy Thai Adults[NCT05071079] | 16 participants (Anticipated) | Interventional | 2022-05-23 | Recruiting | |||
| A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border[NCT01074905] | Phase 3 | 655 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers[NCT05203744] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-05-10 | Not yet recruiting | ||
| A Randomized, Active-control, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults[NCT01290601] | Phase 2 | 70 participants (Actual) | Interventional | 2003-09-15 | Terminated (stopped due to Failure to meet pre-specified endpoint for the day 28 cure rate) | ||
| A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria.[NCT01376167] | Phase 2 | 851 participants (Actual) | Interventional | 2014-04-24 | Completed | ||
| FocaL Mass Drug Administration for Vivax Malaria Elimination (FLAME): a Pragmatic Cluster Randomized Controlled Trial in Peru[NCT05690841] | Phase 3 | 7,700 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | ||
| A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria[NCT02216123] | Phase 3 | 251 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection[NCT02691910] | Phase 2/Phase 3 | 204 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Improving the Radical Cure of Vivax Malaria: A Multicentre Randomised Comparison of Short and Long Course Primaquine Regimens[NCT01814683] | 2,388 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| Ethiopia In-vivo Efficacy Study 2009: Evaluating the Efficacy of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Infection and Either Artemether-lumefantrine or Chloroquine for P. Vivax Infection[NCT01052584] | 354 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup[NCT01288820] | Phase 3 | 331 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Phase 1/2a Open-label Dose Safety, Reactogenicity, Immunogenicity and Efficacy of the Candidate Plasmodium Vivax Malaria Protein 001 (VMP001) Administered Intramuscularly With GlaxoSmithKline (GSK) Biologicals' Adjuvant System AS01B in Healthy Malaria-Naï[NCT01157897] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Chloroquine in Healthy Thai Adult Subjects[NCT01218932] | Phase 1 | 16 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers: Clinical Evaluation of Primaquine Enantiomer[NCT02898779] | Phase 1 | 36 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Pyronaridine-Artesunate in Healthy Adult Subjects[NCT01552330] | Phase 1 | 17 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Comparison of the Effectiveness of Two Scheme Treatments to Treat Plasmodium Vivax Cases in Patients Living in Communities With Persistence of Transmission in Oaxaca and Chiapas, Mexico[NCT02394197] | Phase 4 | 153 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Effectiveness of Momordica Charantia Extract Compared to the Standard Antimalarial Drug Combination Dihydroartemisinin Piperaquine-primaquine in Patients With Uncomplicated Falciparum Malaria, in Sumba Barat Daya District of Indonesia[NCT05829187] | Phase 2 | 36 participants (Actual) | Interventional | 2022-11-01 | Completed | ||
| Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua[NCT06036030] | Phase 2 | 50 participants (Actual) | Interventional | 2019-01-11 | Completed | ||
| A Placebo Controlled, Randomised Evaluation of an Eight Week Primaquine Regimen for the Treatment of Vivax Malaria.[NCT00158587] | Phase 3 | 150 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria[NCT00902811] | Phase 4 | 600 participants (Anticipated) | Interventional | 2008-12-31 | Recruiting | ||
| Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda[NCT01365598] | Phase 3 | 468 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Comparison of the Susceptibility of Naive and Pre-immune Volunteers to Infectious Challenge With Viable Plasmodium Vivax Sporozoites.[NCT01585077] | Phase 1/Phase 2 | 16 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax[NCT02083068] | Phase 2 | 32 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers[NCT01083095] | Early Phase 1 | 18 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers[NCT00367380] | Phase 2 | 18 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia. (NCT03610399)
Timeframe: 168 days
| Intervention | participants (Number) |
|---|---|
| Primaquine Regular Dose Unsupervised | 29 |
| Primaquine Regular Dose Supervised | 44 |
| Primaquine Double Dose Unsupervised | 67 |
Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 28. Those are participants who at day 28 did not present clinical deterioration or presence of parasitemia. (NCT03610399)
Timeframe: 28 days
| Intervention | participants (Number) |
|---|---|
| Primaquine Regular Dose Unsupervised | 61 |
| Primaquine Regular Dose Supervised | 88 |
| Primaquine Double Dose Unsupervised | 90 |
Participants with microsatellite-corrected adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia with homologous (same genotype) parasites. (NCT03610399)
Timeframe: 168 days
| Intervention | Participants (Number) |
|---|---|
| Primaquine Regular Dose Unsupervised | 29 |
| Primaquine Regular Dose Supervised | 44 |
| Primaquine Double Dose Unsupervised | 67 |
Measure of body temperature every 12 hours through day 7 was used to determine the time (to nearest 12 hours) from initiation of treatment until subjects temperature decreased to 37.2C and remained at or below that level for a minimum of 24 hours. (NCT01290601)
Timeframe: through day 7
| Intervention | Hours (Mean) |
|---|---|
| Cohort 1 Tafenoquine | 41.5 |
| Cohort 1-Chloroquine | 24.7 |
A subject will be considered a success (cure) if they have an Adequate Clinical Response (ACR). Tafenoquine was efficacious if the lower bound of the two-sided 90% confidence interval for the day 28 cure rate was not less than 85% (NCT01290601)
Timeframe: 28 Days
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Adequate Clinical Response (ACR) | Early Treatment Failure | Late Treatment Failure | |
| Cohort 1 Tafenoquine | 40 | 5 | 1 |
| Cohort 1-Chloroquine | 22 | 0 | 2 |
"Number of subjects without relapse of P. vivax at 2, 3 and 4 months~- Blood smears were obtained at Days 28, 60, 90 and 120 to confirm the continued absence of P. vivax parasitemia" (NCT01290601)
Timeframe: Day 28, Months 2, 3 and 4
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cleared at Day 28 | Relapsed by Day 60 | Relapsed by Day 90 | Relapsed by Day 120 | Without Relapse by Day 120 | Unevaluable by Day 120 | |
| Cohort 1 Tafenoquine | 40 | 0 | 0 | 0 | 35 | 5 |
| Cohort 1-Chloroquine | 22 | 0 | 1 | 1 | 19 | 2 |
Serial blood smears to detect the presence of P. vivax parasites and gametocytes, conducted every 12 hours up to and including day 7, until blood smear became negative were utilized to determine the time to clearance. PCT and GCT were considered cleared if 2 consecutive blood smears were negative. (NCT01290601)
Timeframe: up to day 7 after baseline smear
| Intervention | Hours (Mean) | |
|---|---|---|
| Parasite Clearance Time | Gametocyte Clearance Time | |
| Cohort 1 Tafenoquine | 83.4 | 48.3 |
| Cohort 1-Chloroquine | 40.0 | 22.7 |
To evaluate the safety and tolerability of the tafenoquine dosing regimens as defined by the most common AE's overall, occurring in >10% of subjects in either treatment group (NCT01290601)
Timeframe: 90 Days
| Intervention | AEs (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood methemoglobin present | Headache | Keratopathy | Upper respiratory tract infection | Dizziness | Retinopathy | Eosinophilia | Abdominal pain | Nausea | Thrombocytopenia | Eosinophil count increased | Pyrexia | |
| Cohort 1 Tafenoquine | 46 | 14 | 14 | 13 | 12 | 9 | 8 | 6 | 6 | 6 | 5 | 5 |
| Cohort 1-Chloroquine | 22 | 4 | 0 | 5 | 3 | 1 | 7 | 5 | 3 | 0 | 3 | 3 |
The number of participants who received blood transfusion as a result of hemoglobin decline has been summarized. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) |
|---|---|
| CQ Only | 0 |
| TQ + CQ | 0 |
| PQ + CQ | 0 |
There were no participants with acute renal failure in the study. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) |
|---|---|
| CQ Only | 0 |
| TQ + CQ | 0 |
| PQ + CQ | 0 |
A participant (par) was considered to have demonstrated recurrence-free efficacy at 4 months if: a) Par had non-zero P vivax asexual parasite count at Baseline. b) Par showed initial clearance of P vivax parasitemia. c) Par had no positive asexual P vivax parasite count at any assessment prior to or on Study Day 130 following initial parasite clearance. d) Par did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment after Study Day 109 (up to and including Study Day 130). e) Par is parasite-free at 4 months defined as a negative asexual P vivax parasite count at the first parasite assessment performed after Study Day 109 (up to and including Study Day 130). Par were censored if they did not have P.vivax at Baseline, or took a drug with anti-malarial action despite not having malaria parasites or did not have a 4 month assessment. The number of par with recurrence-free efficacy at 4 months has been summarized. (NCT01376167)
Timeframe: 4 months post dose
| Intervention | Participants (Number) |
|---|---|
| CQ Only | 47 |
| TQ + CQ | 177 |
| PQ + CQ | 90 |
A participant was considered to have demonstrated recurrence-free efficacy at 6 months if: a) Participant had non-zero P vivax asexual parasite count at Baseline. b) Participant showed initial clearance of P vivax parasitemia defined as two negative asexual P vivax parasite counts, with at least 6 hours between the counts, and no positive counts in the interval. c) Participant had no positive asexual P vivax parasite count at any assessment prior to or on Study Day 201 following initial parasite clearance. d) Participant did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment. e) Participant is parasite-free at 6 months. Participants were censored if they did not have P.vivax at Baseline, or took a drug with anti-malarial action despite not having malaria parasites, or did not have a 6 month assessment. The number of participants with recurrence-free efficacy at 6 months has been summarized. (NCT01376167)
Timeframe: 6 months post dose
| Intervention | Participants (Number) |
|---|---|
| CQ Only | 35 |
| TQ + CQ | 155 |
| PQ + CQ | 83 |
Apparent population oral clearance of TQ (NCT01376167)
Timeframe: Day 2, Day 8, Day 15, Day 29 and Day 60
| Intervention | Liters per hour (Median) |
|---|---|
| Participants in TQ Only Arms | 2.96 |
Fever clearance time was defined as time from first dose of treatment to the time when body temperature falls to normal within Study Days 1-4 and remains normal for at least 48 hours up to the Day 8 visit. Fever clearance was considered to have been achieved once an initial temperature of more than 37.40 degree Celsius is reduced to a value less than or equal to 37.40 degree Celsius and in the absence of value more than 37.40 degree Celsius in the following 48 hours up to the Day 8 visit. The time taken to achieve fever clearance was analyzed using Kaplan Meier Methodology. The median fever clearance time along with 95% confidence interval has been presented for each treatment group. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Hours (Median) |
|---|---|
| CQ Only | 7 |
| TQ + CQ | 7 |
| PQ + CQ | 8 |
Parasite clearance time was defined as time needed to clear asexual parasite from the blood that is, parasite numbers falling below the limit of detection in the thick blood smear and remaining undetectable after 6 to 12 hours. The time taken to achieve parasite clearance was analyzed using Kaplan Meier Methodology. The median parasite clearance time along with 95% confidence interval has been presented for each treatment group. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Hours (Median) |
|---|---|
| CQ Only | 43 |
| TQ + CQ | 45 |
| PQ + CQ | 42 |
Recurrence was defined as the first confirmed presence of P vivax asexual stage parasites after clearance of initial parasitemia following CQ treatment. Time to recurrence was defined as the time (in days) from initial parasite clearance to recurrence. The time to recurrence was analyzed by the Kaplan-Meier method. NA indicates data was not available due to insufficient number of participants with events during the follow up period in the study. The median number of days to recurrence along with 95% confidence interval has been presented for each treatment group. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Days (Median) |
|---|---|
| CQ Only | 86 |
| TQ + CQ | NA |
| PQ + CQ | NA |
Apparent population central volume of distribution of TQ (NCT01376167)
Timeframe: Day 2, Day 8, Day 15, Day 29 and Day 60
| Intervention | Liters (Median) |
|---|---|
| Participants in TQ Only Arms | 915 |
Methemoglobin assessment was made with the aid of a non-invasive signal extraction pulse CO-Oximeter handheld machine (Masimo). The change from Baseline in percent methemoglobin by treatment, time and sex has been summarized. The last assessment performed prior to the first dose of study medication (CQ or randomized treatment) was considered as Baseline. Change from Baseline was calculated as the post baseline assessment minus the Baseline assessment for percent methemoglobin. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Baseline and up to Day 120
| Intervention | Percent Methemoglobin (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 2, Male | Day 2, Female | Day 3, Male | Day 3, Female | Day 5, Male | Day 5, Female | Day 8, Male | Day 8, Female | Day 11, Male | Day 11, Female | Day 15, Male | Day 15, Female | Day 22, Male | Day 22, Female | Day 29, Male | Day 29, Female | Day 60, Male | Day 60, Female | Day 120, Male | Day 120, Female | |
| CQ Only | -0.18 | -0.22 | -0.15 | -0.20 | -0.28 | -0.20 | -0.12 | -0.16 | -0.07 | -0.13 | 0.12 | -0.08 | 0.07 | -0.05 | -0.10 | -0.18 | 0.44 | 0.19 | 0.20 | 0.10 |
| PQ + CQ | -0.10 | -0.01 | -0.02 | 0.11 | 1.28 | 0.90 | 3.01 | 2.58 | 3.61 | 3.41 | 3.51 | 3.63 | 1.96 | 1.86 | 0.58 | 0.49 | 0.20 | 0.16 | 0.37 | 0.37 |
| TQ + CQ | -0.03 | 0.10 | -0.01 | 0.26 | 0.42 | 1.37 | 0.98 | 2.04 | 1.17 | 2.13 | 0.94 | 1.67 | 0.54 | 0.93 | 0.23 | 0.24 | -0.10 | 0.03 | 0.07 | -0.03 |
Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests. The cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital (inpatient/outpatient), traditional healer, other). The reported costs by type and by site has been summarized. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | US Dollars (USD) (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Brazil (Drug shop for care) | Brazil (Enrollment clinic for care) | Brazil (other location for care) | Peru (Drug shop for care) | Peru (Enrollment clinic for care) | Peru (Attended another clinic) | Peru (Other location for care) | Thailand (Drug shop for care) | Thailand (Enrollment clinic for care) | Thailand (In-hospital care) | |
| First Malaria Recurrence | 4.76 | 6.17 | 4.23 | 1.47 | 8.78 | 2.71 | 0.72 | 4.60 | 19.15 | 6.13 |
Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests. The cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital (inpatient/outpatient), traditional healer, other). The reported costs by type and by site has been summarized. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | US Dollars (USD) (Mean) | |||
|---|---|---|---|---|
| Brazil (Enrollment clinic for care) | Peru (Enrollment clinic for care) | Peru (Attended another clinic) | Peru (Other location for care) | |
| First Malaria Recurrence Follow-up | 6.15 | 8.54 | 3.94 | 1.30 |
"Health outcomes were evaluated based on the cost of medications purchased. The reported total medication cost for paracetamol associated with recurrence episode of P vivax malaria has been reported by site. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Medications recorded as Other and medications without costs are excluded from the analysis. Only those participants with data available at the specified data points were analyzed." (NCT01376167)
Timeframe: Up to Day 180
| Intervention | USD (Mean) |
|---|---|
| Peru, n=23, 3 | |
| First Malaria Recurrence Follow-up | 0.32 |
"Health outcomes were evaluated based on the cost of medications purchased. The reported total medication cost for paracetamol associated with recurrence episode of P vivax malaria has been reported by site. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Medications recorded as Other and medications without costs are excluded from the analysis. Only those participants with data available at the specified data points were analyzed." (NCT01376167)
Timeframe: Up to Day 180
| Intervention | USD (Mean) | |
|---|---|---|
| Peru, n=23, 3 | Brazil, n=6, 0 | |
| First Malaria Recurrence | 0.49 | 1.70 |
Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Best corrected visual acuity was assessed individually for each eye. Scores were recorded as a ratio. The values were used to derive a logMAR score for statistical analysis where logMAR=-1x log10 (ratio score). The mean and standard deviation of logMAR score for each treatment group has been summarized. High scores were associated with worse vision, and low scores with better vision. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | logMAR scores (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline; right eye | Baseline; left eye | Day 29; right eye | Day 29; left eye | Day 90; right eye | Day 90; left eye | |
| CQ Only | 0.041 | 0.048 | 0.039 | 0.032 | 0.044 | 0.041 |
Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Best corrected visual acuity was assessed individually for each eye. Scores were recorded as a ratio. The values were used to derive a logMAR score for statistical analysis where logMAR=-1x log10 (ratio score). The mean and standard deviation of logMAR score for each treatment group has been summarized. High scores were associated with worse vision, and low scores with better vision. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | logMAR scores (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline; right eye | Baseline; left eye | Day 29; right eye | Day 29; left eye | Day 90; right eye | Day 90; left eye | Day 180; right eye | Day 180; left eye | |
| PQ + CQ | 0.029 | 0.048 | 0.021 | 0.045 | 0.016 | 0.041 | 0.000 | 0.000 |
| TQ + CQ | 0.046 | 0.039 | 0.049 | 0.032 | 0.038 | 0.028 | 0.033 | 0.033 |
Health outcomes were evaluated based on the actions taken by the participants to treat recurrence episode of P vivax malaria. The reported action taken by site is summarized. Where no action by site have been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil, Nothing | Brazil, Drug shop | Brazil, Trial clinic | Brazil, Other | Cambodia, Nothing | Ethiopia, Nothing | Ethiopia, Another clinic | Ethiopia, Other | Ethiopia, Trial clinic | Peru, Nothing | Peru, Drug shop | Peru, Trial clinic | Peru, Another clinic | Peru, Other | Thailand, Nothing | Thailand, Drug shop | Thailand, Trial clinic | Thailand, In hospital | |
| First Malaria Recurrence Follow-up | 5 | 0 | 76 | 0 | 14 | 13 | 0 | 0 | 1 | 0 | 0 | 63 | 54 | 1 | 16 | 0 | 0 | 0 |
Health outcomes were evaluated based on the actions taken by the participants to treat recurrence episode of P vivax malaria. The reported action taken by site is summarized. Where no action by site have been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil, Nothing | Brazil, Drug shop | Brazil, Trial clinic | Brazil, Other | Cambodia, Nothing | Ethiopia, Nothing | Ethiopia, Another clinic | Ethiopia, Other | Ethiopia, Trial clinic | Peru, Nothing | Peru, Drug shop | Peru, Trial clinic | Peru, Another clinic | Peru, Other | Philippines, Nothing | Thailand, Nothing | Thailand, Drug shop | Thailand, Trial clinic | Thailand, In hospital | |
| First Malaria Recurrence | 21 | 2 | 62 | 2 | 13 | 12 | 1 | 1 | 0 | 1 | 8 | 61 | 10 | 15 | 1 | 1 | 1 | 13 | 1 |
Blood samples were collected for the evaluation of clinical chemistry parameters including Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk. Phos), Aspartate Aminotransferase (AST), bilirubin, creatine kinase, creatinine, glomerular filtration rate (GFR), indirect bilirubin and urea. The number of participants with clinical chemistry laboratory data outside the extended normal range (F3) was presented. The upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 120
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ALT, High | Alk Phos, High | AST, High | Bilirubin, High | Creatine kinase, High | Creatinine, High | GFR, Low | Indirect bilirubin | Urea, High | |
| CQ Only | 11 | 3 | 5 | 18 | 8 | 0 | 0 | 11 | 42 |
| PQ + CQ | 5 | 1 | 2 | 12 | 8 | 0 | 0 | 8 | 46 |
| TQ + CQ | 10 | 1 | 7 | 23 | 5 | 1 | 1 | 22 | 85 |
Gastrointestinal tolerability was analyzed by the number of par experiencing gastrointestinal disorders such as abdominal pain, heartburn, diarrhea, constipation, nausea, and vomiting. The number of participants with gastrointestinal disorders for each treatment group has been summarized. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Nausea | Vomiting | Abdominal pain upper | Diarrhoea | Abdominal pain | Dyspepsia | |
| CQ Only | 12 | 9 | 13 | 6 | 5 | 5 |
| PQ + CQ | 9 | 11 | 7 | 5 | 6 | 2 |
| TQ + CQ | 21 | 22 | 11 | 15 | 8 | 6 |
Blood samples were collected for the evaluation of hematology parameters including eosinophils, leukocytes, lymphocytes, neutrophils, platelets, reticulocytes and methemoglobin. The number of participants with hematology laboratory data outside the extended normal range (F3) was presented. The upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 120
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Blood eosinophils, High | Blood leukocytes, Low | Blood lymphocytes, Low | Blood lymphocytes, High | Blood neutrophils, Low | Blood platelets, Low | Blood reticulocytes, High | Methemoglobin, High | |
| CQ Only | 18 | 0 | 7 | 23 | 2 | 14 | 72 | 4 |
| PQ + CQ | 28 | 2 | 0 | 13 | 7 | 15 | 85 | 11 |
| TQ + CQ | 38 | 3 | 4 | 32 | 5 | 35 | 141 | 5 |
Glucose-6-phosphate dehydrogenase deficiency (G6PD) deficiency is known to be a risk factor for hemolysis in participants treated with 8-aminoquinolines. Blood samples were collected for the evaluation of hemoglobin levels. Hemoglobin decreases of >=30% or >3 grams/deciliter (g/dL) from Baseline; or, an overall drop in hemoglobin below 6.0 g/dL in the first 15 days of the study were considered as protocol defined serious adverse events (SAEs). Number of participants with maximum hemoglobin decline from Baseline over first 29 days of study has been summarized. Safety Population consisted of all randomized participants who received at least one dose of study medication. (NCT01376167)
Timeframe: Baseline and up to Day 29
| Intervention | Participants (Number) | ||
|---|---|---|---|
| <=20 grams/liter (g/L) | >20g/L to <=30 g/L | >30 g/L or >=30% | |
| CQ Only | 120 | 11 | 2 |
| PQ + CQ | 114 | 12 | 3 |
| TQ + CQ | 214 | 31 | 14 |
Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. The number of participants displaying keratopathy in each eye was summarized for each visit. The number of participants with new keratopathy at any time post Baseline was also reported. Ophthalmic Safety Population comprised of all participants in the Safety Population who have results from any eye assessments. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline; right eye | Baseline; left eye | Day 1; right eye | Day 1; left eye | Day 29; right eye | Day 29; left eye | Day 90; right eye | Day 90; left eye | Any time post Baseline; right eye | Any time post Baseline; left eye | |
| CQ Only | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. The number of participants displaying keratopathy in each eye was summarized for each visit. The number of participants with new keratopathy at any time post Baseline was also reported. Ophthalmic Safety Population comprised of all participants in the Safety Population who have results from any eye assessments. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline; right eye | Baseline; left eye | Day 1; right eye | Day 1; left eye | Day 29; right eye | Day 29; left eye | Day 90; right eye | Day 90; left eye | Day 180; right eye | Day 180; left eye | Any time post Baseline; right eye | Any time post Baseline; left eye | |
| PQ + CQ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TQ + CQ | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Change from Baseline was calculated as the post Baseline assessment minus the Baseline assessment. The number of participants with definite retinal change and questionable (ques) retinal change from Baseline was presented. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Baseline and up to Day 180
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 29, Definite change, right eye | Day 29, Ques change, right eye | Day 29, Definite change, left eye | Day 29, Ques change, left eye | Day 90, Definite change, right eye | Day 90, Ques change, right eye | Day 90, Definite change, left eye | Day 90, Ques change, left eye | Day 180, Definite change, right eye | Day 180, Ques change, right eye | Day 180, Definite change, left eye | Day 180, Ques change, left eye | |
| CQ Only | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| TQ + CQ | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Change from Baseline was calculated as the post Baseline assessment minus the Baseline assessment. The number of participants with definite retinal change and questionable (ques) retinal change from Baseline was presented. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Baseline and up to Day 180
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 29, Definite change, right eye | Day 29, Ques change, right eye | Day 29, Definite change, left eye | Day 29, Ques change, left eye | Day 90, Definite change, right eye | Day 90, Ques change, right eye | Day 90, Definite change, left eye | Day 90, Ques change, left eye | |
| PQ + CQ | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 |
An AE is defined as any untoward medical occurrence in a participant under clinical investigation, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/ birth defect, other situations and is associated with possible drug induced liver injury with hyperbilirubinemia. TEAEs is defined as AEs with an onset date and time on or after that of the start of first dose of study medication (including CQ). Number of participants with TEAEs and serious TEAEs have been presented. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |
|---|---|---|
| TEAEs | Serious TEAEs | |
| CQ Only | 86 | 6 |
| PQ + CQ | 76 | 4 |
| TQ + CQ | 164 | 21 |
An AE is defined as any untoward medical occurrence in a participant under clinical investigation, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is defined as AEs with an onset date and time on or after that of the start of first dose of study medication (including CQ). Number of participants with AEs based on severity has been presented. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Mild or Grade 1 | Moderate or Grade 2 | Severe or Grade 3 | Grade 4 | Grade 5 | |
| CQ Only | 30 | 52 | 3 | 1 | 0 |
| PQ + CQ | 38 | 37 | 1 | 0 | 0 |
| TQ + CQ | 70 | 89 | 2 | 0 | 1 |
TEAEs are defined as adverse events (AEs) with an onset date and time on or after that of the start of first dose of study medication (including CQ). The number of participants with TEAEs potentially related to hemoglobin decrease has been presented. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Haemoglobin decreased | Fatigue | Hyperbilirubinaemia | Pallor | |
| CQ Only | 2 | 2 | 1 | 0 |
| PQ + CQ | 2 | 0 | 0 | 0 |
| TQ + CQ | 14 | 1 | 0 | 1 |
Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria. The reported time lost due to recurrence episode of P vivax malaria has been summarized by category and by site. Where categories by site have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Days (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil, Housework | Brazil, Farming | Brazil, paid employment | Brazil, Other | Cambodia, Farming | Ethiopia, Housework | Ethiopia, Farming | Ethiopia, Student | Ethiopia, Paid employment | Ethiopia, Other | Peru, Housework | Peru, Farming | Peru, Student | Peru, Paid employment | Peru, Other | Thailand, paid employment | Thailand, Other | |
| First Malaria Recurrence Follow-up | 0 | 0 | 0 | 5 | 24 | 3 | 3 | 0 | 4 | 7 | 29 | 28 | 6 | 8.5 | 32 | 0 | 0 |
Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria. The reported time lost due to recurrence episode of P vivax malaria has been summarized by category and by site. Where categories by site have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Days (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil, Housework | Brazil, Farming | Brazil, paid employment | Brazil, Other | Cambodia, Farming | Ethiopia, Housework | Ethiopia, Farming | Ethiopia, Student | Ethiopia, Paid employment | Ethiopia, Other | Peru, Housework | Peru, Farming | Peru, Student | Peru, Paid employment | Peru, Other | Philippines, Farming | Thailand, paid employment | Thailand, Other | |
| First Malaria Recurrence | 1 | 8 | 8 | 3 | 17 | 4 | 2.5 | 3 | 2 | 1 | 24 | 19 | 1 | 6 | 26 | 0 | 20 | 1 |
Health outcomes were evaluated based on cost incurred due to clinically relevant hemolysis. The total cost was evaluated based on the amount spent on treatment, transport, medication and test. The costs associated with hemolysis event has been presented. The aim of this outcome measure was to determine the cost to a participant due to an event of hemolysis, regardless of treatment received in the study. It was not expected there would be major cost differences with hemoglobin decrease between the treatment arms. This was pre-specified in the statistical analysis plan. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | USD (Mean) |
|---|---|
| Participants With Clinically Relevant Hemolysis | 9.174 |
"Health outcomes were evaluated based on the cost of medications purchased. The total medication cost associated with hemolysis event has been presented. Medications recorded as Other and medications without costs are excluded from the analysis. The aim of this outcome measure was to determine the cost to a participant due to an event of hemolysis, regardless of treatment received in the study. It was not expected there would be major cost differences with hemoglobin decrease between the treatment arms. This was pre-specified in the statistical analysis plan." (NCT02216123)
Timeframe: Up to Day 180
| Intervention | USD (Mean) |
|---|---|
| Participants With Clinically Relevant Hemolysis | 0 |
Health outcomes were evaluated based on total time lost by participants or care givers due to a hemolysis event. The number of participants or care givers who took days off from work due to a hemolysis event has been presented based on the normal occupation. The aim of this outcome measure was to determine the time taken off by participants due to an event of hemolysis, regardless of treatment received in the study. It was not expected there would be major differences in time taken off by participants with hemoglobin decrease between the treatment arms. This was pre-specified in the statistical analysis plan. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) |
|---|---|
| Participants With Clinically Relevant Hemolysis | 0 |
Health outcomes were evaluated based on the actions taken by the participants to treat hemolysis events. The number of participants in Brazil who attended the trial clinic to treat a hemolysis event has been presented. The aim of this outcome measure was to determine the action taken by a participant due to an event of hemolysis, regardless of treatment received in the study. It was not expected there would be major differences in action taken by the participants with hemoglobin decrease between the treatment arms. This was pre-specified in the statistical analysis plan. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) |
|---|---|
| Participants With Clinically Relevant Hemolysis | 1 |
Microscopic blood slides (two thick film and one thin film slide) were prepared and examined for asexual parasite count. The number of participants with positive P. falciparum asexual parasite count post Baseline has been summarized for each treatment arm. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) |
|---|---|
| TQ+CQ | 4 |
| PQ+CQ | 3 |
Recrudescence is defined as any P. vivax parasitemia occurring on or before Day 32 (that is, blood stage treatment failure). A participant was considered to have had a recrudescence if both of the following were true: a) Participant had a positive P. vivax asexual parasite count at Baseline and demonstrated clearance (that is, did not have two negative asexual P. vivax parasite counts, with at least 6 hours between the counts, and no positive counts in the interval). b) Participant had a positive genetically homologous asexual P. vivax parasite count, after their zero count in Days 1 to 5, but on or before Study Day 32. The number of participants with recrudescence before Study Day 33 has been presented. (NCT02216123)
Timeframe: Up to Day 32
| Intervention | Participants (Number) |
|---|---|
| TQ+CQ | 0 |
| PQ+CQ | 0 |
Apparent population oral clearance of TQ (NCT02216123)
Timeframe: Day 2, Day 3, Day 8, Day 15, Day 29, Day 60 and Day 180
| Intervention | Liters per hour (Median) |
|---|---|
| Participants in TQ Only Arms | 2.96 |
Clinically relevant hemolysis is defined as a decrease in hemoglobin of >=30% or >3 grams per deciliter (g/dL) from Baseline; or, an overall drop in hemoglobin below 6.0 g/dL at any visit after the first dose of study medication. The percentage of participants with clinically relevant hemolysis has been summarized. Safety Population comprised of all randomized participants who received at least one dose of blinded study medication. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Percentage of participants (Number) |
|---|---|
| TQ+CQ | 2.41 |
| PQ+CQ | 1.18 |
A participant was considered to have demonstrated recurrence-free efficacy at 4 months if: a) Participant had non-zero P. vivax asexual parasite count at Baseline. b) Participant showed initial clearance of P. vivax parasitemia. c) Participant had no positive asexual P. vivax parasite count at any assessment prior to or on Study Day 130 following initial parasite clearance. d) Participant did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment after Study Day 109 (up to and including Study Day 130). e) Participant is parasite-free at 4 months. The rate of relapse-free efficacy was estimated by Kaplan-Meier methodology. The percentage of participants who were relapse-free at 4 months post dose has been presented along with 95% confidence interval. (NCT02216123)
Timeframe: 4 months post dose
| Intervention | Percentage of participants (Number) |
|---|---|
| TQ+CQ | 82.3 |
| PQ+CQ | 79.7 |
A participant was considered to have demonstrated relapse-free efficacy at 6 months if: a) Participant had non-zero P. vivax asexual parasite count at Baseline. b) Participant showed initial clearance of P. vivax parasitemia defined as two negative asexual P. vivax parasite counts, with at least 6 hours between the counts, and no positive counts in the interval. c) Participant had no positive asexual P. vivax parasite count at any assessment prior to or on Study Day 201 following initial parasite clearance. d) Participant did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment. e) Participant is parasite-free at 6 months. The rate of relapse-free efficacy was estimated by Kaplan-Meier methodology. The percentage of participants who were relapse-free at 6 months post dose has been presented along with 95% confidence interval. (NCT02216123)
Timeframe: 6 months post dose
| Intervention | Percentage of participants (Number) |
|---|---|
| TQ+CQ | 72.7 |
| PQ+CQ | 75.1 |
Fever clearance time is defined as the time from first dose of treatment to the time when body temperature falls to normal within Study Days 1-4 and remains normal for at least 48 hours up to the Day 8 visit. Fever clearance was considered to have been achieved once an initial temperature of more than 37.4 degree Celsius is reduced to a value less than or equal to 37.4 degree Celsius, in the absence of value more than 37.4 degree Celsius in the following 48 hours up to the Day 8 visit. The time taken to achieve fever clearance was analyzed by Kaplan-Meier method. (NCT02216123)
Timeframe: Up to Day 9
| Intervention | Hours (Median) |
|---|---|
| TQ+CQ | 10 |
| PQ+CQ | 13 |
Gametocyte clearance time is defined as time from first dose until the first slide that was gametocyte negative and remained so at the next slide reading. The time taken to achieve gametocyte clearance was analyzed by Kaplan-Meier method. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Hours (Median) |
|---|---|
| TQ+CQ | 38 |
| PQ+CQ | 41 |
Parasite clearance time is defined as time needed to clear asexual parasite from the blood that is, parasite numbers falling below the limit of detection in the thick blood smear and remaining undetectable after 6 to 12 hours later. The time to achieve parasite clearance was analyzed by Kaplan-Meier methodology. The median parasite clearance time along with 95% confidence interval has been presented for each treatment group. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Hours (Median) |
|---|---|
| TQ+CQ | 41 |
| PQ+CQ | 44 |
Relapse is defined by a positive blood smear with or without vivax symptoms. Relapse is described as any recurrence of malaria that occurred after Day 32 of the study. The time to relapse was analyzed by the Kaplan-Meier method. The median number of days to relapse along with 95% confidence interval has been presented for each treatment group. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Days (Median) |
|---|---|
| TQ+CQ | NA |
| PQ+CQ | NA |
Apparent population central volume of distribution of TQ (NCT02216123)
Timeframe: Day 2, Day 3, Day 8, Day 15, Day 29, Day 60 and Day 180
| Intervention | Liters (Median) |
|---|---|
| Participants in TQ Only Arms | 915 |
Methemoglbin is an oxidized and inactive form of hemoglobin. Methemoglobin assessment was made with the aid of a non-invasive signal extraction pulse CO-Oximeter handheld machine. The change from Baseline in percent methemoglobin by treatment, time and sex has been summarized. The latest pre-treatment assessment where treatment is their first dose of study medication (CQ/PQ/TQ/Placebo) was considered as Baseline value. Change from Baseline is the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 120
| Intervention | Percent change (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 2, Male, n=114, 53 | Day 2, Female, n=52, 32 | Day 3, Male, n=114, 53 | Day 3, Female, n=52, 32 | Day 5, Male, n=113, 53 | Day 5, Female, n=52, 32 | Day 8, Male, n=112, 52 | Day 8, Female, n=52, 32 | Day 11, Male, n=112, 52 | Day 11, Female, n=51, 32 | Day 15, Male, n=113, 52 | Day 15, Female, n=52, 32 | Day 22, Male, n=112, 52 | Day 22, Female, n=52, 32 | Day 29, Male, n=111, 52 | Day 29, Female, n=52, 32 | Day 60, Male, n=107, 51 | Day 60, Female, n=52, 32 | Day 120, Male, n=109, 50 | Day 120, Female, n=50, 31 | |
| PQ+CQ | 0.02 | -0.06 | 0.03 | 0.17 | 0.89 | 1.32 | 2.63 | 2.81 | 3.30 | 3.44 | 3.26 | 3.61 | 1.58 | 2.30 | 0.46 | 0.84 | 0.20 | 0.14 | -0.01 | 0.04 |
| TQ+CQ | 0.02 | -0.16 | 0.18 | 0.08 | 0.77 | 0.63 | 1.22 | 1.00 | 1.16 | 1.04 | 1.01 | 0.81 | 0.61 | 0.32 | 0.24 | -0.02 | 0.05 | -0.09 | 0.06 | 0.14 |
Vital signs were measured twice a day on Days 1 through 3, at least 4 hours apart, and immediately prior to PK measurements. The mean and standard deviation of pulse rate has been presented. The values presented does not include Day 3 assessments for participant number 570. Baseline value is defined as the latest pre-treatment assessment where treatment is their first dose of study medication (CQ/PQ/TQ/Placebo). Change from Baseline is the value at post dose minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180
| Intervention | beats per minute (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 assessment 4; n=161, 84 | Day 2 assessment 1; n=166, 85 | Day 2 assessment 4; n=166, 85 | Day 3 assessment 1; n=166, 83 | Day 3 assessment 4; n=166, 82 | Day 8; n=164, 84 | Day 11; n=163, 84 | Day15; n=165, 84 | Day 22; n=164, 84 | Day 29; n=163, 84 | Day 60; n=160, 83 | Day 90; n=160, 82 | Day 120; n=159, 81 | Day 150; n=161, 82 | Day180; n=160, 83 | |
| PQ+CQ | -9.3 | -9.9 | -11.8 | -18.2 | -17.5 | -14.6 | -15.5 | -16.9 | -16.8 | -17.5 | -18.5 | -18.6 | -19.1 | -17.9 | -18.3 |
| TQ+CQ | -10.8 | -9.9 | -11.9 | -15.1 | -16.5 | -12.7 | -13.4 | -13.5 | -14.7 | -16.9 | -16.7 | -16.3 | -16.7 | -16.8 | -18.0 |
Vital signs were measured twice a day on Days 1 through 3, at least 4 hours apart, and immediately prior to pharmacokinetic (PK) measurements. MAP was calculated as the sum of SBP and two times DBP divided by 3. The mean and standard deviation of SBP, DBP and MAP has been presented. The values presented does not include Day 3 assessments for participant number 570. Baseline value is defined as the latest pre-treatment assessment where treatment is their first dose of study medication (CQ/PQ/TQ/Placebo). Change from Baseline is the value at post dose minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180
| Intervention | millimeter of mercury (mmHg) (Mean) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP, Day 1 assessment 4; n=161, 84 | SBP, Day 2 assessment 1; n=166, 85 | SBP, Day 2 assessment 4; n=166, 85 | SBP, Day 3 assessment 1; n=166, 83 | SBP, Day 3 assessment 4; n=166, 82 | SBP, Day 8; n=164, 84 | SBP, Day 11; n=163, 84 | SBP, Day15; n=165, 84 | SBP, Day 22; n=164, 84 | SBP, Day 29; n=163, 84 | SBP, Day 60; n=160, 83 | SBP, Day 90; n=160, 82 | SBP, Day 120; n=159, 81 | SBP, Day 150; n=161, 82 | SBP, Day180; n=160, 83 | DBP, Day 1 assessment 4; n=161, 84 | DBP, Day 2 assessment 1; n=166, 85 | DBP, Day 2 assessment 4; n=166, 85 | DBP, Day 3 assessment 1; n=166, 83 | DBP, Day 3 assessment 4; n=166, 82 | DBP, Day 8; n=164, 84 | DBP, Day 11; n=163, 84 | DBP, Day15; n=165, 84 | DBP, Day 22; n=164, 84 | DBP, Day 29; n=163, 84 | DBP, Day 60; n=160, 83 | DBP, Day 90; n=160, 82 | DBP, Day 120; n=159, 81 | DBP, Day 150; n=161, 82 | DBP, Day180; n=160, 83 | MAP, Day 1 assessment 4; n=161, 84 | MAP, Day 2 assessment 1; n=166, 85 | MAP, Day 2 assessment 4; n=166, 85 | MAP, Day 3 assessment 1; n=166, 83 | MAP, Day 3 assessment 4; n=166, 82 | MAP, Day 8; n=164, 84 | MAP, Day 11; n=163, 84 | MAP, Day15; n=165, 84 | MAP, Day 22; n=164, 84 | MAP, Day 29; n=163, 84 | MAP, Day 60; n=160, 83 | MAP, Day 90; n=160, 82 | MAP, Day 120; n=159, 81 | MAP, Day 150; n=161, 82 | MAP, Day180; n=160, 83 | |
| PQ+CQ | -0.9 | -2.3 | -2.7 | -2.1 | -2.2 | 0.8 | 1.2 | 2.5 | 2.9 | 4.4 | 4.3 | 5.3 | 3.1 | 4.9 | 5.7 | -1.5 | -2.2 | -2.6 | -1.3 | -1.9 | 1.1 | -0.5 | 0.4 | 1.3 | 1.5 | 1.9 | 3.5 | 2.4 | 4.1 | 3.7 | -1.3 | -2.2 | -2.6 | -1.6 | -2.0 | 1.0 | 0.1 | 1.1 | 1.8 | 2.4 | 2.7 | 4.1 | 2.6 | 4.4 | 4.4 |
| TQ+CQ | 1.2 | 0.4 | -0.8 | -0.6 | -2.7 | 2.2 | 1.3 | 3.2 | 3.3 | 2.6 | 4.4 | 3.8 | 3.8 | 4.4 | 3.7 | 1.1 | -0.1 | -0.8 | -0.2 | -1.9 | 0.9 | -0.0 | 1.5 | 1.2 | 0.9 | 3.1 | 2.7 | 3.3 | 3.2 | 2.9 | 1.1 | 0.0 | -0.8 | -0.3 | -2.2 | 1.3 | 0.4 | 2.0 | 1.9 | 1.5 | 3.5 | 3.1 | 3.5 | 3.6 | 3.2 |
Vital signs were performed twice a day on Days 1 through 3, at least 4 hours apart, and immediately prior to PK measurements. The mean and standard deviation of pulse rate has been presented. The values presented does not include Day 3 assessments for participant number 570. Baseline value is defined as the latest pre-treatment assessment where treatment is their first dose of study medication (CQ/PQ/TQ/Placebo). Change from Baseline is the value at post dose minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180
| Intervention | Celsius (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 assessment 4; n=161, 84 | Day 2 assessment 1; n=166, 85 | Day 2 assessment 4; n=166, 85 | Day 3 assessment 1; n=166, 83 | Day 3 assessment 4; n=166, 82 | Day 8; n=164, 84 | Day 11; n=163, 84 | Day15; n=165, 84 | Day 22; n=164, 84 | Day 29; n=163, 84 | Day 60; n=160, 83 | Day 90; n=160, 82 | Day 120; n=159, 81 | Day 150; n=161, 82 | Day180; n=160, 83 | |
| PQ+CQ | -0.5 | -0.6 | -0.6 | -0.9 | -1.0 | -0.9 | -0.9 | -1.0 | -1.0 | -1.0 | -1.0 | -1.0 | -0.9 | -1.0 | -1.0 |
| TQ+CQ | -0.6 | -0.6 | -0.6 | -1.0 | -1.0 | -1.0 | -1.0 | -0.9 | -1.0 | -1.0 | -1.0 | -1.0 | -1.0 | -1.0 | -1.0 |
Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests. The cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital emergency center, other). The costs associated with a relapse episode of P. vivax malaria has been presented. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180
| Intervention | US Dollars (USD) (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Brazil; enrollment clinic for care; n=19, 17 | Colombia; hospital emergency center; n=1,1 | Peru; enrollment clinic for care; n=32, 33 | Peru; attended another clinic; n=8, 30 | Thailand; enrollment clinic for care; n=0, 1 | Vietnam; drug shop for care;n=1, 2 | Vietnam; attended another clinic; n=0, 1 | |
| First Malaria Relapse Follow-up | 8.032 | 16.775 | 8.815 | 3.959 | 1.534 | 2.809 | 0.936 |
Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests. The cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital emergency center, other). The costs associated with a relapse episode of P. vivax malaria has been presented. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180
| Intervention | US Dollars (USD) (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Brazil; enrollment clinic for care; n=19, 17 | Colombia; enrollment clinic for care; n=1,0 | Colombia; attended another clinic; n=1,0 | Colombia; hospital emergency center; n=1,1 | Peru; enrollment clinic for care; n=32, 33 | Peru; attended another clinic; n=8, 30 | Peru; Other; n=8, 0 | Vietnam; drug shop for care;n=1, 2 | Vietnam; Other; n=1, 0 | |
| First Malaria Relapse | 8.208 | 42.776 | 4.194 | 16.775 | 9.244 | 1.677 | 0.818 | 0.702 | 1.873 |
"Health outcomes were evaluated based on the cost of medications purchased. The total medication cost for paracetamol associated with relapse episode of P vivax malaria has been presented. Medications recorded as Other and medications without costs are excluded from the analysis. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title)." (NCT02216123)
Timeframe: Up to Day 180
| Intervention | USD (Mean) | ||
|---|---|---|---|
| Colombia; n=2, 1 | Peru; n=6, 2 | Vietnam; n=1, 1 | |
| First Malaria Relapse | 2.516 | 0.491 | 0.468 |
| First Malaria Relapse Follow-up | 4.194 | 0.327 | 2.341 |
Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria. The number of participants or care givers who had taken off from their normal occupation due to relapse episode of P vivax malaria has been presented by country. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil; Housework; n=2, 1 | Brazil; Farming; n=1, 1 | Brazil; Student; n=1, 1 | Brazil; Paid employment; n=7, 7 | Brazil; Other; n=8, 7 | Colombia; Farming; n=2, 2 | Colombia; Paid employment; n=1, 1 | Peru; Housework; n=18, 18 | Peru, Farming; n=4, 4 | Peru; Student; n=3, 3 | Peru; Paid employment; n=1, 1 | Peru; Other; n=7, 7 | Thailand; Farming; n=1, 1 | Vietnam; Farming; n=4, 4 | Vietnam; Paid employment; n=0, 3 | |
| First Malaria Relapse Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 15 | 4 | 2 | 1 | 6 | 1 | 1 | 2 |
Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria. The number of participants or care givers who had taken off from their normal occupation due to relapse episode of P vivax malaria has been presented by country. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil; Housework; n=2, 1 | Brazil; Farming; n=1, 1 | Brazil; Student; n=1, 1 | Brazil; Paid employment; n=7, 7 | Brazil; Other; n=8, 7 | Colombia; Housework; n=1, 0 | Colombia; Farming; n=2, 2 | Colombia; Paid employment; n=1, 1 | Peru; Housework; n=18, 18 | Peru, Farming; n=4, 4 | Peru; Student; n=3, 3 | Peru; Paid employment; n=1, 1 | Peru; Other; n=7, 7 | Thailand; Farming; n=1, 1 | Vietnam; Farming; n=4, 4 | |
| First Malaria Relapse | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 14 | 4 | 2 | 1 | 7 | 1 | 3 |
Mid-stream urine was collected and analyzed for bilirubin, glucose, ketones, leukocyte esterase (LE), nitrites, occult blood, proteins and urobilinogen by dipstick method. The number of participants with abnormal urinalysis results (Trace, +, ++, +++, ++++) has been presented. Only those participants with data available at the specified data points were analyzed. (NCT02216123)
Timeframe: Up to Day 120
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bilirubin, Day 1, Trace | Bilirubin, Day 1, + | Bilirubin, Day1, ++ | Bilirubin, Day 3, + | Bilirubin, Day 3, ++ | Bilirubin, Day 5, Trace | Bilirubin, Day 5, + | Bilirubin, Day 8, + | Bilirubin, Day 11, Trace | Bilirubin, Day 22, Trace | Bilirubin, Day 22, + | Bilirubin, Day 60, Trace | Bilirubin, Day 60, + | Bilirubin, Day 90, + | Bilirubin, Day 120, + | Glucose, Day 1, + | Glucose, Day 1, ++ | Glucose, Day1, +++ | Glucose, Day1, ++++ | Glucose, Day 3, + | Glucose, Day 3, ++ | Glucose, Day 3, +++ | Glucose, Day 3, ++++ | Glucose, Day 5, ++ | Glucose, Day 5, +++ | Glucose, Day 8, + | Glucose, Day 8, ++ | Glucose, Day 8,+++ | Glucose, Day 11, Trace | Glucose, Day 11, + | Glucose, Day 11, ++ | Glucose, Day 11, +++ | Glucose, Day 15, ++ | Glucose, Day 15, +++ | Glucose, Day 15, ++++ | Glucose, Day 22, + | Glucose, Day 22, +++ | Glucose, Day 29, Trace | Glucose, Day 29, ++ | Glucose, Day 60, + | Glucose, Day 60, ++ | Glucose, Day 90, + | Glucose, Day 90, ++ | Glucose, Day 90, +++ | Glucose, Day 120, Trace | Glucose, Day 120, + | Glucose, Day 120, ++ | Glucose, Day 120, +++ | Glucose, Day 120, ++++ | Ketones, Day 1, Trace | Ketones, Day 1, + | Ketones, Day1, ++ | Ketones, Day1, +++ | Ketones, Day 3, Trace | Ketones, Day 3, + | Ketones, Day 3, ++ | Ketones, Day 3, +++ | Ketones, Day 5, + | Ketones, Day 8, + | Ketones, Day 11, Trace | Ketones, Day 22, Trace | Ketones, Day 22, + | Ketones, Day 90, Trace | Ketones, Day 90, + | Ketones, Day 90, ++ | Ketones, Day 120, Trace | Ketones, Day 120, + | Ketones, Day 120, ++ | LE, Day 1, Trace | LE, Day 1, + | LE, Day1, ++ | LE, Day1, +++ | LE, Day 3, Trace | LE, Day 3, + | LE, Day 3, ++ | LE, Day 3, +++ | LE, Day 5, Trace | LE, Day 5, + | LE, Day 5, ++ | LE, Day 5, +++ | LE, Day 8, Trace | LE, Day 8, + | LE, Day 8, ++ | LE, Day 8, +++ | LE, Day 11, Trace | LE, Day 11, + | LE, Day 11, ++ | LE, Day 11, +++ | LE, Day 15, Trace | LE, Day 15, + | LE, Day 15, ++ | LE, Day 15, +++ | LE, Day 22, Trace | LE, Day 22, + | LE, Day 22, ++ | LE, Day 22, +++ | LE, Day 29, Trace | LE, Day 29, + | LE, Day 29, ++ | LE, Day 29, +++ | LE, Day 60, Trace | LE, Day 60, + | LE, Day 60, ++ | LE, Day 60, +++ | LE, Day 90, Trace | LE, Day 90, + | LE, Day 90, ++ | LE, Day 90, +++ | LE, Day 120, Trace | LE, Day 120, + | LE, Day 120, ++ | LE, Day 120, +++ | Nitrite, Day 1, Trace | Nitrite, Day 1, + | Nitrite, Day 3, + | Nitrite, Day 5, + | Nitrite, Day 5, +++ | Nitrite, Day 8, +++ | Nitrite, Day 11, + | Nitrite, Day 15, + | Nitrite, Day 22, Trace | Nitrite, Day 29, + | Nitrite, Day 60, + | Nitrite, Day 90, Trace | Nitrite, Day 90, + | Nitrite, Day 120, + | Nitrite, Day 120, ++ | Occult blood, Day 1, Trace | Occult blood, Day 1, + | Occult blood, Day 1, ++ | Occult blood, Day1, +++ | Occult blood, Day1, ++++ | Occult blood, Day 3, Trace | Occult blood, Day 3, + | Occult blood, Day 3, ++ | Occult blood, Day 3, +++ | Occult blood, Day 3, ++++ | Occult blood, Day 5, Trace | Occult blood, Day 5, + | Occult blood, Day 5, ++ | Occult blood, Day 5, +++ | Occult blood, Day 5, ++++ | Occult blood, Day 8, Trace | Occult blood, Day 8, + | Occult blood, Day 8, ++ | Occult blood, Day 8,+++ | Occult blood, Day 11, Trace | Occult blood, Day 11, + | Occult blood, Day 11, ++ | Occult blood, Day 11, +++ | Occult blood, Day 11, ++++ | Occult blood, Day 15, Trace | Occult blood, Day 15, + | Occult blood, Day 15, ++ | Occult blood, Day 15, +++ | Occult blood, Day 15, ++++ | Occult blood, Day 22, Trace | Occult blood, Day 22, + | Occult blood, Day 22, ++ | Occult blood, Day 22, +++ | Occult blood, Day 22, ++++ | Occult blood, Day 29, Trace | Occult blood, Day 29, + | Occult blood, Day 29, ++ | Occult blood, Day 29, +++ | Occult blood, Day 29, ++++ | Occult blood, Day 60, Trace | Occult blood, Day 60, + | Occult blood, Day 60, ++ | Occult blood, Day 60, +++ | Occult blood, Day 60, ++++ | Occult blood, Day 90, Trace | Occult blood, Day 90, + | Occult blood, Day 90, ++ | Occult blood, Day 90, +++ | Occult blood, Day 90, ++++ | Occult blood, Day 120, Trace | Occult blood, Day 120, + | Occult blood, Day 120, ++ | Occult blood, Day 120, +++ | Occult blood, Day 120, ++++ | Protein, Day 1, Trace | Protein, Day 1, + | Protein, Day1, ++ | Protein, Day 3, Trace | Protein, Day 3, + | Protein, Day 3, ++ | Protein, Day 5, Trace | Protein, Day 5, + | Protein, Day 5, ++ | Protein, Day 8, Trace | Protein, Day 8, + | Protein, Day 8,++ | Protein, Day 11, Trace | Protein, Day 11, + | Protein, Day 11, ++ | Protein, Day 15, + | Protein, Day 15, ++ | Protein, Day 22, Trace | Protein, Day 22, + | Protein, Day 22, ++ | Protein, Day 29, Trace | Protein, Day 29, + | Protein, Day 29, ++ | Protein, Day 60, Trace | Protein, Day 60, + | Protein, Day 60, ++ | Protein, Day 90, Trace | Protein Day 90, + | Protein, Day 120, Trace | Protein, Day 120, + | Protein, Day 120, ++ | Urobilinogen, Day 1, Trace | Urobilinogen, Day 1, + | Urobilinogen, Day1, ++ | Urobilinogen, Day1, +++ | Urobilinogen, Day 3, Trace | Urobilinogen, Day 3, + | Urobilinogen, Day 3, ++ | Urobilinogen Day 3, +++ | Urobilinogen, Day 3, ++++ | Urobilinogen, Day 5, Trace | Urobilinogen, Day 5, + | Urobilinogen, Day 8, Trace | Urobilinogen, Day 8, + | Urobilinogen, Day 8, ++ | Urobilinogen, Day 8,+++ | Urobilinogen, Day 11, Trace | Urobilinogen, Day 11, + | Urobilinogen, Day 11, ++ | Urobilinogen, Day 15, Trace | Urobilinogen, Day 15, + | Urobilinogen, Day 15, ++ | Urobilinogen, Day 22, Trace | Urobilinogen, Day 29, Trace | Urobilinogen, Day 29, + | Urobilinogen, Day 60, Trace | Urobilinogen, Day 60, + | Urobilinogen, Day 90, Trace | Urobilinogen, Day 90, + | Urobilinogen, Day 120, Trace | Urobilinogen, Day 120, + | Urobilinogen, Day 120, ++ | |
| PQ+CQ | 1 | 2 | 0 | 3 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 0 | 1 | 2 | 1 | 0 | 2 | 4 | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 2 | 0 | 0 | 2 | 3 | 1 | 1 | 3 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 9 | 2 | 2 | 0 | 5 | 1 | 0 | 1 | 4 | 2 | 2 | 3 | 4 | 1 | 2 | 2 | 3 | 3 | 1 | 2 | 8 | 3 | 1 | 2 | 4 | 0 | 1 | 0 | 6 | 4 | 0 | 3 | 4 | 2 | 1 | 1 | 7 | 2 | 1 | 1 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 4 | 7 | 4 | 2 | 1 | 3 | 6 | 3 | 3 | 1 | 1 | 3 | 3 | 2 | 2 | 4 | 4 | 0 | 2 | 1 | 3 | 2 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 5 | 1 | 1 | 1 | 2 | 5 | 1 | 4 | 0 | 0 | 7 | 3 | 0 | 0 | 1 | 7 | 2 | 3 | 2 | 2 | 5 | 3 | 0 | 2 | 8 | 8 | 1 | 6 | 13 | 1 | 5 | 1 | 1 | 4 | 2 | 0 | 3 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 5 | 4 | 1 | 2 | 11 | 4 | 3 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
| TQ+CQ | 1 | 9 | 3 | 8 | 2 | 1 | 4 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 3 | 2 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 3 | 4 | 4 | 2 | 0 | 5 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 3 | 19 | 5 | 1 | 4 | 13 | 2 | 1 | 3 | 11 | 3 | 3 | 7 | 10 | 6 | 2 | 6 | 11 | 3 | 3 | 8 | 4 | 4 | 2 | 4 | 13 | 3 | 1 | 5 | 11 | 1 | 4 | 8 | 8 | 5 | 2 | 6 | 13 | 2 | 0 | 5 | 12 | 5 | 0 | 1 | 4 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 0 | 2 | 2 | 1 | 2 | 18 | 9 | 12 | 6 | 4 | 14 | 9 | 5 | 3 | 4 | 7 | 6 | 4 | 3 | 4 | 12 | 3 | 3 | 2 | 8 | 3 | 3 | 1 | 2 | 11 | 3 | 2 | 0 | 4 | 11 | 4 | 2 | 1 | 5 | 17 | 3 | 3 | 1 | 5 | 15 | 2 | 3 | 1 | 4 | 13 | 7 | 4 | 2 | 2 | 13 | 3 | 6 | 0 | 15 | 19 | 4 | 8 | 21 | 3 | 5 | 4 | 2 | 6 | 6 | 1 | 1 | 4 | 1 | 2 | 1 | 2 | 2 | 1 | 3 | 4 | 1 | 3 | 3 | 1 | 4 | 3 | 2 | 6 | 1 | 8 | 23 | 10 | 3 | 6 | 14 | 8 | 0 | 0 | 3 | 3 | 2 | 0 | 0 | 0 | 1 | 2 | 0 | 3 | 1 | 1 | 3 | 4 | 2 | 3 | 1 | 4 | 3 | 2 | 2 | 0 |
Health outcomes were evaluated based on the actions taken by the participants to treat relapse episode of P vivax malaria. The number of participants with the type of action taken to treat relapse episode of P vivax malaria has been presented by country. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil; Trial clinic; n=19, 17 | Brazil; Other; n=19, 17 | Colombia; Nothing; n=4, 3 | Colombia; Trial clinic; n=4, 3 | Colombia; Another clinic; n=4, 3 | Colombia; Hospital emergency center; n=4, 3 | Peru; Trial clinic; n=33, 33 | Peru; Another clinic; n=33, 33 | Peru; Other; n=33, 33 | Thailand; Nothing; n=1, 1 | Thailand; Trial Clinic; n=1, 1 | Vietnam; Nothing; n=4, 7 | Vietnam; Drug Shop; n=4, 7 | Vietnam; Other; n=4, 7 | Vietnam; Another clinic; n=4, 7 | |
| First Malaria Relapse | 19 | 5 | 2 | 1 | 1 | 1 | 32 | 8 | 9 | 1 | 0 | 1 | 2 | 1 | 0 |
| First Malaria Relapse Follow-up | 17 | 0 | 2 | 0 | 0 | 1 | 33 | 33 | 0 | 0 | 1 | 5 | 2 | 0 | 1 |
Ophthalmic assessments were carried out at pre-qualified sites prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Change from Baseline is the value at post dose visit minus the Baseline value. Best corrected visual acuity was assessed individually for each eye. Scores were recorded as a ratio. The values were used to derive a logMAR score for statistical analysis where logMAR=-1x log10 (ratio score). The number of participants with change in Best Corrected Visual Acuity Test Scores from Baseline has been presented where possible change is defined as a change from Baseline >=0.12 to <0.3 and definite change is defined as a change from Baseline >=0.3 logMAR score. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180
| Intervention | Participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum change; possible; right eye; n=27, 13 | Maximum change; definite; right eye; n=27, 13 | Maximum change; possible; left eye; n=27, 13 | Maximum change; definite; left eye; n=27, 13 | Day 29; possible change; right eye; n=27, 13 | Day 29; definite change; right eye; n=27, 13 | Day 29; possible change; left eye; n=27, 13 | Day 29; definite change; left eye; n=27, 13 | Day 90; possible change; right eye; n=27, 12 | Day 90; definite change; right eye; n=27, 12 | Day 90; possible change; left eye; n=27, 12 | Day 90; definite change; left eye; n=27, 12 | Day 180; possible change; right eye; n=2, 2 | Day 180; definite change; right eye; n=2, 2 | Day 180; possible change; left eye; n=2, 2 | Day 180; definite change; left eye; n=2, 2 | |
| PQ+CQ | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| TQ+CQ | 1 | 0 | 2 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
Plasma or serum samples were anlalyzed to evaluate clinical chemistry parameters such as alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), bilirubin, creatine kinase, creatinine, glomerular filtration rate (GFR), indirect bilirubin and urea. The number of participants with clinical chemistry laboratory values outside the extended normal range (F3) has been presented. The upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. Safety Population consisted of all randomized participants who received at least one dose of blinded study medication. (NCT02216123)
Timeframe: Up to Day 120
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ALT, High | ALP, High | AST, High | Bilirubin, High | Creatine kinase, High | Creatinine, High | GFR, Low | Indirect bilirubin, High | Urea, High | |
| PQ+CQ | 0 | 1 | 3 | 18 | 4 | 0 | 0 | 21 | 19 |
| TQ+CQ | 8 | 0 | 6 | 28 | 3 | 0 | 0 | 36 | 40 |
12 lead ECG was performed with the participant in a semi-supine position having rested in this position for at least 10 minutes. ECG assessments were performed in triplicate at screening followed by single ECGs 12 hours after the first dose of study medication and at Day 29. The number of participants with abnormal-clinically significant ECG findings have been presented. The 12 Hour Post Randomized Treatment (11.5-12.5 Hours) timepoint included all readings taken between 11.5 and 12.5 hours post randomized treatment. The 12 Hour Post Randomized Treatment (8-72 Hours) timepoint is a sensitivity analysis of the 12 Hour post randomized treatment timepoint, including all readings taken between 8 and 72 hours post randomized treatment. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 29
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 11.5 to 12.5 hours Day 1, Assessment 1; n=143, 75 | 11.5 to 12.5 hours Day 1 Assessment 2; n=6, 6 | 11.5 to 12.5 hours Day 1 Assessment 3; n=5, 5 | 8 to 72 hours Day 1 Assessment 1; n=166, 85 | 8 to 72 hours Day 1 Assessment 2; n=6, 6 | 8 to 72 hours Day 1 Assessment 3; n=5, 5 | Day 29; n=161, 84 | |
| PQ+CQ | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TQ+CQ | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Two drops of peripheral blood were collected onto pre-printed filter paper for subsequent deoxyribonucleic acid (DNA) extraction and polymerase chain reaction (PCR) analysis of Plasmodium species on all participants at screening (Day 1; pre-dose) and; if necessary, at the time of the first recrudescence/relapse or re-infection. PCR of the P. vivax genes, was used to distinguish between genetically homologous and genetically heterologous infection. The number of participants with genetically homologous and genetically heterologous P. vivax infections has been summarized for each treatment group. Only those participants with an infection occuring on or after Study Day 33 were analyzed. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Heterologous P. vivax | Homologous P. vivax | Unknown genetic classification | |
| PQ+CQ | 9 | 10 | 1 |
| TQ+CQ | 8 | 29 | 5 |
Blood samples were collected for the evaluation of hematology parameters including eosinophils, leukocytes, lymphocytes, neutrophils, platelets, reticulocytes and methemoglobin. The number of participants with hematology laboratory data outside the extended normal range (F3) has been presented. The upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. Participants having both High and Low values for Normal Ranges at any post-baseline visits for safety parameters were counted in both the High and Low categories. (NCT02216123)
Timeframe: Up to Day 120
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Blood eosinophils, High | Blood leukocytes, Low | Blood lymphocytes, Low | Blood lymphocytes, High | Blood neutrophils, Low | Blood platelets, Low | Blood reticulocytes, High | Methemoglobin, High | |
| PQ+CQ | 15 | 0 | 1 | 4 | 3 | 8 | 39 | 3 |
| TQ+CQ | 32 | 0 | 8 | 11 | 5 | 13 | 80 | 2 |
Ophthalmic assessments were carried out at pre-qualified sites prior to randomization and at Days 29 and 90 and at withdrawal follow-up visit. Assessments were carried out at Day 180 (and up to resolution) if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. The number of participants displaying keratopathy in each eye has been summarized for each visit. The number of participants with new keratopathy at any time post Baseline is also reported. Ophthalmic Safety Population comprised of all participants in the Safety Population who have results from any eye assessments. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline; right eye; n=27, 13 | Baseline; left eye; n=27, 13 | Day 1; right eye; n=27, 13 | Day 1; left eye; n=27, 13 | Day 29; right eye; n=27, 13 | Day 29; left eye; n=27, 13 | Day 90; right eye; n=27, 12 | Day 90; left eye; n=27, 12 | Day 180; right eye; n=2, 2 | Day 180; left eye; n=2, 2 | Any time post Baseline; right eye; n=27, 13 | Any time post Baseline; left eye; n=27, 13 | |
| PQ+CQ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TQ+CQ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ophthalmic assessments were carried out at pre-qualified sites prior to randomization and at Days 29 and 90 and at withdrawal follow-up. Assessments were carried out at Day 180 (and up to resolution) if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Change from Baseline was calculated as the value at post dose visit minus the Baseline value. The number of participants with definite retinal change and questionable (ques) retinal change from Baseline has been presented. The number of participants with maximum change post-Baseline (definite when absent or questionable at Baseline) has been presented for either eye. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180
| Intervention | Participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 29, Definite change, right eye; n=22, 13 | Day 29, Ques change, right eye; n=22, 13 | Day 29, Definite change, left eye; n=22, 13 | Day 29, Ques change, left eye; n=22, 13 | Day 90, Definite change, right eye; n=24, 11 | Day 90, Ques change, right eye; n=24, 11 | Day 90, Definite change, left eye; n=24, 11 | Day 90, Ques change, left eye; n=24, 11 | Day 180, Definite change, right eye; n=3, 2 | Day 180, Ques change, right eye; n=3, 2 | Day 180, Definite change, left eye; n=3, 2 | Day 180, Ques change, left eye; n=3, 2 | Maximum change post-Baseline; either eye; n=27, 13 | |
| PQ+CQ | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TQ+CQ | 0 | 2 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant under clinical investigation, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/ birth defect, other situations such as important medical events and events of possible drug induced liver injury with hyperbilirubinemia. TEAEs are defined as AEs with an onset date and time on or after that of the start of first dose of study medication (including CQ). Number of participants with TEAEs and serious TEAEs have been presented. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |
|---|---|---|
| TEAEs | Serious TEAEs | |
| PQ+CQ | 64 | 1 |
| TQ+CQ | 119 | 6 |
"Subjects were ranked according to time of onset of parasitemia and a non-parametric rankorder statistical test (eg, Log-Rank or Mann-Whitney) was performed to evaluate delays in parasitemia induced by vaccination. Cox Proportional Hazards model was used to calculate days to parasitemia and Kaplan-Meier plots were used to display time to first positive malaria blood smear.~Hazard Ratio (HR). Time starts once subject has received t infectious bites. Time stops when subject has first positive blood smear. If subject does not become parasitemic then time stops the day he/she begins anti-malarial therapy." (NCT01157897)
Timeframe: 280 day (during the study through 6 months aftr challenge)
| Intervention | days (Mean) |
|---|---|
| Cohort 1: 15 μg VMP001 | 0.137 |
| Cohort 2: 30 μg VMP001 | 0.073 |
| Cohort 3: 60 μg VMP001 | 0.042 |
Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI). Peak responses were compared by performing Student's t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences. ELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means. Units that were reported as '>50' were converted to '1'. (NCT01157897)
Timeframe: study duration
| Intervention | Geometric Mean Titier of European Units (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Pre-vaccination | 2wks post first vaccination | Day of second vaccination | 2wks post second vaccination | Day of third vaccination | 2wks post third vaccination | 4wks post challenge | 6mths post challenge | |
| Cohort 1: 15 μg VMP001 | 1 | 133.72 | 244.35 | 20161.18 | 9053.32 | 61203.48 | 54843.38 | 10860.7 |
| Cohort 2: 30 μg VMP001 | 1 | 750.38 | 1450.22 | 81143.72 | 31071.01 | 68730.4 | 56472.17 | 12519.16 |
| Cohort 3: 60 μg VMP001 | 3.09 | 836.68 | 1711.63 | 61711.8 | 36405.66 | 41879.99 | 32178.39 | 5500.73 |
Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI). Peak responses were compared by performing Student's t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences. ELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means. Units that were reported as '>50' were converted to '1'. (NCT01157897)
Timeframe: study duration
| Intervention | Geometric Mean Titer of European Units (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Pre-vaccination | 2wks post first vaccination | Day of second vaccination | 2wks post second vaccination | Day of third vaccination | 2wks post third vaccination | 4wks post challenge | 6months post challenge | |
| Cohort 1: 15 μg VMP001 | 1 | 151.39 | 281.79 | 21862.22 | 9921.61 | 59883.77 | 54843.38 | 10860.7 |
| Cohort 2: 30 μg VMP001 | 1.5 | 526.18 | 1175.41 | 74608.62 | 28498.43 | 68730.4 | 56472.17 | 12519.16 |
| Cohort 3: 60 μg VMP001 | 3.09 | 836.68 | 1711.63 | 61711.8 | 36405.66 | 41879.99 | 32178.39 | 5500.73 |
Adverse events were evaluated for 7 days after each vaccination during the vaccine phase. (NCT01157897)
Timeframe: 7 days after immunization
| Intervention | participants with AEs (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Solicited Local: Injection site erythema | Solicited Local: Injection site induration | Solicited Local: Injection site pain | Solicited Systemic: Diarrhea | Solicited Systemic: Nausea | Solicited Systemic: Vomiting | Solicited Systemic: Fatigue | Solicited Systemic: Pyrexia | Solicited Systemic: Arthralgia | Solicited Systemic: Myalgia | Solicited Systemic: Headache | |
| Cohort 1: 15 μg VMP001 | 2 | 0 | 10 | 0 | 5 | 2 | 8 | 4 | 4 | 4 | 8 |
| Cohort 2: 30 μg VMP001 | 3 | 1 | 10 | 0 | 3 | 0 | 4 | 2 | 2 | 4 | 6 |
| Cohort 3: 60 μg VMP001 | 6 | 2 | 10 | 1 | 4 | 2 | 7 | 1 | 3 | 7 | 5 |
Adverse events were evaluated over a 28 day follow-up period after each vaccination during the vaccine phase (NCT01157897)
Timeframe: 28 days following immunization
| Intervention | participants with AEs (Number) | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ear discomfort | Abdominal discomfort | Abdominal pain | Feces discolored | Food poisoning | Nausea | Toothache | Axillary pain | Chills | Feeling hot | Injection site erythema | Injection site pruritus | Injection site swelling | Injection site warmth | Malaise | Hypertransaminasaemia | Seasonal allergy | Nasopharyngitis | Upper respiratory tract infection | Contusion | Excoriation | Postprocedural discomfort | Posttraumatic pain | Scratch | Skin laceration | Haemoglobin decreased | Platelet count decreased | Gout | Back pain | Muscle spasms | Musculoskeletal discomfort | Myalgia | Pain in extremity | Dizziness | Headache | Sinus headache | Nasal Congestion | Cold sweat | Dermatitis contact | Erythema | Hypertension | |
| Cohort 1: 15 μg VMP001 | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 0 | 5 | 5 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 1 |
| Cohort 2: 30 μg VMP001 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 6 | 0 | 0 | 2 | 1 | 5 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 1 | 0 |
| Cohort 3: 60 μg VMP001 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 7 | 7 | 1 | 1 | 3 | 2 | 7 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 2 | 1 | 0 | 1 | 1 | 2 | 0 | 0 | 0 |
Thick blood smear was performed to patients daily on days 7 to 23, and every other day until day 29. Any prove of P. vivax infection was considered positive and confirmed later by real time polymerase chain reaction (rPCR). (NCT00367380)
Timeframe: Twenty eight days
| Intervention | days (Mean) |
|---|---|
| Group 1 | 11 |
| Group 2 | 11 |
| Group 3 | 9 |
53 reviews available for primaquine and Plasmodium vivax Malaria
| Article | Year |
|---|---|
Tafenoquine for the treatment of
Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2022 |
Tafenoquine for
Topics: Aminoquinolines; Antimalarials; Female; Humans; Malaria, Vivax; Plasmodium vivax; Pregnancy; Primaqu | 2021 |
Global scenario of Plasmodium vivax occurrence and resistance pattern.
Topics: Antimalarials; Chloroquine; Humans; Malaria; Malaria, Vivax; Plasmodium vivax; Primaquine | 2022 |
Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
Topics: Antimalarials; Folic Acid Antagonists; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurre | 2023 |
The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Humans; Malaria, Vivax; Plas | 2019 |
Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis.
Topics: Diagnostic Tests, Routine; Endemic Diseases; Female; Glucosephosphate Dehydrogenase; Glucosephosphat | 2019 |
Advances and roadblocks in the treatment of malaria.
Topics: Antimalarials; Artemisinins; Drug Resistance; Drug Therapy, Combination; Humans; Malaria; Malaria, F | 2022 |
Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
Topics: Adult; Antimalarials; Child; Drug Administration Schedule; Glucosephosphate Dehydrogenase; Humans; M | 2020 |
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Drug Administration Schedule; Glucosephosphate D | 2020 |
Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions.
Topics: Antimalarials; Chloroquine; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine | 2021 |
[Role of primaquine in malaria control and elimination in French-speaking Africa].
Topics: Africa; Africa, Northern; Disease Eradication; Humans; Infection Control; Language; Malaria, Falcipa | 2017 |
Anti-malarial treatment outcomes in Ethiopia: a systematic review and meta-analysis.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chloroquine; Drug Combinatio | 2017 |
Primaquine-induced haemolysis in females heterozygous for G6PD deficiency.
Topics: Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Heterozygote; Humans; M | 2018 |
Malaria Elimination: Time to Target All Species.
Topics: Animals; Anopheles; Antimalarials; Chloroquine; Disease Eradication; Host-Parasite Interactions; Hum | 2018 |
The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dru | 2018 |
ON THE EPIDEMIOLOGY OF COMPLICATED VIVAX MALRIA.
Topics: Animals; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine | 2016 |
Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines.
Topics: Aminoquinolines; Animals; Antimalarials; Humans; Macaca mulatta; Malaria, Vivax; Primaquine | 2018 |
The Primaquine Problem-and the Solution? Point-of-care Diagnostics for Glucose 6-Phosphate Dehydrogenase Deficiency.
Topics: Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Plasmodium vivax; Point-of-Care S | 2019 |
Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria.
Topics: Antimalarials; Drug Administration Schedule; Humans; Malaria, Vivax; Primaquine; Primary Prevention; | 2019 |
The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
Topics: Adult; Anemia, Hemolytic; Antimalarials; Chloroquine; Female; Glucosephosphate Dehydrogenase Deficie | 2019 |
Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi | 2013 |
Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine.
Topics: Adult; Antimalarials; Child; Chloroquine; Drug Administration Schedule; Humans; Malaria, Vivax; Plas | 2013 |
Reversible myelopathy in Plasmodium vivax malaria: report of a case and review of literature.
Topics: Adult; Animals; Antimalarials; Chloroquine; Diagnosis, Differential; Humans; India; Magnetic Resonan | 2013 |
Spatial distribution of G6PD deficiency variants across malaria-endemic regions.
Topics: Antimalarials; Gene Frequency; Genetic Variation; Global Health; Glucosephosphate Dehydrogenase Defi | 2013 |
Spatial distribution of G6PD deficiency variants across malaria-endemic regions.
Topics: Antimalarials; Gene Frequency; Genetic Variation; Global Health; Glucosephosphate Dehydrogenase Defi | 2013 |
Spatial distribution of G6PD deficiency variants across malaria-endemic regions.
Topics: Antimalarials; Gene Frequency; Genetic Variation; Global Health; Glucosephosphate Dehydrogenase Defi | 2013 |
Spatial distribution of G6PD deficiency variants across malaria-endemic regions.
Topics: Antimalarials; Gene Frequency; Genetic Variation; Global Health; Glucosephosphate Dehydrogenase Defi | 2013 |
Mass primaquine treatment to eliminate vivax malaria: lessons from the past.
Topics: Anemia, Hemolytic; Antimalarials; Asia; Chemoprevention; Disease Eradication; Drug Therapy; Glucosep | 2014 |
Clinical complications of G6PD deficiency in Latin American and Caribbean populations: systematic review and implications for malaria elimination programmes.
Topics: Caribbean Region; Disease Eradication; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; | 2014 |
G6PD deficiency in Latin America: systematic review on prevalence and variants.
Topics: Antimalarials; Caribbean Region; Contraindications; Female; Geographic Mapping; Glucosephosphate Deh | 2014 |
Plasmodium vivax malaria elimination: should innovative ideas from the past be revisited?
Topics: Antimalarials; Brazil; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; Prima | 2014 |
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, V | 2015 |
Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria.
Topics: Anemia; Antimalarials; Chemical and Drug Induced Liver Injury; Glucosephosphate Dehydrogenase Defici | 2015 |
Therapeutic efficacy of alternative primaquine regimens to standard treatment in preventing relapses by Plasmodium vivax: A systematic review and meta-analysis.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Administration Schedule; Humans; Malaria, | 2015 |
Primaquine treatment and relapse in Plasmodium vivax malaria.
Topics: Antimalarials; Humans; Malaria, Vivax; Middle Aged; Plasmodium vivax; Primaquine; Recurrence; Treatm | 2016 |
Therapeutic failure of primaquine and need for new medicines in radical cure of Plasmodium vivax.
Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Treatment Failure | 2016 |
Evaluation of Efficacy of Chloroquine for Plasmodium Vivax Infection Using Parasite Clearance Times: A 10-Year Study and Systematic Review.
Topics: Antimalarials; Chloroquine; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Malaria, | 2016 |
Management of relapsing Plasmodium vivax malaria.
Topics: Antimalarials; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Humans; Liver; | 2016 |
Resistance to therapies for infection by Plasmodium vivax.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Folic Acid Antagonists; Humans; Malaria, Vivax | 2009 |
Review: Malaria chemoprophylaxis for travelers to Latin America.
Topics: Antimalarials; Atovaquone; Drug Combinations; Drug Therapy, Combination; Humans; Latin America; Mala | 2011 |
Primaquine in vivax malaria: an update and review on management issues.
Topics: Aminoquinolines; Antimalarials; Artemisinins; Chloroquine; Clinical Trials as Topic; Drug Resistance | 2011 |
The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi | 2011 |
Primaquine radical cure of Plasmodium vivax: a critical review of the literature.
Topics: Antimalarials; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Ma | 2012 |
[Plasmodium vivax malaria recurrence according to the use of primaquine: analysis of longitudinal descriptive studies].
Topics: Antimalarials; Humans; Longitudinal Studies; Malaria, Vivax; Primaquine; Secondary Prevention | 2012 |
The treatment of imported malaria in children: an update.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antimalarials; Artemisinins; Child; Drug T | 2013 |
Diagnosis and treatment of Plasmodium vivax malaria.
Topics: Animals; Antimalarials; Drug Discovery; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; P | 2012 |
G6PD deficiency: global distribution, genetic variants and primaquine therapy.
Topics: Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Mutation; Prevalen | 2013 |
Cerebral malaria owing to Plasmodium vivax: case report.
Topics: Animals; Antimalarials; Brain; Child, Preschool; Chloroquine; Humans; Malaria, Cerebral; Malaria, Vi | 2006 |
Primaquine for preventing relapses in people with Plasmodium vivax malaria.
Topics: Adult; Antimalarials; Child; Chloroquine; Humans; Malaria, Vivax; Primaquine; Randomized Controlled | 2007 |
Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy.
Topics: Animals; Antimalarials; Body Weight; Brazil; Humans; India; Malaria, Vivax; Plasmodium vivax; Primaq | 2007 |
Management of vivax malaria with primaquine.
Topics: Antimalarials; Drug Administration Schedule; Humans; Malaria, Vivax; Primaquine | 2007 |
Neglect of Plasmodium vivax malaria.
Topics: Animals; Antimanic Agents; Chloroquine; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine | 2007 |
Primaquine resistance in Plasmodium vivax.
Topics: Animals; Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine | 1996 |
Primaquine resistance in Plasmodium vivax.
Topics: Animals; Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine | 1996 |
Primaquine resistance in Plasmodium vivax.
Topics: Animals; Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine | 1996 |
Primaquine resistance in Plasmodium vivax.
Topics: Animals; Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine | 1996 |
[The treatment of malaria].
Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Malar | 1997 |
[Epidemiological and therapeutic aspects of plasmodial infection from Plasmodium vivax].
Topics: Antimalarials; Chloroquine; Clinical Protocols; Drug Resistance; Drug Therapy, Combination; Humans; | 2000 |
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
Topics: Aminoquinolines; Antimalarials; Australia; Controlled Clinical Trials as Topic; Endemic Diseases; Hu | 2001 |
91 trials available for primaquine and Plasmodium vivax Malaria
| Article | Year |
|---|---|
Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Cambodia; Child; Child, Preschool; Erythrocytes; Female; Gen | 2021 |
Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial.
Topics: Antimalarials; Australia; Humans; Indonesia; Infant; Malaria, Falciparum; Malaria, Vivax; Primaquine | 2022 |
Pharmacokinetics of chloroquine and primaquine in healthy volunteers.
Topics: Adult; Antimalarials; Brazil; Chloroquine; Cross-Over Studies; Dose-Response Relationship, Drug; Fem | 2022 |
Higher-Dose Primaquine to Prevent Relapse of
Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Directly Obser | 2022 |
Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas-a randomized controlled trial (PRIMA).
Topics: Antimalarials; Hemoglobinuria; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Male; Plasmodiu | 2022 |
Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Humans; Malaria; Malari | 2023 |
Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Therapy, Combination; Humans; Malaria; Malaria, Vivax | 2023 |
Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency.
Topics: Afghanistan; Biological Assay; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, V | 2023 |
Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Australia; Humans; Malaria; Ma | 2023 |
Resolving the cause of recurrent Plasmodium vivax malaria probabilistically.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Female; Humans; Infant; Malaria, Vivax; M | 2019 |
The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Asymptomatic Infections; Female; Humans; Laos; Malar | 2020 |
Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Cambodia; Child; Female; Humans; Malaria, Falciparum | 2020 |
Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with Plasmodium vivax Malaria.
Topics: Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Humans; Malaria, Vivax; Primaquine | 2021 |
Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Ch | 2017 |
Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Blood; Child; Child, Prescho | 2017 |
Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial.
Topics: Adult; Aged; Artemisinins; Brazil; Chloroquine; Dose-Response Relationship, Drug; Drug Therapy, Comb | 2018 |
The ethics of using placebo in randomised controlled trials: a case study of a Plasmodium vivax antirelapse trial.
Topics: Biomedical Research; Double-Blind Method; Ethics, Research; Humans; Malaria, Vivax; Patient Selectio | 2018 |
Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Female; Humans; Infant; Inf | 2018 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs.
Topics: Adult; Antimalarials; Artemisinins; Artesunate; Cross-Over Studies; Drug Interactions; Drug Therapy, | 2018 |
A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India.
Topics: Adult; Aged; Antimalarials; Dose-Response Relationship, Drug; Female; Humans; India; Malaria, Vivax; | 2018 |
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method | 2019 |
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method | 2019 |
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method | 2019 |
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method | 2019 |
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method | 2019 |
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method | 2019 |
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method | 2019 |
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method | 2019 |
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Monitoring the Efficacy of Chloroquine-Primaquine Therapy for Uncomplicated Plasmodium vivax Malaria in the Main Transmission Hot Spot of Brazil.
Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Drug Therapy, | 2019 |
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr | 2019 |
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr | 2019 |
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr | 2019 |
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr | 2019 |
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Double-Blind Method; Drug Administration | 2019 |
Blood stage of Plasmodium vivax in central China is still susceptible to chloroquine plus primaquine combination therapy.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; China; Chloroquine; Drug Therapy, C | 2013 |
In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.
Topics: Adolescent; Adult; Aged; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Chloroqui | 2013 |
A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Com | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn | 2013 |
Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Artemisinins; Child; Child, Preschool; China; Chloroquin | 2013 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation | 2014 |
Pharmacokinetic interactions between primaquine and chloroquine.
Topics: Adult; Antimalarials; Chloroquine; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Ma | 2014 |
Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon Basin of Peru.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Sc | 2014 |
Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects.
Topics: Administration, Oral; Adult; Antimalarials; Artemisinins; Artesunate; Cross-Over Studies; Drug Inter | 2015 |
Confirmed Plasmodium vivax Resistance to Chloroquine in Central Vietnam.
Topics: Adolescent; Adult; Anemia; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Fem | 2015 |
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
Topics: Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method; | 2016 |
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
Topics: Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method; | 2016 |
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
Topics: Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method; | 2016 |
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
Topics: Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method; | 2016 |
Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dia | 2015 |
Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens.
Topics: Afghanistan; Antimalarials; Double-Blind Method; Ethiopia; Glucosephosphate Dehydrogenase; Humans; I | 2015 |
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V | 2015 |
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V | 2015 |
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V | 2015 |
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V | 2015 |
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
Topics: Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax | 2016 |
Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment.
Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Chloroquine; Female; Humans; Malaria, Vivax; Male; M | 2016 |
Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Cohort Studies; Dose-Response Relationshi | 2017 |
The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
Topics: Adult; Aminoquinolines; Animals; Antimalarials; Australia; Dose-Response Relationship, Drug; Female; | 2008 |
The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
Topics: Adult; Aminoquinolines; Animals; Antimalarials; Australia; Dose-Response Relationship, Drug; Female; | 2008 |
The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
Topics: Adult; Aminoquinolines; Animals; Antimalarials; Australia; Dose-Response Relationship, Drug; Female; | 2008 |
The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
Topics: Adult; Aminoquinolines; Animals; Antimalarials; Australia; Dose-Response Relationship, Drug; Female; | 2008 |
A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antimalarials; Child; Child, Preschool; Drug Adm | 2008 |
Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment.
Topics: Adult; Animals; Antimalarials; Drug Administration Schedule; Female; Glucosephosphate Dehydrogenase; | 2009 |
Prevention of Plasmodium vivax malaria recurrence: efficacy of the standard total dose of primaquine administered over 3 days.
Topics: Adolescent; Adult; Antimalarials; Chemoprevention; Child; Child, Preschool; Colombia; Female; Humans | 2009 |
Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Drug | 2010 |
A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand.
Topics: Adolescent; Adult; Animals; Antimalarials; Dose-Response Relationship, Drug; Drug Administration Sch | 2010 |
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Dr | 2010 |
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Dr | 2010 |
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Dr | 2010 |
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Dr | 2010 |
Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border.
Topics: Adolescent; Antimalarials; Child; Child, Preschool; Chloroquine; Directly Observed Therapy; Female; | 2010 |
Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.
Topics: Adult; Animals; Antimalarials; Chloroquine; Duffy Blood-Group System; Female; Fever; Humans; Malaria | 2011 |
Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.
Topics: Adult; Animals; Antimalarials; Chloroquine; Duffy Blood-Group System; Female; Fever; Humans; Malaria | 2011 |
Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.
Topics: Adult; Animals; Antimalarials; Chloroquine; Duffy Blood-Group System; Female; Fever; Humans; Malaria | 2011 |
Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.
Topics: Adult; Animals; Antimalarials; Chloroquine; Duffy Blood-Group System; Female; Fever; Humans; Malaria | 2011 |
Evaluation of the safety and tolerability of a short higher-dose primaquine regimen for presumptive anti-relapse therapy in healthy subjects.
Topics: Abdominal Pain; Adult; Antimalarials; Cyanosis; Drug Administration Schedule; Female; Headache; Huma | 2011 |
Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Chronic Disease; Female; Genotype; Genotyping Techniq | 2012 |
Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age.
Topics: Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Therapy, Combination; Female; Humans | 2012 |
Therapeutic efficacy of artemether-lumefantrine for Plasmodium vivax infections in a prospective study in Guyana.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Ch | 2012 |
Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia.
Topics: Adult; Antimalarials; Artemisinins; Artesunate; Drug Administration Schedule; Drug Dosage Calculatio | 2013 |
In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Therapy, Combinat | 2013 |
Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Endemic Diseases; F | 2002 |
Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand.
Topics: Administration, Oral; Adolescent; Animals; Antimalarials; Artemisinins; Artesunate; Drug Administrat | 2003 |
Compliance with 14-day primaquine therapy for radical cure of vivax malaria--a randomized placebo-controlled trial comparing unsupervised with supervised treatment.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Cluster Analysis; Directly Observed | 2004 |
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Fe | 2004 |
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Fe | 2004 |
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Fe | 2004 |
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Fe | 2004 |
Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Artesunate; Child; Chloroquine; Drug Resist | 2004 |
Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army.
Topics: Antimalarials; Chemoprevention; Chloroquine; Disease Outbreaks; Humans; Incidence; Korea; Malaria, V | 2005 |
A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria in India.
Topics: Adult; Aged; Animals; Antimalarials; Azithromycin; Chloroquine; Double-Blind Method; Drug Administra | 2005 |
Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand.
Topics: Adolescent; Adult; Animals; Antimalarials; Chloroquine; Female; Humans; Malaria, Vivax; Male; Middle | 2006 |
Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia.
Topics: Adult; Animals; Antimalarials; Chloroquine; Colombia; Female; Follow-Up Studies; Humans; Malaria, Vi | 2006 |
[Plasmodium vivax malaria: treatment of primary attacks with primaquine, in three different doses, and a fixed dose of chloroquine, Antioquia, Colombia, 2003-2004].
Topics: Acute Disease; Adult; Antimalarials; Chloroquine; Colombia; Female; Humans; Malaria, Vivax; Male; Pr | 2006 |
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; DNA Primers; Humans; India; Malaria, | 2007 |
Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.
Topics: Adolescent; Aged; Animals; Antimalarials; Artemether; Artemisinins; Chloroquine; Drug Therapy, Combi | 2007 |
High-dose primaquine regimens against relapse of Plasmodium vivax malaria.
Topics: Adolescent; Adult; Antimalarials; Dose-Response Relationship, Drug; Drug Administration Schedule; Fe | 2008 |
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Administration Schedule; Hu | 1995 |
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Administration Schedule; Hu | 1995 |
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Administration Schedule; Hu | 1995 |
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Administration Schedule; Hu | 1995 |
Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia.
Topics: Adolescent; Adult; Animals; Anopheles; Child; Chloroquine; Confounding Factors, Epidemiologic; Drug | 1995 |
Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers.
Topics: Adolescent; Adult; Aged; Child; Chloroquine; Drug Therapy, Combination; Female; Germany; Humans; Mal | 1995 |
Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine.
Topics: Adolescent; Animals; Child; Chloroquine; Drug Administration Schedule; Drug Resistance; Drug Therapy | 1995 |
Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Animals; Chloroquine; Drug Resistance; Drug Therapy, Combination; Follow-Up Studi | 1994 |
[Halofantrine in the treatment of imported malaria in nonimmune travelers].
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Drug Therapy, Combination; Drug Tolerance; Female; | 1993 |
Recent military experience with malaria chemoprophylaxis.
Topics: Antimalarials; Australia; Chloroquine; Dapsone; Doxycycline; Drug Administration Schedule; Drug Comb | 1993 |
Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis.
Topics: Antimalarials; Chloroquine; Disease Susceptibility; Follow-Up Studies; Humans; Incidence; Indonesia; | 1997 |
Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia.
Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Follow-Up Studies; Humans; Indonesia; | 1997 |
Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antimalarials; Colombia; Double-Blind Method; Gastrointestinal Diseases; Humans; | 1998 |
The effect of drug packaging on patients' compliance with treatment for Plasmodium vivax malaria in China.
Topics: Adolescent; Adult; Analysis of Variance; Antimalarials; China; Chloroquine; Drug Packaging; Female; | 1998 |
Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers.
Topics: Antimalarials; Chloroquine; Colombia; Double-Blind Method; Humans; Malaria; Malaria, Falciparum; Mal | 1999 |
Chloroquine sensitivity of Plasmodium vivax in Thailand.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Humans; Mala | 1999 |
Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug R | 1999 |
Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections.
Topics: Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Combination; Humans; India; | 1999 |
Plasmodium vivax clinically resistant to chloroquine in Colombia.
Topics: Animals; Antimalarials; Chloroquine; Colombia; Drug Therapy, Combination; Humans; Malaria, Vivax; Ma | 2001 |
Plasmodium vivax clinically resistant to chloroquine in Colombia.
Topics: Animals; Antimalarials; Chloroquine; Colombia; Drug Therapy, Combination; Humans; Malaria, Vivax; Ma | 2001 |
Plasmodium vivax clinically resistant to chloroquine in Colombia.
Topics: Animals; Antimalarials; Chloroquine; Colombia; Drug Therapy, Combination; Humans; Malaria, Vivax; Ma | 2001 |
Plasmodium vivax clinically resistant to chloroquine in Colombia.
Topics: Animals; Antimalarials; Chloroquine; Colombia; Drug Therapy, Combination; Humans; Malaria, Vivax; Ma | 2001 |
Plasmodium vivax polymorphism in a clinical drug trial.
Topics: Administration, Oral; Animals; Antimalarials; Double-Blind Method; Drug Administration Schedule; Dru | 2001 |
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
Topics: Aminoquinolines; Antimalarials; Australia; Controlled Clinical Trials as Topic; Endemic Diseases; Hu | 2001 |
Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India.
Topics: Antimalarials; Drug Administration Schedule; Follow-Up Studies; Humans; India; Malaria, Vivax; Prima | 2001 |
327 other studies available for primaquine and Plasmodium vivax Malaria
| Article | Year |
|---|---|
Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antimalarials; Body Weight; Child; Child, P | 2021 |
The acceptability of targeted mass treatment with primaquine for local elimination of vivax malaria in a northern Myanmar township: a mixed-methods study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Cross-Sectional Studies; Disease Eradicat | 2021 |
Primaquine and the power of adherence in radical cure.
Topics: Humans; Malaria, Vivax; Plasmodium vivax; Primaquine | 2022 |
A Profile of Glucose-6-Phosphate Dehydrogenase Variants and Deficiency of Multicultural Families in Korea.
Topics: Adolescent; Antimalarials; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency | 2021 |
Frequency of Electrocardiographic Alterations and Pericardial Effusion in Patients With Uncomplicated Malaria.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Brazil; Case-Control Studies; Chlor | 2022 |
Measurements of 5,6-Orthoquinone, a Surrogate for the Presumed Active Primaquine Metabolite 5-Hydroxyprimaquine, in the Urine of Cambodian Adults.
Topics: Adult; Antimalarials; Asian People; Cytochrome P-450 CYP2D6; Humans; Malaria, Vivax; Plasmodium viva | 2022 |
Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine.
Topics: Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; Malaria, Vivax; Plasmodiu | 2022 |
Active Pharmacovigilance for Primaquine Radical Cure of Plasmodium vivax Malaria in Odisha, India.
Topics: Antimalarials; Chloroquine; Female; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Hemolysi | 2022 |
Prevalence of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency among Malaria Patients in Southern Thailand: 8 Years Retrospective Study.
Topics: Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; Malaria, | 2022 |
Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function.
Topics: Antimalarials; Cytochrome P-450 CYP2D6; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; | 2022 |
Real-life quantitative G6PD screening in Plasmodium vivax patients in the Brazilian Amazon: A cost-effectiveness analysis.
Topics: Antimalarials; Brazil; Cost-Benefit Analysis; Glucosephosphate Dehydrogenase Deficiency; Humans; Mal | 2022 |
Primaquine and
Topics: Antimalarials; Brazil; Humans; Malaria, Vivax; Primaquine; Reinfection | 2022 |
Recurrence in
Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium | 2022 |
Recurrence in
Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium | 2022 |
Recurrence in
Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium | 2022 |
Recurrence in
Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium | 2022 |
Cost-effectiveness analysis of G6PD diagnostic test for Plasmodium vivax radical cure in Lao PDR: An economic modelling study.
Topics: Antimalarials; Cost-Benefit Analysis; Diagnostic Tests, Routine; Female; Glucosephosphate Dehydrogen | 2022 |
Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study.
Topics: Antimalarials; Cohort Studies; Humans; Malaria, Vivax; Primaquine; Recurrence | 2022 |
Tafenoquine for the prevention of Plasmodium vivax malaria relapse.
Topics: Aminoquinolines; Humans; Malaria, Vivax; Primaquine; Recurrence | 2021 |
Variation in Glucose-6-Phosphate Dehydrogenase activity following acute malaria.
Topics: Antimalarials; Cross-Sectional Studies; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogena | 2022 |
Mechanisms of 8-aminoquinoline induced haemolytic toxicity in a G6PDd humanized mouse model.
Topics: Aminoquinolines; Animals; Antimalarials; Disease Models, Animal; Glucosephosphate Dehydrogenase Defi | 2022 |
Cost-Benefit Analysis of Tafenoquine for Radical Cure of
Topics: Aminoquinolines; Antimalarials; Cost-Benefit Analysis; Humans; Malaria, Vivax; Primaquine; Recurrenc | 2022 |
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2022 |
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2022 |
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply.
Topics: Antimalarials; Chronic Disease; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2022 |
Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency.
Topics: Antimalarials; Female; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; He | 2023 |
An Evaluation of a New Quantitative Point-of Care Diagnostic to Measure Glucose-6-phosphate Dehydrogenase Activity.
Topics: Antimalarials; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Ma | 2022 |
Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre, Eastern Ethiopia.
Topics: Antimalarials; Cross-Sectional Studies; Ethiopia; Female; Glucosephosphate Dehydrogenase Deficiency; | 2022 |
How does primaquine prevent Plasmodium vivax malarial recurrences?
Topics: Animals; Antimalarials; Malaria, Vivax; Mice; Plasmodium vivax; Primaquine; Recurrence | 2022 |
Glucose 6 Phosphate Dehydrogenase (G6PD) quantitation using biosensors at the point of first contact: a mixed method study in Cambodia.
Topics: Antimalarials; Biosensing Techniques; Cambodia; Glucosephosphate Dehydrogenase; Glucosephosphate Deh | 2022 |
Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients.
Topics: Antimalarials; Cytochrome P-450 CYP2D6; Cytochrome P450 Family 2; Humans; Malaria, Vivax; Phenotype; | 2022 |
G6PD testing and radical cure for Plasmodium vivax in Cambodia: A mixed methods implementation study.
Topics: Adult; Antimalarials; Cambodia; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Defic | 2022 |
Moving towards malaria elimination with safer treatment for children with G6PD deficiency.
Topics: Child; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; M | 2023 |
Moving towards malaria elimination with safer treatment for children with G6PD deficiency.
Topics: Child; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; M | 2023 |
Moving towards malaria elimination with safer treatment for children with G6PD deficiency.
Topics: Child; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; M | 2023 |
Moving towards malaria elimination with safer treatment for children with G6PD deficiency.
Topics: Child; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; M | 2023 |
Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.
Topics: Antimalarials; Cytochrome P-450 CYP2D6; Genetic Variation; Glucosephosphate Dehydrogenase; Hemolysis | 2022 |
Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.
Topics: Antimalarials; Cytochrome P-450 CYP2D6; Genetic Variation; Glucosephosphate Dehydrogenase; Hemolysis | 2022 |
Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.
Topics: Antimalarials; Cytochrome P-450 CYP2D6; Genetic Variation; Glucosephosphate Dehydrogenase; Hemolysis | 2022 |
Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.
Topics: Antimalarials; Cytochrome P-450 CYP2D6; Genetic Variation; Glucosephosphate Dehydrogenase; Hemolysis | 2022 |
Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function.
Topics: Antimalarials; Australia; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Malaria; Mal | 2023 |
Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function.
Topics: Antimalarials; Australia; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Malaria; Mal | 2023 |
Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function.
Topics: Antimalarials; Australia; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Malaria; Mal | 2023 |
Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function.
Topics: Antimalarials; Australia; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Malaria; Mal | 2023 |
Blood-stage antiplasmodial activity and oocyst formation-blockage of metallo copper-cinchonine complex.
Topics: Animals; Antimalarials; Chloroquine; Copper; Malaria, Falciparum; Malaria, Vivax; Mice; Oocysts; Par | 2022 |
Performance of a Commercial Multiplex Allele-Specific Polymerase Chain Reaction Kit to Genotype African-Type Glucose-6-Phosphate Dehydrogenase Deficiency.
Topics: Alleles; Antimalarials; Female; Genotype; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydroge | 2023 |
Community acceptability, participation, and adherence to mass drug administration with primaquine for Plasmodium vivax elimination in Southern Thailand: a mixed methods approach.
Topics: Antimalarials; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Female; Hum | 2023 |
Single-Nucleotide Polymorphisms in Glucose-6-Phosphate Dehydrogenase and their Relevance for the Deployment of Primaquine as a Radical Cure for Malaria.
Topics: Antimalarials; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Ma | 2023 |
Novel Transmission-Blocking Antimalarials Identified by High-Throughput Screening of Plasmodium berghei Ookluc.
Topics: Animals; Antimalarials; Culicidae; High-Throughput Screening Assays; Humans; Malaria; Malaria, Falci | 2023 |
Factors hindering coverage of targeted mass treatment with primaquine in a malarious township of northern Myanmar in 2019-2020.
Topics: Antimalarials; Child; Child, Preschool; Cross-Sectional Studies; Glucosephosphate Dehydrogenase Defi | 2023 |
Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response.
Topics: Antimalarials; Chloroquine; Ethiopia; Humans; Malaria, Vivax; Parasitemia; Plasmodium vivax; Primaqu | 2023 |
Prevalence of G6PD deficiency and diagnostic accuracy of a G6PD point-of-care test among a population at risk of malaria in Myanmar.
Topics: Cross-Sectional Studies; Genotype; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase De | 2023 |
Adherence to 14-day radical cure for Plasmodium vivax malaria in Papua, Indonesia: a mixed-methods study.
Topics: Antimalarials; Humans; Indonesia; Malaria; Malaria, Vivax; Plasmodium vivax; Primaquine | 2023 |
Short-course, high-dose primaquine regimens for the treatment of liver-stage vivax malaria in children.
Topics: Antimalarials; Child; Humans; Liver; Malaria, Vivax; Plasmodium vivax; Primaquine; Treatment Outcome | 2023 |
Transmission-blocking activity of antimalarials for Plasmodium vivax malaria in Anopheles darlingi.
Topics: Animals; Anopheles; Antimalarials; Chloroquine; Humans; Malaria; Malaria, Vivax; Plasmodium vivax; P | 2023 |
Primaquine and chloroquine nano-sized solid dispersion-loaded dissolving microarray patches for the improved treatment of malaria caused by Plasmodium vivax.
Topics: Animals; Antimalarials; Chloroquine; Malaria, Vivax; Mice; Plasmodium vivax; Primaquine; Rats | 2023 |
Severe Hemolysis during Primaquine Radical Cure of Plasmodium vivax Malaria: Two Systematic Reviews and Individual Patient Data Descriptive Analyses.
Topics: Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Malaria, Vivax; Plasmod | 2023 |
A fatal respiratory complication of malaria caused by Plasmodium vivax.
Topics: Adult; Antimalarials; Female; Humans; Malaria; Malaria, Vivax; Plasmodium vivax; Primaquine | 2023 |
Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders.
Topics: Antimalarials; Humans; Malaria; Malaria, Vivax; Medication Adherence; Myanmar; Plasmodium vivax; Pri | 2023 |
Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis.
Topics: Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Primaquine | 2023 |
Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Cytochrome P-450 CYP2D6; Ghana; Humans; Inacti | 2019 |
Killing of Plasmodium vivax by Primaquine and Tafenoquine.
Topics: Aminoquinolines; Antimalarials; Humans; Hydrogen Peroxide; Malaria, Vivax; Plasmodium vivax; Primaqu | 2019 |
Cost-utility of tafenoquine vs. primaquine for the radical cure (prevention of relapse) of
Topics: Aminoquinolines; Antimalarials; Cost-Benefit Analysis; Humans; Malaria, Vivax; Markov Chains; Monte | 2020 |
Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency.
Topics: Adolescent; Adult; Antimalarials; Asian People; Chemoprevention; Child; Child, Preschool; Female; Gl | 2019 |
Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Ethiopia; Female | 2019 |
Multiple Splenic Infarcts Complicating Plasmodium vivax Malaria.
Topics: Acute Kidney Injury; Administration, Intravenous; Administration, Oral; Adolescent; Antimalarials; A | 2019 |
Declining Burden of
Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Retrospective Studies; Thailand | 2020 |
Vivax malaria in pregnancy and lactation: a long way to health equity.
Topics: Adolescent; Aminoquinolines; Anemia; Antimalarials; Artemether, Lumefantrine Drug Combination; Femal | 2020 |
Evaluation of the CareStart™ glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in the field settings and assessment of perceived risk from primaquine at the community level in Cambodia.
Topics: Adult; Cambodia; Diagnostic Tests, Routine; Female; Glucosephosphate Dehydrogenase; Glucosephosphate | 2020 |
Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.
Topics: Adolescent; Adult; Antibodies, Protozoan; Antimalarials; Brazil; Child; Cytochrome P-450 CYP2D6; Fem | 2020 |
Cost-Effectiveness Analysis of Sex-Stratified
Topics: Adult; Afghanistan; Aminoquinolines; Anemia, Hemolytic; Antimalarials; Chloroquine; Cost-Benefit Ana | 2020 |
Case Report: Primaquine Failure for Radical Cure of
Topics: Adult; Antimalarials; Chemoprevention; Chloroquine; Ethiopia; Humans; Malaria, Vivax; Male; Middle A | 2020 |
Prevalence of CYP2D6 Genotypes and Predicted Phenotypes in a Cohort of Cambodians at High Risk for Infections with
Topics: Antimalarials; Artemisinins; Asian People; Cambodia; Cytochrome P-450 CYP2D6; Drug Therapy, Combinat | 2020 |
Case report: recurrence of Plasmodium vivax malaria due to defective cytochrome P450 2D6 function in Pos Lenjang, Pahang, Malaysia.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Cytochrome P-450 CYP2D6 | 2020 |
Primaquine for Plasmodium vivax malaria treatment.
Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine | 2020 |
Primaquine for Plasmodium vivax malaria treatment - Authors' reply.
Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine | 2020 |
Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
Topics: Antimalarials; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Phenotype; Plasmodium vivax; | 2020 |
Increasing Malaria Parasite Clearance Time after Chloroquine Therapy, South Korea, 2000-2016.
Topics: Animals; Antimalarials; Chloroquine; Drug Therapy, Combination; Malaria; Malaria, Vivax; Parasites; | 2020 |
Doses of primaquine administered to children with
Topics: Adolescent; Antimalarials; Child; Child, Preschool; Drug Administration Schedule; Humans; Infant; Ma | 2020 |
Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil.
Topics: Adolescent; Adult; Antimalarials; Brazil; Case-Control Studies; Child; Chloroquine; Female; Humans; | 2020 |
Mass radical treatment of a group of foreign workers to mitigate the risk of re-establishment of malaria in Sri Lanka.
Topics: Antimalarials; Chloroquine; Humans; India; Malaria, Vivax; Mass Drug Administration; Plasmodium viva | 2020 |
Impact of Plasmodium vivax malaria and antimalarial treatment on cytochrome P450 activity in Brazilian patients.
Topics: Adult; Antimalarials; Brazil; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Humans; Malaria, Vi | 2021 |
Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Humans; Malaria, V | 2020 |
The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia.
Topics: Adolescent; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Administration Schedule; Drug | 2020 |
Liver-targeted polymeric prodrugs of 8-aminoquinolines for malaria radical cure.
Topics: Aminoquinolines; Animals; Antimalarials; Liver; Malaria; Malaria, Vivax; Mice; Mice, Inbred NOD; Mic | 2021 |
Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters.
Topics: Animals; Antimalarials; Humans; Liver; Malaria, Vivax; Parasites; Plasmodium vivax; Primaquine | 2021 |
Towards one standard treatment for uncomplicated Plasmodium falciparum and Plasmodium vivax malaria: Perspectives from and for the Peruvian Amazon.
Topics: Adult; Aminoquinolines; Artemisinins; Female; Humans; Malaria, Falciparum; Malaria, Vivax; Peru; Pla | 2021 |
Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study).
Topics: Antimalarials; Brazil; Glucosephosphate Dehydrogenase Deficiency; Health Personnel; Hemolysis; Human | 2021 |
Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Clinical Decision-Making; Cost Savings; C | 2021 |
Treatment of relapsing Plasmodium vivax malaria during pregnancy.
Topics: Aminoquinolines; Antimalarials; Female; Humans; Malaria, Vivax; Plasmodium vivax; Pregnancy; Primaqu | 2021 |
Evaluation of the effect of supervised anti-malarial treatment on recurrences of Plasmodium vivax malaria.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Malaria, Vivax; Male; Middle A | 2021 |
The mystery of 'saturation gap' and falsely normal G6PD: a case of primaquine-induced haemolysis in Plasmodium vivax malaria infection.
Topics: Antimalarials; Glucosephosphate Dehydrogenase; Hemolysis; Humans; Malaria; Malaria, Vivax; Primaquin | 2021 |
Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area.
Topics: Antimalarials; Chronic Disease; Humans; Malaria; Malaria, Vivax; Plasmodium ovale; Plasmodium vivax; | 2022 |
Genotypes and phenotypes of G6PD deficiency among Indonesian females across diagnostic thresholds of G6PD activity guiding safe primaquine therapy of latent malaria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Female; Gene Expression Regulation | 2021 |
Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases.
Topics: Adult; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Female; Humans; Malaria, Vivax; Ma | 2021 |
Case report of Plasmodium ovale curtisi malaria in Sri Lanka: relevance for the maintenance of elimination status.
Topics: Adult; Antimalarials; Chloroquine; Fever; Humans; Liberia; Malaria; Malaria, Vivax; Male; Molecular | 2017 |
Primaquine in Plasma and Methemoglobinemia in Patients with Malaria Due to
Topics: Adolescent; Adult; Antimalarials; Brazil; Chloroquine; Drug Administration Schedule; Drug Therapy, C | 2017 |
Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis.
Topics: Adult; Antimalarials; Cost-Benefit Analysis; Diagnostic Tests, Routine; Female; Glucosephosphate Deh | 2017 |
Molecular and immunological analyses of confirmed Plasmodium vivax relapse episodes.
Topics: Adolescent; Adult; Antimalarials; Cohort Studies; Drug Resistance; Follow-Up Studies; Genotype; Huma | 2017 |
G6PD deficiency alleles in a malaria-endemic region in the Western Brazilian Amazon.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Anemia, Hemolytic; Antimalarials; Brazil; Cross | 2017 |
An outbreak of locally acquired Plasmodium vivax malaria among migrant workers in Oman.
Topics: Adult; Animals; Anopheles; Antigens, Protozoan; Antimalarials; Chloroquine; Communicable Diseases, E | 2017 |
Barriers to routine G6PD testing prior to treatment with primaquine.
Topics: Administrative Personnel; Bangladesh; Cambodia; China; Diagnostic Tests, Routine; Glucosephosphate D | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co | 2017 |
Implementation of G6PD testing and primaquine for
Topics: Antimalarials; Cambodia; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; | 2017 |
Analysis of Plasmodium vivax Chloroquine Resistance Transporter Mutant Isoforms.
Topics: Amino Acid Substitution; Antimalarials; Biological Transport; Cell Membrane; Chloroquine; Colony Cou | 2017 |
SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria.
Topics: Adult; Antimalarials; Brazil; Chloroquine; Drug Therapy, Combination; Female; Genotype; Humans; Live | 2017 |
Malaria cases in Switzerland from 2005 to 2015 and recent rise of imported Plasmodium vivax malaria.
Topics: Eritrea; Humans; Incidence; Liechtenstein; Malaria, Vivax; Plasmodium vivax; Primaquine; Refugees; S | 2017 |
A clinical tool to predict Plasmodium vivax recurrence in Malaysia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antimalarials; Area Under Curve; Child; Chi | 2017 |
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
Topics: Antimalarials; Asia, Southeastern; Cytochrome P-450 CYP2D6; Glucosephosphate Dehydrogenase Deficienc | 2018 |
CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
Topics: Adolescent; Adult; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Cytochrome P-450 CYP | 2018 |
Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures.
Topics: Adolescent; Adult; Antimalarials; Area Under Curve; Breast Feeding; Child, Preschool; Female; Humans | 2018 |
Expanding the Use of Primaquine for the Radical Cure of Plasmodium vivax.
Topics: Antimalarials; Female; Humans; Infant; Lactation; Malaria, Vivax; Plasmodium vivax; Primaquine | 2018 |
Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency | 2018 |
Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood.
Topics: Adult; Aminoquinolines; Antimalarials; Area Under Curve; Biosensing Techniques; Clinical Enzyme Test | 2018 |
A Malaria Case Followed By Relapse.
Topics: Animals; Anopheles; Antimalarials; Chronic Disease; Diagnosis, Differential; Humans; Malaria, Vivax; | 2018 |
Primaquine 30 mg/day versus 15 mg/day during 14 days for the prevention of Plasmodium vivax relapses in adults in French Guiana: a historical comparison.
Topics: Adult; Antimalarials; Dose-Response Relationship, Drug; Female; French Guiana; Humans; Malaria, Viva | 2018 |
Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group.
Topics: Antimalarials; Asia; Humans; Malaria, Vivax; Pacific Islands; Plasmodium vivax; Primaquine; Treatmen | 2018 |
Improving Plasmodium vivax malaria treatment: a little more chloroquine.
Topics: Antimalarials; Chloroquine; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine | 2018 |
Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities.
Topics: Africa; Aminoquinolines; Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency; Health Kn | 2019 |
A 38-year-old man with fever and a history of malaria.
Topics: Adult; Antimalarials; Chloroquine; Diagnosis, Differential; Fever; Humans; Malaria, Vivax; Male; Pri | 2018 |
Levels of primaquine and carboxyprimaquine in patients with malaria vivax from the Brazilian Amazon basin.
Topics: Adult; Antimalarials; Brazil; Chromatography, High Pressure Liquid; Drug Administration Schedule; Dr | 2018 |
G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Female; Glucosephosphate Dehydrogenase Deficiency; He | 2018 |
Concomitant
Topics: Adult; Anti-Bacterial Agents; Antimalarials; Chloroquine; Coinfection; Female; Fever; Humans; Malari | 2018 |
Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
Topics: Adult; Antimalarials; Case-Control Studies; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Malar | 2018 |
Tafenoquine - A Radical Improvement?
Topics: Aminoquinolines; Humans; Malaria, Vivax; Primaquine; Recurrence | 2019 |
Evaluation of Plasmodium vivax malaria recurrence in Brazil.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Brazil; Child; Child, Presc | 2019 |
Clinical Spectrum of Primaquine-induced Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficiency: A 9-Year Hospitalization-based Study From the Brazilian Amazon.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antimalarials; Brazil; Child; Child, Preschool; | 2019 |
Factors associated with children's health facility visits for primaquine treatment in rural Papua New Guinea.
Topics: Adolescent; Adult; Antimalarials; Child; Child Health; Child, Preschool; Cross-Sectional Studies; Fe | 2019 |
Five cases of Plasmodium vivax malaria treated with artemisinin derivatives: the advantages of a unified approach to treatment.
Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Italy; Malaria, Vivax | 2019 |
Prevalence of G6PD Viangchan variant in malaria endemic areas in Lao PDR: an implication for malaria elimination by 2030.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Disease Eradication; Female; Ge | 2019 |
Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Chronic Disease; Drug Therapy, Combination; Female; F | 2019 |
Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia.
Topics: Antimalarials; Female; Hematologic Diseases; Hemolysis; Humans; Indonesia; Infant; Infant, Newborn; | 2019 |
Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
Topics: Alleles; Antimalarials; Australia; Cytochrome P-450 CYP2D6; Humans; Malaria, Vivax; Military Personn | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply.
Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence | 2019 |
Plasmodium vivax morbidity after radical cure: A cohort study in Central Vietnam.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedule | 2019 |
A shorter course for anti-relapse therapy against vivax malaria.
Topics: Antimalarials; Chronic Disease; Humans; Malaria, Vivax; Primaquine; Recurrence | 2019 |
Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria.
Topics: Adult; Antimalarials; Biotransformation; Chloroquine; Drug Tolerance; Genome, Protozoan; High-Throug | 2013 |
Assessment of the efficacy of 8 weeks of primaquine for the prevention of relapse in vivax malaria patients using SSCP-PCR and sequencing in South and South-East Iran, 2008-2011.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; DNA, Protozoan; Drug Administration Sched | 2013 |
Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report.
Topics: Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; Primaqu | 2014 |
The burden of Plasmodium vivax relapses in an Amerindian village in French Guiana.
Topics: Antimalarials; Child; Child, Preschool; Cohort Studies; Drug Prescriptions; Female; Follow-Up Studie | 2013 |
Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria.
Topics: Antimalarials; Child; Drug Administration Schedule; Female; Humans; Malaria, Vivax; Male; Primaquine | 2014 |
Population structure and spatio-temporal transmission dynamics of Plasmodium vivax after radical cure treatment in a rural village of the Peruvian Amazon.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Cohort Studies; Female; Gene | 2014 |
Paucity of Plasmodium vivax mature schizonts in peripheral blood is associated with their increased cytoadhesive potential.
Topics: Antimalarials; Cell Adhesion; Chloroquine; Erythrocytes; Humans; Malaria, Vivax; Parasitemia; Plasmo | 2014 |
Hemophagocytic syndrome associated with severe Plasmodium vivax malaria in a child in Bikaner (northwestern India).
Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Biopsy, Needle; Bone Marrow; Child; Ethanolamin | 2013 |
A population survey of the glucose-6-phosphate dehydrogenase (G6PD) 563C>T (Mediterranean) mutation in Afghanistan.
Topics: Afghanistan; DNA Primers; Genotype; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase D | 2014 |
Validation of a method for the simultaneous quantification of chloroquine, desethylchloroquine and primaquine in plasma by HPLC-DAD.
Topics: Calibration; Chloroquine; Chromatography, High Pressure Liquid; Humans; Limit of Detection; Malaria, | 2014 |
Improving the radical cure of Plasmodium vivax malaria.
Topics: Antimalarials; Chloroquine; Female; Humans; Malaria, Vivax; Male; Primaquine | 2014 |
Performance of the CareStart glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in Gressier, Haiti.
Topics: Adolescent; Antimalarials; Child; Contraindications; Enzyme Assays; Female; Glucosephosphate Dehydro | 2014 |
Imported malaria is stable from Africa but declining from Asia.
Topics: Adolescent; Adult; Africa; Aged; Antimalarials; Asia; Atovaquone; Chemoprevention; Child; Child, Pre | 2014 |
Quality of antimalarial drugs and antibiotics in Papua New Guinea: a survey of the health facility supply chain.
Topics: Amodiaquine; Amoxicillin; Antimalarials; Artemether; Artemisinins; Biosimilar Pharmaceuticals; Chlor | 2014 |
First evaluation of glucose-6-phosphate dehydrogenase (G6PD) deficiency in vivax malaria endemic regions in the Republic of Korea.
Topics: Base Sequence; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Molecular Sequence | 2014 |
High frequency of diabetes and impaired fasting glucose in patients with glucose-6-phosphate dehydrogenase deficiency in the Western brazilian Amazon.
Topics: Adolescent; Adult; Aged; Antimalarials; Blood Glucose; Brazil; Child; Contraindications; Diabetes Co | 2014 |
Hemophagocytic syndrome in Plasmodium vivax malaria.
Topics: Artemisinins; Ceftriaxone; Child; Female; Hemoglobins; Humans; India; Leukocyte Count; Lymphohistioc | 2014 |
Compliance to recommendations for the management of curative treatment of Plasmodium vivax/ovale infections.
Topics: Adolescent; Adult; Antimalarials; Child; Chloroquine; Guideline Adherence; Humans; Malaria; Malaria, | 2014 |
[Two imported and relapsed of Plasmodium vivax malaria cases and primaquine prophylaxis].
Topics: Antimalarials; Chloroquine; Humans; Life Cycle Stages; Liver; Malaria, Vivax; Male; Plasmodium vivax | 2014 |
Imported malaria in a non-endemic area: the experience of the university of Campinas hospital in the Brazilian Southeast.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anemia; Antimalarials; Artemether; Artemisini | 2014 |
Primaquine-induced severe methemoglobinemia developed during treatment of Plasmodium vivax malarial infection in an Indian family associated with a novel mutation (p.Agr57Trp) in the CYB5R3 gene.
Topics: Adolescent; Adult; Cytochrome-B(5) Reductase; Female; Humans; India; Malaria, Vivax; Male; Methemogl | 2014 |
Evaluation of antimalarial activity and toxicity of a new primaquine prodrug.
Topics: Aedes; Animals; Antimalarials; Cell Line; Chloroquine; Dipeptides; Glucosephosphate Dehydrogenase; H | 2014 |
Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta).
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Administration Schedule; Drug Ther | 2014 |
Interactive medical case. A chilly fever.
Topics: Adult; Antimalarials; Chloroquine; Diagnosis, Differential; Fever; Humans; Life Cycle Stages; Malari | 2014 |
The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea.
Topics: Antimalarials; Doxycycline; Female; Humans; Malaria, Vivax; Middle Aged; New Zealand; Papua New Guin | 2014 |
Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Female; Genotype; Huma | 2015 |
Suitability of capillary blood for quantitative assessment of G6PD activity and performances of G6PD point-of-care tests.
Topics: Aminoquinolines; Antimalarials; Capillaries; Clinical Enzyme Tests; Erythrocytes; Female; Glucosepho | 2015 |
G6PD deficiency at Sumba in Eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing Vivax malaria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antimalarials; Child; Child, Preschool; Female; | 2015 |
Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo.
Topics: Aged; Animals; Antimalarials; Artemisinins; Artesunate; Chloroquine; Female; Humans; Liver; Malaria, | 2015 |
Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice.
Topics: Animals; Antimalarials; Chemoprevention; Chimera; Disease Models, Animal; Humans; Liver; Malaria, Vi | 2015 |
G6PD deficiency in male individuals infected by Plasmodium vivax malaria in the Brazilian Amazon: a cost study.
Topics: Antimalarials; Brazil; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Male; Plas | 2015 |
Primaquine dosing errors: the human cost of a pharmaceutical anachronism.
Topics: Adult; Antimalarials; Chemoprevention; Cohort Studies; Dosage Forms; Female; Humans; Israel; Malaria | 2015 |
Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Coinfection; Drug Therapy, Combination; Female; | 2015 |
Patients' adherence and clinical effectiveness of a 14-day course of primaquine when given with a 3-day chloroquine in patients with Plasmodium vivax at the Thai-Myanmar border.
Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Humans; Malaria, Vivax; Male; | 2015 |
Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency.
Topics: Adolescent; Adult; Anemia, Hemolytic; Antimalarials; Blood Transfusion; Cambodia; Child; Comorbidity | 2015 |
The challenges of introducing routine G6PD testing into radical cure: a workshop report.
Topics: Antimalarials; Female; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Hu | 2015 |
Efficacy in the treatment of malaria by Plasmodium vivax in Oiapoque, Brazil, on the border with French Guiana: the importance of control over external factors.
Topics: Adolescent; Adult; Antimalarials; Brazil; Child; Chloroquine; Drug Therapy, Combination; Female; Fre | 2015 |
Repeated Plasmodium vivax malaria relapses in a Peruvian sailor.
Topics: Adult; Antimalarials; Body Weight; Genotype; Genotyping Techniques; Humans; Malaria, Vivax; Male; Mi | 2015 |
Point-of-care G6PD diagnostics for Plasmodium vivax malaria is a clinical and public health urgency.
Topics: Antimalarials; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Ma | 2015 |
Fatal Primaquine-Induced Hemolysis in a Patient With Plasmodium vivax Malaria and G6PD A(-) Variant in the Brazilian Amazon.
Topics: Antimalarials; Brazil; Fatal Outcome; Genetic Diseases, X-Linked; Glucosephosphate Dehydrogenase; Gl | 2016 |
UK malaria treatment guidelines 2016.
Topics: Adult; Antimalarials; Artemisinins; Artesunate; Breast Feeding; Child; Child, Preschool; Female; Hum | 2016 |
Validation of G6PD Point-of-Care Tests among Healthy Volunteers in Yangon, Myanmar.
Topics: Adult; Antimalarials; Equipment Design; Female; Fluorescence; Glucosephosphate Dehydrogenase; Glucos | 2016 |
Prospective Study of Plasmodium vivax Malaria Recurrence after Radical Treatment with a Chloroquine-Primaquine Standard Regimen in Turbo, Colombia.
Topics: Antimalarials; Chloroquine; Colombia; Humans; Kaplan-Meier Estimate; Malaria, Vivax; Plasmodium viva | 2016 |
Factors associated with non-adherence to the treatment of vivax malaria in a rural community from the Brazilian Amazon Basin.
Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Chloroquine; Female; Humans; Malaria, Vivax; Male; M | 2016 |
Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India.
Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Glucosephosphate Dehydrogenase | 2016 |
Changes in serum lipid profile in the acute and convalescent Plasmodium vivax malaria: A cohort study.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Cholesterol; Cholesterol, HD | 2016 |
Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses.
Topics: Adolescent; Adult; Antimalarials; Child; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2D6; Female; G | 2016 |
Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil.
Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Drug Therapy, | 2016 |
High Efficacy of Primaquine Treatment for Plasmodium vivax in Western Thailand.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Dose-Response Relationship, Drug; Drug Resistance; Fe | 2016 |
Plasmodium vivax Malaria in Cambodia.
Topics: Adolescent; Adult; Antimalarials; Cambodia; Child; Child, Preschool; Disease Outbreaks; Female; Gluc | 2016 |
Rapid diagnostic test for G6PD deficiency in Plasmodium vivax-infected men: a budget impact analysis based in Brazilian Amazon.
Topics: Antimalarials; Brazil; Budgets; Decision Support Techniques; Diagnostic Techniques and Procedures; G | 2017 |
A Curious Case of "Septic Shock".
Topics: Adult; Anti-Bacterial Agents; Antimalarials; Artemisinins; Artesunate; Ceftriaxone; Drug Combination | 2017 |
Synthesis of primaquine glyco-conjugates as potential tissue schizontocidal antimalarial agents.
Topics: Animals; Antimalarials; Female; Glycoconjugates; Macaca mulatta; Malaria; Malaria, Vivax; Male; Mice | 2017 |
Modelling primaquine-induced haemolysis in G6PD deficiency.
Topics: Anemia, Hemolytic; Antimalarials; Bayes Theorem; Cell Death; Erythrocytes; Female; Glucosephosphate | 2017 |
[Plasmodium vivax malaria in the Brazilian Amazon: some aspects of its epidemiology, clinical spectrum and naturally induced immune responses].
Topics: Animals; Antibodies, Protozoan; Antimalarials; Brazil; Chloroquine; Drug Resistance; Humans; Immunit | 2008 |
Recurrence rate of vivax malaria in the Republic of Korea.
Topics: Adult; Antimalarials; Drug Administration Schedule; Humans; Malaria, Vivax; Male; Military Personnel | 2009 |
The participation of secondary clinical episodes in the epidemiology of vivax malaria during pre- and post-implementation of focal control in the state of Oaxaca, Mexico.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Cohort Studies; Drug T | 2009 |
[Malaria--current diagnosis and therapy].
Topics: Antimalarials; Blood; Developing Countries; Diagnosis, Differential; Female; Humans; Malaria, Vivax; | 2009 |
Clinical and laboratory features of human Plasmodium knowlesi infection.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Blood Chemical Analysis; Chloroquine; Female; Hemog | 2009 |
Biological resistance of hydroxychloroquine for Plasmodium vivax malaria in the Republic of Korea.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Hydroxychloroquine; Korea; Mala | 2009 |
Determination of the Plasmodium vivax relapse pattern in Camopi, French Guiana.
Topics: Animals; Antimalarials; Chloroquine; Cohort Studies; Female; Follow-Up Studies; French Guiana; Human | 2009 |
Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia.
Topics: Animals; Antimalarials; Brazil; Chloroquine; Drug Resistance; Haplotypes; Humans; Malaria, Vivax; Mi | 2009 |
Retinal hemorrhage in Plasmodium vivax malaria.
Topics: Antimalarials; Chloroquine; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; Primaquine; | 2010 |
Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimalarials; Child; Child, Preschool; Cultura | 2010 |
Primaquine administration after falciparum malaria treatment in malaria hypoendemic areas with high incidence of falciparum and vivax mixed infection: pros and cons.
Topics: Antimalarials; Cost-Benefit Analysis; Endemic Diseases; Humans; Incidence; Malaria, Falciparum; Mala | 2010 |
Severe Plasmodium vivax malaria, Brazilian Amazon.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Brazil; Child; Child, Preschool; Chloroqu | 2010 |
First autochthonous malaria case due to Plasmodium vivax since eradication, Spain, October 2010.
Topics: Adult; Antimalarials; Chloroquine; Endemic Diseases; Humans; Malaria, Vivax; Microscopy; Plasmodium | 2010 |
[A case of malarial hepatitis by Plasmodium vivax].
Topics: Abdomen; Antimalarials; Erythrocytes; Fatigue; Hepatitis; Humans; Malaria, Vivax; Male; Mefloquine; | 2010 |
Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria.
Topics: Animals; Anopheles; Antimalarials; Carcinoma, Hepatocellular; Cryopreservation; Disease Models, Anim | 2010 |
The reality of using primaquine.
Topics: Adult; Antimalarials; Chloroquine; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Mal | 2010 |
Auto-immune haemolytic anaemia concurrent with Plasmodium vivax infection: a case report.
Topics: Anemia, Hemolytic, Autoimmune; Antimalarials; Chloroquine; Humans; Immunosuppressive Agents; Infant; | 2011 |
Directly observed therapy with primaquine to reduce the recurrence rate of plasmodium vivax infection along the Thai-Myanmar border.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dir | 2011 |
Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Female; Humans; M | 2011 |
Resistance to chloroquine unhinges vivax malaria therapeutics.
Topics: Aminoquinolines; Antimalarials; Chloroquine; Drug Interactions; Drug Resistance; Humans; Malaria, Vi | 2011 |
Therapeutic efficacy of chloroquine in Plasmodium vivax and the pvmdr1 polymorphisms in the Republic of Korea under mass chemoprophylaxis.
Topics: Antimalarials; Chloroquine; Drug Resistance; Humans; Hydroxychloroquine; Malaria, Vivax; Multidrug R | 2011 |
Three unusual presentations of plasmodium vivax malaria.
Topics: Adult; Animals; Antimalarials; Artemisinins; Artesunate; Chloroquine; Female; Humans; Malaria, Vivax | 2011 |
Adherence to Plasmodium vivax malaria treatment in the Brazilian Amazon Region.
Topics: Adolescent; Adult; Aged; Brazil; Child; Child, Preschool; Chloroquine; Disease Transmission, Infecti | 2011 |
Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America.
Topics: Antimalarials; Chloroquine; Drug Resistance; Honduras; Humans; Malaria, Falciparum; Malaria, Vivax; | 2011 |
Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age.
Topics: Aging; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Cohort Studies | 2012 |
In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009-2010.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dru | 2011 |
Plasmodium vivax malaria presenting with skin rash--a case report.
Topics: Antimalarials; Child; Chloroquine; Exanthema; Female; Fever; Histamine Antagonists; Humans; Malaria, | 2011 |
Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses.
Topics: Adult; Antimalarials; DNA, Protozoan; Genotype; Humans; Malaria, Vivax; Male; Middle Aged; Oceania; | 2012 |
Plasmodium vivax remains responsive to chloroquine with primaquine treatment regimen: a prospective cohort study from tertiary care teaching hospital in southern India.
Topics: Adult; Antimalarials; Chloroquine; Cohort Studies; Drug Therapy, Combination; Female; Humans; Malari | 2012 |
Status of Plasmodium vivax malaria in the Republic of Korea, 2008-2009: decrease followed by resurgence.
Topics: Antimalarials; Chemoprevention; Disease Outbreaks; Drug Resistance; Female; Humans; Incidence; Malar | 2012 |
Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances.
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Evaluation, Preclinical; Macaca mu | 2012 |
Relapse of imported Plasmodium vivax malaria is related to primaquine dose: a retrospective study.
Topics: Adolescent; Adult; Aged; Antimalarials; Female; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodiu | 2012 |
Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil.
Topics: Adolescent; Adult; Animals; Antimalarials; Brazil; Female; Humans; Malaria, Vivax; Male; Middle Aged | 2012 |
New treatment policy of malaria as a part of malaria control program in Indonesia.
Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Disease Eradication; Drug Resistance; Drug Ther | 2012 |
[A case of vivax malaria with acute hemolysis from treatment of chloroquine combined with primaquine].
Topics: Antimalarials; Chloroquine; Hemolysis; Humans; Malaria, Vivax; Male; Primaquine; Young Adult | 2012 |
A local outbreak of autochthonous Plasmodium vivax malaria in Laconia, Greece--a re-emerging infection in the southern borders of Europe?
Topics: Adult; Aged; Animals; Anopheles; Antimalarials; Chloroquine; Communicable Diseases, Emerging; Diseas | 2013 |
The potential elimination of Plasmodium vivax malaria by relapse treatment: insights from a transmission model and surveillance data from NW India.
Topics: Antimalarials; Disease Eradication; Humans; India; Malaria, Vivax; Models, Statistical; Primaquine; | 2013 |
Control of malaria: a successful experience from Viet Nam.
Topics: Antimalarials; Bedding and Linens; Child; Child, Preschool; Communicable Disease Control; Female; He | 2002 |
A mathematical model for the transmission of Plasmodium vivax malaria.
Topics: Age Distribution; Animals; Chloroquine; Computer Simulation; Insect Vectors; Malaria, Vivax; Models, | 2003 |
Case report: An unusual late relapse of Plasmodium vivax malaria.
Topics: Animals; Antimalarials; Chloroquine; Diagnosis, Differential; DNA, Protozoan; Drug Administration Sc | 2003 |
Can primaquine therapy for vivax malaria be improved?
Topics: Animals; Antimalarials; Dose-Response Relationship, Drug; Glucosephosphate Dehydrogenase; Humans; Li | 2003 |
Toxicity related to chloroquine treatment of resistant vivax malaria.
Topics: Adult; Animals; Antimalarials; Atovaquone; Chloroquine; Drug Overdose; Humans; Malaria, Vivax; Male; | 2003 |
Prevalence of malaria in Aligarh.
Topics: Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Humans; India; | 2002 |
The clinical and epidemiological features of childhood malaria in a moderately endemic area of Sri Lanka.
Topics: Administration, Oral; Antimalarials; Arthralgia; Case-Control Studies; Child; Child Welfare; Child, | 2002 |
Efficacy of a five-day course of primaquine in preventing relapses in Plasmodium vivax malaria--a pilot study.
Topics: Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; | 2003 |
The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Resistance; Drug | 2003 |
Clinical efficacy of chloroquine followed by primaquine for Plasmodium vivax treatment in Azerbaijan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimalarials; Azerbaijan; Child; Chloroquine; | 2003 |
Studies in human malaria. XXXI. Comparison of primaquine, isopentaquine, SN-3883, and pamaquine as curative agents against Chesson strain vivax malaria.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria; Malaria, Vivax; Primaquine | 1953 |
Korean vivax malaria. II. Curative treatment with pamaquine and primaquine.
Topics: Aminoquinolines; Antimalarials; Asian People; Humans; Malaria; Malaria, Vivax; Primaquine | 1953 |
Korean vivax malaria. III. Curative effect and toxicity of primaquine in doses from 10 to 30 mg. daily.
Topics: Antimalarials; Asian People; Humans; Malaria; Malaria, Vivax; Primaquine | 1953 |
Korean vivax malaria. IV. Curative effect of 15 milligrams of primaquine daily for 7 days.
Topics: Antimalarials; Asian People; Humans; Malaria; Malaria, Vivax; Primaquine | 1953 |
Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency.
Topics: Antimalarials; Asian People; Humans; Malaria; Malaria, Vivax; Primaquine | 1953 |
Relapse of vivax malaria treated with primaquine and report of one case of cyanosis (methemoglobinemia) due to primaquine.
Topics: Antimalarials; Chronic Disease; Cyanosis; Humans; Malaria; Malaria, Vivax; Methemoglobinemia; Primaq | 1954 |
The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria.
Topics: Antimalarials; Chronic Disease; Humans; Malaria; Malaria, Vivax; Primaquine; Recurrence | 1954 |
Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine.
Topics: Antimalarials; Chloroquine; Humans; Malaria; Malaria, Vivax; Primaquine; Quinine | 1955 |
Vivax malaria: a continuing health threat to the Republic of Korea.
Topics: Antimalarials; Chloroquine; Communicable Diseases, Emerging; Geography; Humans; Incidence; Korea; Ma | 2003 |
Induced primaquine resistance in vivax malaria.
Topics: Antimalarials; Humans; Malaria; Malaria, Vivax; Plasmodium vivax; Primaquine | 1961 |
Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report.
Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Hemolysis; Humans; Malaria, Vivax; Male; Primaqu | 1960 |
A combination of amodiaquin and primaquine (camoprim) in the prevention and cure of sporozoite-induced Chesson strain vivax malaria.
Topics: Amodiaquine; Animals; Antimalarials; Biomedical Research; Humans; Malaria, Vivax; Primaquine; Sporoz | 1960 |
The concurrent weekly administration of chloroquine and primaquine for the prevention of Korean vivax malaria.
Topics: Antimalarials; Biomedical Research; Chloroquine; Humans; Malaria, Vivax; Primaquine | 1961 |
Primaquine and quinocide as curative agents against sporozoite-induced Chesson strain vivax malaria.
Topics: Aminoquinolines; Animals; Humans; Malaria; Malaria, Vivax; Primaquine; Quinolines; Sporozoites | 1962 |
LATENT INFECTIONS WITH PLASMODIUM OVALE MALARIA.
Topics: Africa, Western; Aminoquinolines; Canada; Chloroquine; Communicable Diseases; Diagnosis; Drug Therap | 1965 |
Correlation between Plasmodium vivax variants in Belém, Pará State, Brazil and symptoms and clearance of parasitaemia.
Topics: Animals; Antimalarials; Brazil; Chloroquine; Genetic Variation; Genotype; Humans; Malaria, Vivax; Pa | 2003 |
Primaquine for prevention of malaria in travelers.
Topics: Adult; Animals; Antimalarials; Chemoprevention; Clinical Trials as Topic; Drug Tolerance; Humans; Ma | 2003 |
Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand.
Topics: Aminoquinolines; Animals; Anopheles; Antimalarials; Artemisinins; Dose-Response Relationship, Drug; | 2003 |
Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria; Malaria, Vivax; Naphthalenes; Primaquine | 1950 |
Primaquine; a new drug for the radical cure of relapsing vivax malaria.
Topics: Humans; Malaria; Malaria, Vivax; Primaquine; Quinolines | 1952 |
Mass therapy of subclinical vivax malaria with primaquine.
Topics: Malaria; Malaria, Vivax; Primaquine; Quinolines; Uricosuric Agents | 1952 |
Cure of Korean vivax malaria with pamaquine and primaquine.
Topics: Aminoquinolines; Asian People; Humans; Malaria; Malaria, Vivax; Primaquine; Quinolines; Uricosuric A | 1952 |
PRIMAQUINE for vivax malaria.
Topics: Humans; Malaria; Malaria, Vivax; Primaquine; Quinolines; Uricosuric Agents | 1952 |
Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria.
Topics: Adult; Antimalarials; Humans; Korea; Malaria, Vivax; Male; Primaquine | 2004 |
Assessment of therapeutic efficacy of chloroquine for vivax malaria in Thailand.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimalarials; Child; Chloroquine; Drug Resista | 2004 |
Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax.
Topics: Adult; Animals; Antimalarials; Chemoprevention; Drug Resistance; Humans; Malaria, Vivax; Male; Milit | 2005 |
Diagnostic and prognostic utility of an inexpensive rapid on site malaria diagnostic test (ParaHIT f) among ethnic tribal population in areas of high, low and no transmission in central India.
Topics: Adult; Antimalarials; Child; Chloroquine; Ethnicity; Female; Humans; India; Infant; Malaria, Falcipa | 2005 |
Pseudo-borreliosis in patients with malaria.
Topics: Adult; Antimalarials; Borrelia Infections; Chloroquine; Diagnostic Errors; Female; Humans; India; Is | 2005 |
Targeting primaquine into liver using chylomicron emulsions for potential vivax malaria therapy.
Topics: Animals; Antimalarials; Chromatography, High Pressure Liquid; Chylomicrons; Drug Delivery Systems; D | 2005 |
[How much primaquine is needed to eradicate Plasmodium vivax hypnozoites?].
Topics: Adult; Animals; Antimalarials; Drug Tolerance; Humans; Malaria, Vivax; Middle Aged; Plasmodium vivax | 2006 |
Lack of sex effect on the pharmacokinetics of primaquine.
Topics: Adult; Animals; Antimalarials; Australia; Body Weight; Female; Humans; Malaria, Vivax; Male; Metabol | 2006 |
Frequency of malaria and glucose-6-phosphate dehydrogenase deficiency in Tajikistan.
Topics: Adult; Chloroquine; Glycogen Storage Disease Type I; Hemolysis; Humans; Malaria; Malaria, Vivax; Mal | 2006 |
Management of vivax malaria with low sensitivity to primaquine.
Topics: Adult; Drug Resistance; Humans; Malaria, Vivax; Male; Middle Aged; Primaquine; Travel | 2007 |
Plasmodium vivax malaria relapses after primaquine prophylaxis.
Topics: Aged; Antimalarials; Humans; Malaria, Vivax; Male; Primaquine; Recurrence | 2006 |
A rare glimpse at the efficacy of primaquine.
Topics: Animals; Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Secondary Prevention | 2007 |
Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine.
Topics: Administration, Oral; Adolescent; Adult; Animals; Antimalarials; Artemisinins; Artesunate; Drug Ther | 2007 |
A case of symptomatic splenic infarction in vivax malaria.
Topics: Adult; Animals; Humans; Malaria, Vivax; Male; Plasmodium vivax; Primaquine; Splenic Infarction | 2007 |
Pulmonary edema due to Plasmodium vivax malaria in an American missionary.
Topics: Animals; Antimalarials; Doxycycline; Humans; Malaria, Vivax; Male; Middle Aged; Missionaries; Plasmo | 2007 |
Congenital malaria in the United States: a review of cases from 1966 to 2005.
Topics: Female; Humans; Infant, Newborn; Malaria; Malaria, Vivax; Population Surveillance; Pregnancy; Pregna | 2007 |
Chloroquine-resistant Plasmodium vivax, Brazilian Amazon.
Topics: Animals; Antimalarials; Brazil; Chloroquine; Dose-Response Relationship, Drug; Drug Resistance; Drug | 2007 |
Alteration of platelet counts and lipid profiles after treatment of acute Plasmodium vivax.
Topics: Adolescent; Adult; Animals; Antimalarials; Female; Humans; Hydroxychloroquine; Lipids; Malaria, Viva | 2008 |
A woman from Honduras with a painful forearm and fever.
Topics: Adult; Animals; Antimalarials; Female; Fever; Honduras; Humans; Malaria, Vivax; Mefloquine; Pain; Pl | 2008 |
Malaria. Local transmission of Plasmodium vivax malaria, Houston, Texas, 1994.
Topics: Adult; Animals; Anopheles; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Humans; Ma | 1995 |
The use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (G6PD) deficiency in Myanmar.
Topics: Developing Countries; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythrocytes; | 1994 |
Quality of antimalarial drugs and resistance to Plasmodium vivax in Amazonian region.
Topics: Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Primaquine; Venezuela | 1995 |
Effectiveness of doxycycline combined with primaquine for malaria prophylaxis.
Topics: Australia; Doxycycline; Drug Evaluation; Drug Therapy, Combination; Humans; Malaria, Falciparum; Mal | 1995 |
Combined chloroquine and primaquine resistant Plasmodium vivax malaria in a patient returning from India.
Topics: Adult; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Malaria, Vivax; Prim | 1995 |
Halofantrine in acute malaria.
Topics: Acute Disease; Antimalarials; Drug Resistance, Multiple; Humans; Malaria, Falciparum; Malaria, Vivax | 1994 |
[Plasmodium vivax resistance to primaquine].
Topics: Adult; Aged; Animals; Drug Resistance; Female; Humans; Malaria, Vivax; Male; Plasmodium vivax; Prima | 1994 |
Unexpected high primaquine concentrations in acutely ill malaria patients.
Topics: Acute Disease; Humans; Malaria; Malaria, Vivax; Primaquine; Time Factors | 1993 |
Poor response to primaquine in two cases of Plasmodium vivax malaria from Guatemala.
Topics: Chloroquine; Drug Resistance; Drug Therapy, Combination; Guatemala; Humans; Malaria, Vivax; Male; Pr | 1994 |
Antimalarial effects of rifampin in Plasmodium vivax malaria.
Topics: Adolescent; Adult; Animals; Chloroquine; Drug Therapy, Combination; Humans; Malaria, Vivax; Male; Mi | 1994 |
[Recurrence problems with preventive primaquine treatment in patients with malaria].
Topics: Adult; Drug Resistance, Microbial; Gastrointestinal Diseases; Humans; Malaria, Falciparum; Malaria, | 1993 |
Changes in glutathione metabolic enzymes in erythrocytes of Plasmodium vivax infected patients.
Topics: Adult; Animals; Antioxidants; Chloroquine; Erythrocytes; Glutathione; Humans; India; Malaria, Vivax; | 1993 |
[A case of vivax malaria in which remission was achieved by primaquine at 1.5 times the standard dose after two earlier relapses].
Topics: Adult; Drug Administration Schedule; Humans; Malaria, Vivax; Male; Primaquine; Recurrence; Remission | 1993 |
Chloroquine-resistant Plasmodium vivax: how common?
Topics: Adult; Animals; Chloroquine; Drug Resistance; Humans; Indonesia; Malaria, Vivax; Male; Plasmodium vi | 1993 |
High-performance liquid chromatographic determination of primaquine and carboxyprimaquine concentrations in plasma and blood cells in Plasmodium vivax malaria cases following chronic dosage with primaquine.
Topics: Adolescent; Adult; Antimalarials; Chromatography, High Pressure Liquid; Humans; Malaria, Vivax; Midd | 1996 |
A case of vivax malaria presenting with psychosis.
Topics: Adult; Antimalarials; Chloroquine; Humans; Malaria, Cerebral; Malaria, Vivax; Male; Neurocognitive D | 1996 |
Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America.
Topics: Adult; Animals; Chloroquine; Drug Therapy, Combination; Follow-Up Studies; Guyana; Humans; Malaria, | 1996 |
Substandard primaquine phosphate for US Peace Corps personnel.
Topics: Antimalarials; Drug Industry; Female; Government Agencies; Humans; Malaria, Vivax; Namibia; Primaqui | 1996 |
Short report: primaquine-tolerant Plasmodium vivax in an Italian traveler from Guatemala.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Resistance, Microbial; Drug Therapy, Combination; F | 1996 |
[A study of relapsed cases of vivax malaria after the standard primaquine therapy].
Topics: Adult; Antimalarials; Asia, Southeastern; Drug Administration Schedule; Humans; Japan; Malaria, Viva | 1996 |
A standard regimen for treatment of plasmodium vivax malaria.
Topics: Antimalarials; Humans; Infant; Malaria, Cerebral; Malaria, Falciparum; Malaria, Vivax; Primaquine; Q | 1996 |
Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia.
Topics: Adolescent; Adult; Animals; Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Male; Mefloquine | 1997 |
Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Therapy, Combination; F | 1996 |
Studies on a primaquine-tolerant strain of Plasmodium vivax from Brazil in Aotus and Saimiri monkeys.
Topics: Animals; Anopheles; Antimalarials; Aotidae; Brazil; Chloroquine; Disease Models, Animal; Drug Resist | 1997 |
Early diagnosis and treatment of malaria in a refugee population in Sri Lanka.
Topics: Adult; Antimalarials; Blood; Child; Chloroquine; Cost-Benefit Analysis; Developing Countries; Health | 1997 |
Drug resistant Plasmodium vivax malaria.
Topics: Animals; Antimalarials; Asia; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Pacific Islands; | 1997 |
[Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment].
Topics: Adult; Antimalarials; Drug Tolerance; Female; Humans; Malaria, Vivax; Male; Middle Aged; Primaquine; | 1997 |
Primaquine-tolerant vivax malaria in Thailand.
Topics: Adult; Antimalarials; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Stu | 1997 |
New aspects of malaria imported from Ethiopia.
Topics: Animals; Antimalarials; Chloroquine; Culicidae; Disease Reservoirs; Drug Therapy, Combination; Ethio | 1998 |
A relapsed case of imported tertian malaria after a standard course of hydroxychloroquine and primaquine therapy.
Topics: Adult; Animals; Antimalarials; Humans; Hydroxychloroquine; Malaria, Vivax; Male; Primaquine; Recurre | 1998 |
Adaptation of a strain of Plasmodium vivax from Mauritania to New World monkeys and anopheline mosquitoes.
Topics: Adaptation, Physiological; Animals; Anopheles; Antimalarials; Aotidae; Chloroquine; Disease Models, | 1998 |
[Hemolysis and primaquine treatment. Preliminary report].
Topics: Anemia, Hemolytic; Angola; Antimalarials; Contraindications; Cuba; Erythrocytes; Glucosephosphate De | 1997 |
Drug overdoses with antimalarial agents: prescribing and dispensing errors.
Topics: Aged; Aged, 80 and over; Antifungal Agents; Antimalarials; Drug Overdose; Female; Humans; Malaria, V | 1998 |
[Therapeutic failure wtih chloroquine and primaquine in malaria by Plasmodium vivax].
Topics: Antimalarials; Chloroquine; Humans; Malaria, Vivax; Male; Middle Aged; Primaquine; Treatment Failure | 1998 |
Primaquine prophylaxis against malaria.
Topics: Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Falciparum; Malar | 1999 |
Imported tertian malaria resistant to primaquine.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Male; Middle Aged; Pla | 1999 |
Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1.
Topics: Adult; Animals; Antibodies, Protozoan; Antimalarials; Brazil; Chloroquine; Enzyme-Linked Immunosorbe | 1999 |
[Prevention of malaria].
Topics: Anti-Bacterial Agents; Antimalarials; Chloroquine; Doxycycline; Female; Humans; Malaria; Malaria, Fa | 1999 |
Profound thrombocytopenia in Plasmodium vivax malaria.
Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Humans; Malaria, Vivax; Platel | 1999 |
Different prevalences of Plasmodium vivax phenotypes VK210 and VK247 associated with the distribution of Anopheles albimanus and Anopheles pseudopunctipennis in Mexico.
Topics: Altitude; Animals; Anopheles; Antibodies, Monoclonal; Antibodies, Protozoan; Antimalarials; Chloroqu | 2000 |
An unusual case of multidrug-resistant Plasmodium vivax malaria in Mumbai (Bombay), India.
Topics: Adolescent; Animals; Antimalarials; Artemether; Artemisinins; Chloroquine; Drug Combinations; Drug R | 2000 |
Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria.
Topics: Antimalarials; Body Weight; Drug Resistance; Humans; Malaria, Vivax; Primaquine; Retrospective Studi | 2000 |
In-vivo sensitivity of Plasmodium vivax isolates from Rond nia (western Amazon region, Brazil) to regimens including chloroquine and primaquine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antimalarials; Brazil; Chloroquine; DNA, Protozoan; D | 2000 |
Vivax malaria: also a challenge to biomedical sciences and services.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Mefloquine; Plasmodium | 1999 |
Immunological alterations associated with Plasmodium vivax malaria in South Korea.
Topics: Adolescent; Adult; Antimalarials; Biomarkers; Case-Control Studies; Chloroquine; Eosinophils; Female | 2001 |
A survey of primaquine prescribing habits in the city of Mumbai.
Topics: Developing Countries; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Utilizati | 2000 |
[Does the brief treatment with antimalarials favorably influence drug resistance and recurrences?].
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Malaria, Falciparum; Malaria, | 2001 |
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com | 2001 |
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com | 2001 |
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com | 2001 |
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com | 2001 |
Relapse pattern of Plasmodium vivax in Mumbai: a study of 283 cases of vivax malaria.
Topics: Animals; Antimalarials; Humans; India; Malaria, Vivax; Plasmodium vivax; Polymerase Chain Reaction; | 2002 |
Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand.
Topics: Adult; Anemia, Hemolytic; Antimalarials; Chloroquine; Female; Glucosephosphate Dehydrogenase; Hemato | 2001 |
Relapsing vivax malaria.
Topics: Antimalarials; Australia; Humans; Indonesia; Malaria, Vivax; Male; Military Personnel; Primaquine; S | 2002 |
Sensitivity of Plasmodium vivax to chloroquine in Sa Kaeo Province, Thailand.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Chloroquine; Female; Humans; Malaria, Vivax; Male; | 2002 |
Treatment of primaquine-resistant Plasmodium vivax malaria.
Topics: Adult; Animals; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Male; Plasmodium vivax; Primaq | 1992 |
Chloroquine-resistant Plasmodium vivax: it may be a common problem.
Topics: Animals; Chloroquine; Drug Resistance; Female; Humans; Malaria, Vivax; Male; Mefloquine; Plasmodium | 1992 |
Biochemical alterations in Plasmodium vivax-infected malarial patients before and after radical treatment.
Topics: Adult; Bilirubin; Blood Glucose; Blood Proteins; Chloroquine; Cholesterol; Drug Therapy, Combination | 1992 |
Reinforcement of immunity in Saimiri monkeys following immunization with irradiated sporozoites of Plasmodium vivax.
Topics: Animals; Anopheles; Aotus trivirgatus; Chloroquine; Immunization; Malaria, Vivax; Plasmodium vivax; | 1992 |
Effect of radical treatment on erythrocyte lipid peroxidation in Plasmodium vivax-infected malaria patients.
Topics: Animals; Catalase; Chloroquine; Erythrocytes; Heinz Bodies; Humans; Lipid Peroxidation; Malaria, Viv | 1991 |
The haematology of Plasmodium vivax before and after chloroquine and primaquine treatment in north Madras area.
Topics: Blood Cell Count; Chloroquine; Hematocrit; Hemoglobins; Humans; India; Malaria, Vivax; Primaquine | 1991 |